



CELL & GENE THERAPY INSIGHTS

SPOTLIGHT ON:

Market access: evolving commercialization trends and strategies

GUEST EDITOR: Neil Palmer, President and Principal Consultant President
and Principal Consultant at PDCI Market Access





Market access: evolving commercialization trends and strategies

FOREWORD

Under construction: roadmaps for HTA, pricing and reimbursement of cell and gene therapies

Neil Palmer

1121-1124

EXPERT INSIGHT

Challenges and proposed solutions to value assessment and reimbursement of CAR-T therapies in Europe

Clare L Hague & Martin J Price

1013-1028

COMMENTARY

The heart of market access: opportunities and challenges for cell and gene therapy development for orphan and prevalent cardiovascular diseases

Faraz Ali

1141-1153

INTERVIEW

HTA evolution in Canada: considerations for cell and gene therapy

Suzanne McGurn

985-992

COMMENTARY

Joint collaborations and future perspectives for gene therapies

Monique Dabbous, Eve Hanna, Boris Borislav, Claude Dussart & Mondher Toumi

965-985

COMMENTARY

Challenges in the adoption of regenerative medicine therapies, meeting summary

Maya Chaddah, Allison Brown, Siofradh McMahon, James Kusena, Karen Bremner, Ann Perry & Murray Krahn

887-921

COMMENTARY

Innovative payments for innovative therapies: adopting value-based models in the regenerative medicines & advanced therapy sector

Janet Lambert

941-945

INTERVIEW

From rare monogenic diseases to Parkinson's: market access considerations for gene therapy across large and small indications

Parag V Meswani

1057-1065

COMMENTARY

Bringing advanced therapies to the clinic: the Swedish National ATMP Consortium (CAMP/SWElife ATMP)

Stefan Scheduling, Heather Main & Pontus Blomberg

947-953

INTERVIEW

How should health technology assessment of ATMPs evolve in Europe?

Mondher Toumi

887-921

FOREWORD

Under construction: roadmaps for HTA, pricing and reimbursement of cell and gene therapies



NEIL PALMER is Senior Strategic Adviser and President Emeritus of PDCI Market Access Inc., Canada's leading pricing and reimbursement consultancy that he co-founded in 1996. Prior to PDCI, Neil worked with the Patented Medicine Prices Review Board (PMPRB) where his responsibilities included policy development, overseeing the price review of patented medicines and conducting economic research. Prior to the PMPRB, he worked with the Health Division of Statistics Canada where he was responsible for economic and statistical analysis of health care costs and utilization. After completing his studies at the University of Western Ontario, Neil began his career in Montreal with the research group of the Kellogg Centre for Advanced Studies in Primary Care. He has presented extensively on pharmaceutical pricing and reimbursement issues and is a frequent speaker at conferences in North America and Europe.

Cell & Gene Therapy Insights 2020; 6(7), 1121–1124

DOI: 10.18609/cgti.2020.121

More than a dozen cell and gene therapies (CGT) are already on the market (e.g., LUX-TURNA[®], Kymriah[®], Yescarta[®], Zolgensma[®]) and there are several hundred cell and gene therapies in development [1]. McKinsey reports that “more than 750 trials of CGTs in almost 30,000 patients were underway as of June 2020”, representing a growing proportion of the pharmaceutical industry’s clinical and pre-clinical pipelines [2].

With the promise of significant and clinically meaningful advances in treatment, the early entrants are challenging national Health Technology Assessment (HTA), and pricing and reimbursement infrastructures around the world.

For traditional pharmaceuticals and biologics, the current HTA and market access roadmaps are generally clear, albeit often challenging. Analytical methods, standards and thresholds for assessing clinical and cost effectiveness are well established, limited primarily by gaps in clinical evidence than can sometimes be mitigated through risk sharing agreements with payers.

By comparison, the HTA and reimbursement roadmaps for CGT are still under construction, particularly in cases where there are unique or novel treatment modalities where there is no clear budget or funding mechanism within national or regional health care systems. Some CGTs are more akin to medical/surgical procedures than pharmacotherapy and require significant supporting medical care. And gene therapies for rare diseases may require cross-border travel to a specialized treatment centre (e.g., Strimvelis[®] in Milan) which raises logistics and reimbursement challenges [3].

This issue of *Cell and Gene Therapy Insights* addresses many of the important issues anticipated for HTA, pricing and reimbursement of cell and gene therapies.

Chaddah *et al.* report proceedings of their international workshop on the Challenges in the Adoption of Regenerative Medicine Therapies (CHART) [4]. The authors conclude that although current HTA methods are applicable to CGT, the dearth of long-term

evidence greatly increases uncertainty that CGT are clinically and cost effective. The authors recommend improvement in clinical trial design, establishment of incentives for real world evidence, engagement of multiple stakeholders including policy makers, improvements to patient and data management, and finally, addressing payment challenges for technologies with high upfront costs but uncertain long term benefits.

Dabbous *et al.* provide an informative overview of European multinational collaborations in HTA and procurement of health technologies. Although more than 30 European countries are actively involved in such collaborations, only two have published reviews or activities with respect to gene therapies, a number that will surely grow [5]. However, despite multinational HTA and pricing collaborations, distinct national and sub-national treatment and funding pathways will likely persist given the unique characteristics of the respective healthcare systems.

Hague and Price question whether the value assessment criteria employed by HTA agencies to chimeric antigen receptor T-cell (CAR-T) therapies are fit-for-purpose given CAR-T’s unique treatment characteristics and uncertainties in the evidence base. The authors recommend more systematic inclusion of evidence from patients and carers, a broader perspective of value to include productivity gains to address the limitations of cost-per-QALY value frameworks. They emphasize the important role of outcomes-based agreements to address uncertainty and the need for alignment on registries that will generate the evidence for the outcomes-based payment models [6]. Although, these concerns are not new to HTA agencies or payers as they face very similar challenges with highly specialized pharmaceutical technologies for rare diseases, the authors outline the specific concerns with respect to CAR-T.

The interview with Suzanne McGurn (President & CEO, CADTH) highlights the concerns of HTA agencies and payers that current and emerging CGT are novel and complex treatment technologies that need

to be integrated into the healthcare system. Moreover, CGTs are highly heterogeneous in nature so the HTA review process needs to be adaptable to the technology and its place in the healthcare system. To that end, McGurn describes CADTH's separate review process for CGT including the screening process by which sponsors provide information on the complexity of the CGT and the treatment modality – information that allows CADTH to inform and engage with provincial ministries of health that will be reimbursing/funding the CGT within their respective healthcare systems. The process also allows early engagement between CADTH and sponsors [7].

In his interview, Professor Mondher Toumi addresses how HTA and market access for CGTs will evolve in Europe. And like McGurn, he highlights the heterogeneity of CGT technologies and the challenges of decentralized health care systems. Importantly, he warns that most CGT companies are not headed in the right direction when it comes to HTA, perhaps clinging to the misbelief that being highly specialized, traditional HTA would not apply to their technologies [8]. And while there may be updated HTA processes for HTA of CGT, as McGurn describes, current HTA methods will be adapted to address the unique characteristics of a CGT only if standard drug review process is not appropriate.

The interview with Parag Meswani (SVP, Commercial Strategy & Operations, Axovant Gene Therapies) highlights key learnings from his time with Spark and the commercialization of LUXTURNA® for a rare inherited ophthalmic condition and from his new role where the target is the much larger Parkinson's disease patient population. For rare diseases, the challenge is finding patients; for

larger patient populations, it is identifying those patients who will benefit most from gene therapy and for whom the new technology offers greatest value compared to current treatments. In both cases, genetic testing programs will be important and clinical trial design needs to focus on safety and efficacy, but with HTA evidentiary requirements in mind. He discusses pricing, the importance of mapping pricing evidence requirements and stakeholder needs to support value communication. Finally, he stresses the need for flexibility in payment modalities across payers; to offer options for payers to assess price and to manage cash flow [9].

Janet Lambert (CEO Alliance for Regenerative Medicine) asserts that “payers, policymakers, and other stakeholders must implement the infrastructure necessary to ensure broad patient access and appropriate value-based reimbursement.” [10].

However, the development and implementation of national CGT infrastructures is more likely to be evolutionary than revolutionary. And that evolution is already underway; led by individual firms and their innovative technologies that are blazing new trails for CGT products. There is no doubt that political awareness and informed policy makers are critical to a supportive environment; but it is the early CGT technologies and their pioneering sponsors, in collaboration with HTA authorities and payers, that will have the greatest influence (as borne out by the CHART workshop).

AFFILIATION

W. Neil Palmer

Senior Strategic Adviser and President
Emeritus of PDCI Market Access Inc.

REFERENCES

1. PhRMA. Medicines in Development for Cell and Gene Therapy 2020 (Report). From: <https://phrma.org/Report/Medicines-in-Development-for-Cell-and-Gene-Therapy-2020> (Accessed Sep 2020)
2. GEN, Bright Outlook for the Global Cell and Gene Therapy Market <https://www.genengnews.com/insights/bright-outlook-for-the-global-cell-and-gene-therapy-market/>

3. Nature 'Bubble boy' gene therapy reignites commercial interest <https://www.nature.com/articles/d41587-019-00015-6>
4. Chaddah M, Brown A, McMahon S *et al.* Challenges in the adoption of regenerative medicine therapies, meeting summary. *Cell Gene Ther. Ins.* 2020; 6(7): 887–921.
5. Dabbous M, Hanna E, Boris Borislav B *et al.* Joint collaborations and future perspectives for gene therapies. *Cell Gene Ther. Ins.* 2020; 6(7): 965–83.
6. Hague CL, Price MJ. Challenges and proposed solutions to value assessment and reimbursement of CAR-T therapies in Europe. *Cell Gene Ther. Ins.* 2020; 6(7): 1013–28.
7. McGurn S. HTA evolution in Canada: considerations for cell and gene therapy. *Cell Gene Ther. Ins.* 2020; 6(7): 985–92.
8. Toumi M. How should health technology assessment of ATMPs evolve in Europe? *Cell Gene Ther. Ins.* 2020; 6(7): 1095–101.
9. Meswani PV. From rare monogenic diseases to Parkinson's: market access considerations for gene therapy across large and small indications. *Cell Gene Ther. Ins.* 2020; 6(7): 1057–65.
10. Lambert J. Innovative payments for innovative therapies: adopting value-based models in the regenerative medicines & advanced therapy sector. *Cell Gene Ther. Ins.* 2020; 6(7): 941–5.

EXPERT INSIGHT

Challenges and proposed solutions to value assessment and reimbursement of CAR-T therapies in Europe

Clare L Hague & Martin J Price

Chimeric antigen receptor T-cell (CAR-T) therapy is a recently approved innovation that represents a novel approach to treating cancer. The aim of this paper is to describe some of the challenges to value assessment of CAR-Ts in Europe and put forward potential solutions to remedy these; maintaining the principles of respecting the need to accelerate broad patient access, address affordability concerns and reward innovation to maintain a sustainable life sciences industry. We explore whether the value assessment criteria employed by HTA agencies is appropriate for CAR-T therapies, considering the unique characteristics of treatment and uncertainties in the evidence base. Uncertainty is inevitable if the goal of timely patient access to innovation is to be pursued. We advocate for a more systematic inclusion of evidence from patients and carers in the HTA decision-making process, a broader perspective of value to be adopted by HTA agencies that take into account productivity gains from both patient and carers, and investment in data infrastructures to enable outcomes-based payment models. The limitations of cost-per-QALY value frameworks for CAR-T are highlighted as are their inability to capture productivity gains and solve for uncertainty. The important role that outcomes-based payment models play in enabling faster access through addressing uncertainties from an HTA perspective and payer perspective is emphasized. We conclude that multi-stakeholder collaboration across Europe is critical to ensure alignment on registries used to capture data for the regulatory mandated post-authorization study commitments and any additional data needed to support outcomes-based payment models for HTA agencies and payers.

Cell & Gene Therapy Insights 2020; 6(7), 1013–1028

DOI: [10.18609/cgti.2020.111](https://doi.org/10.18609/cgti.2020.111)

INTRODUCTION

Cancer remains a devastating public health challenge. Scientific research has focused on gaining an advanced understanding of disease, genomics and molecular characterization of tumors. This has led to the development of more targeted and innovative treatments that have altered the natural history of disease, particularly in hematology [1]. Such innovation includes advanced therapy medicinal products (ATMPs) which are medicines for human use based on genes, tissues or cells [2].

What is CAR-T therapy and what makes it different from other cancer therapies?

Autologous chimeric antigen receptor T-cell (CAR-T) therapy is a recently approved innovation that represents a novel approach to cancer treatment. It is typically administered as a one-time treatment where a patient's T-cells are removed from their blood and re-engineered to produce cells that are able to target and bind to cancer cells through recognition of chimeric antigen receptor (CAR) target antigens. CAR-T cells are then multiplied in the laboratory and reintroduced into the patient's body to target and kill cancer cells, and to prevent cancer cells from returning [3].

CAR-T therapies have been described as representing a “breakthrough for treating patients with cancer that have failed to respond to prior treatments” [4]. Whilst data on their long-term benefits are still evolving and hence uncertain, for many patients CAR-T therapy may offer a chance at a cure [5]. CAR-T therapies have however also captured headlines for their high price tags [6–8]. This has raised questions about their affordability and cost-effectiveness [9,10].

In 2018, the European Medicines Agency (EMA) recommended marketing authorizations for two CAR-T cell medicines in the European Union for blood cancer (specifically, for the treatment of acute lymphoblastic

leukemia [ALL] and diffuse large B-cell lymphoma [DLBCL]) [11].

- ▶ Kymriah® (tisagenlecleucel) : indicated for the treatment of paediatric and young adult patients (up to 25 years of age) with B-cell ALL that is refractory or in second or later relapse, and in adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy;
- ▶ Yescarta® (axicabtagene ciloleucel): indicated for the treatment of adult patients with relapsed or refractory DLBCL and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy [11].

Another novel CAR-T, KTE-X19, is currently undergoing regulatory assessment by the EMA for mantle cell lymphoma [12] and there are over 280 Phase 1–3 trials actively recruiting patients diagnosed with multiple myeloma, acute myeloid leukemia, T-cell ALL and solid tumors amongst others (see www.clinicaltrials.gov).

The characteristics of CAR-T therapies that differentiate them from other cancer treatments are well described by Cook *et al.* [13].

In summary:

- ▶ They are ATMPs with a one-time treatment administration and a unique toxicity profile due to activation of the immune system after infusion of engineered T-cells that requires diligent monitoring [14]. The main safety concerns are cytokine release syndrome (CRS), which is a systemic response to the activation and proliferation of CAR-T cells causing high fever and flu-like symptoms, and neurologic toxicities. Both can be life-threatening, and in some cases even fatal [15];
- ▶ A manufacturing process that is complex [16] and where patients may have to wait between 3-4 weeks before their modified CAR-T cells are returned to them;

- ▶ Stringent requirements for formal accreditation of hospitals are mandated to provide CAR-T therapies to patients.

The evidence base underpinning regulatory and HTA approval of CAR-T therapies of the first indications has been epitomized to date by the following characteristics:

- ▶ Open-label, single-arm (non-comparative) clinical studies with small sample sizes and short-term efficacy, safety and health-related quality of life (HRQoL) data but with a compelling treatment effect relative to (indirect comparisons of) alternative treatment options;
- ▶ Contextual comparative evidence generated for the standard(s) of care (SoC) that have been used to perform indirect comparisons of relative efficacy/safety;
- ▶ Post-authorization study commitments in form of safety studies (PASS) and efficacy studies (PAES).

These factors create some challenges for HTA decision-making because of the desire for HTA agencies and payers to understand:

- ▶ Relative efficacy from conventional randomized controlled trials (RCTs);
- ▶ Long-term efficacy, effectiveness, safety and HRQoL consequences of CAR-T therapies vs alternative treatment options;
- ▶ The likelihood of achieving a functional cure with therapy, which cannot always be defined *a priori*.

How do patients access CAR-T therapies outside of the clinical trial setting?

Following marketing authorization from the EMA, in many countries CAR-T innovators will be required to submit their evidence

package to National HTA Agencies for a value assessment and either in tandem, or subsequently (depending on the country), a price for the CAR-T will be negotiated with national and/or regional/local payers. Health Technology Assessment is defined as “a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle, to inform decision-making that promotes an equitable, efficient, and high-quality health system” [17] (see **Supplementary material** for clarifying notes). However, it is important to note that the value assessment for HTA decision-making is typically the value determined at the time of launch based on the available evidence. In some cases, conditions and/or restrictions may be put in place that are contingent on the generation of additional evidence [18]. The challenge of determining when evidence is sufficiently ‘robust’ within a therapy’s overall life cycle to undertake an HTA/cost-effectiveness assessment is summarized by what has been termed ‘Buxton’s law’ (i.e. it is always too early until, unfortunately, it’s suddenly too late) [19]. There are costs and unintended consequences associated with waiting for ‘certainty’ and it is important that these are better understood by all and particularly in relation to CAR-T therapies.

How is value determined by National HTA Agencies & is it appropriate for CAR-Ts?

It is important that the value assessment of CAR-T therapies is framed using a holistic definition of value, reflecting the perspective of all stakeholders, especially patients, where all relevant evidence and outcomes are considered. How value is characterized for CAR-T therapies however is not entirely straightforward.

The overall value will likely vary depending on the perspective taken, the stakeholders involved and the decision-making context [17]. Value for the same product can further

vary by indication, by sub-populations and by line of treatment. The dimensions of value referred to in Note 3 (**Supplementary material**) often include clinical effectiveness, safety, costs and economic implications, ethical, social, cultural and legal issues, organizational and environmental aspects, as well as wider implications for the patients, relatives, caregivers and the population. Additional value attributes for new treatments have also been suggested (see and include the value of ‘hope’, adherence-improving factors, the severity of illness, equity and scientific spillovers [20,21]). These are also applicable to CAR-T therapies.

Some HTA agencies focus exclusively on the clinical value of a new treatment relative to one or more alternative therapies (e.g. Germany). Others consider the cost of treatment more explicitly in their HTA assessment, relative to the costs and benefits of one or more alternative therapies (e.g. UK, Sweden). The economic case for reimbursing a given treatment will depend on many parameters specific to a country, jurisdiction or population such as health services used and their country-specific costs, available treatments, local clinical guidelines and societal impact and is not transferable between jurisdictions. In certain jurisdictions, the carers’ health-related quality of life, the impact on social care and productivity gains are explicitly not permitted in HTA evaluations, recommending the inclusion of direct health-care costs only.

Significant inter-country variation in the time to reimbursement of cancer medicines from EMA approval has been observed [22,23]. Such delays are particularly disconcerting for potentially curative treatments indicated for advanced stages of cancer, where the cost of delays is counted in lives cut short.

For the CAR-Ts in DLBCL, some countries have been very fast to issue a positive reimbursement recommendation (e.g. Germany, UK) whereas others (e.g. Sweden, Denmark, Netherlands, Norway) have taken longer to reach a decision. Uncertainty

is inevitable for such a new technology at the time of regulatory and HTA appraisal if timely access to potentially curative treatment is pursued. Such uncertainty should be identified and managed through access solutions such as ‘payment by results’ e.g. outcomes-based payment agreements, rather than serving as a barrier to formulating timely HTA recommendations.

Despite the significant uncertainty in clinical evidence and cost-effectiveness, patient access to date has been largely reflective of the unmet need, payers’ willingness to access CAR-T therapies and the high level of perceived innovation [24]. HTA agencies have employed the same evaluation criteria to appraise CAR-Ts as they do for other medicines. However, the methods by which ‘value’ is determined and the weight assigned to the various components of the evidence package can differ between countries [25,26].

Whilst all HTA agencies, when evaluating the CAR-T therapies for DLBCL, have expressed a strong preference from CAR-T innovators for RCTs as opposed to non-comparative single arm studies, longer duration of follow-up, mature overall survival, progression free survival and HRQoL data; others have focused more on the robustness of the economic case, the post-progression survival data, the assessment of prognostic markers and predictors of response. There is a need for greater consistency between HTA agencies overall but more explicitly on how CAR-T therapies are evaluated and how ‘uncertainty’ is perceived and handled in submissions.

The aim of this paper is to describe the unique challenges to value assessment of CAR-T therapies in Europe, and put forward potential solutions to remedy these – maintaining the principles of respecting the need to accelerate broad patient access, address affordability concerns and reward innovation to maintain a sustainable life sciences industry. We explore whether the value assessment criteria employed by HTA agencies is appropriate for CAR-T therapies considering the

characteristics of treatment and underpinning evidence.

CHALLENGES FACING THE HTA OF CAR-T THERAPIES USING EXISTING VALUE FRAMEWORKS & BARRIERS TO ADOPTION

In this part of the paper, we will explore some of the unique challenges as they relate to the regulatory approved CAR-T therapies in hematology [27-29] focusing on Kymriah® (tisagenlecleucel) and Yescarta® (axicabtagene ciloleucel).

Clinical value assessment for HTA

For the DLBCL indications submitted to NICE, the clinical evidence on Kymriah® (tisagenlecleucel) came from a Phase 2, open-label single arm study (JULIET) and a small observational study [30]. Results from 111 patients from the JULIET study and 14 patients from the study by Schuster *et al.* (2017) were presented (see Table 1). The NICE appraisal committee concluded the tisagenlecleucel is clinically effective, but immature survival data and the lack of trial data directly comparing tisagenlecleucel with salvage chemotherapy means the size of this benefit is difficult to establish. Results from JULIET showed that all patients having tisagenlecleucel as a CAR T cell therapy had an adverse event after treatment. Most patients had severe adverse events (over grade 3). Cytokine release syndrome is a common toxicity of cellular

immunotherapy and it affected similar proportions of patients in both Schuster and JULIET. The clinical experts explained that cytokine release syndrome is often mild and can be managed by tocilizumab treatment, close observation and supportive care. The committee also noted that more patients in Schuster had neurotoxicity than in JULIET. Neurotoxicity may also need intensive care treatment and monitoring [31].

For axicabtagene ciloleucel the clinical evidence came from ZUMA 1, an ongoing, Phase 1/2, multicentre, open-label, single-arm study. The company presented results from the study using a modified intention-to-treat analysis (only patients enrolled in the study who had axicabtagene ciloleucel infusion were included). All patients having axicabtagene ciloleucel had an adverse event after treatment. Events over grade 3 happened in 95% of patients. In the ZUMA 1 study, CRS affected 93% of patients. However, severe cases (affecting 13% of patients in ZUMA 1) need intensive care treatment and may lead to hemodynamic instability and other organ toxicity. The committee concluded that axicabtagene ciloleucel was clinically effective but agreed that the lack of comparative data made the assessment of comparative effectiveness (and any cost-effectiveness analyses) more challenging (see Table 2) [32].

Economic value assessment

Alongside the clinical assessment, some HTA agencies will also request a health economic evaluation. In some cases, the preferred

▶ **TABLE 1**

Clinical effectiveness results for Kymriah® (tisagenlecleucel) [31].

| Outcome | JULIET (December 2017 data-cut) | Schuster <i>et al.</i> (2017) |
|---|--|---|
| Overall response rate | 51.6% (41-62%) | 50% (23-77%) |
| Complete response rate | 39.8% (not reported) | 43% (18-71%) |
| Median overall survival (95% CI) | 11.7 months (6.6 months - not reached) | 22.2 months (not reached) |
| Median progression-free survival (95% CI) | Results are confidential | 3.2 months (0.9 months - not estimable) |

TABLE 2
Clinical effectiveness results for Yescarta® (axicabtagene ciloleucel [32]).

| Outcome | |
|---|--------------------------------|
| Overall response rate | 82% |
| Complete response rate | 40% |
| Median overall survival (95% CI) | Not reached |
| Median progression-free survival (95% CI) | 5.8 months (3.3 – not reached) |

approach is to perform a budget impact analysis focusing primarily on the costs of treatment. In other cases, cost-utility analysis (CUA) is employed which is where the longer-term costs AND consequences of treatment are estimated through extrapolation/modelling techniques. Cost-utility analysis is the technique most commonly employed by HTA agencies to look at cost-effectiveness. CUA derives a ratio or relationship between costs and health outcomes, where value is defined as the outcomes achieved relative to costs spent for one treatment (Treatment A) vs other(s) (Treatments B, C, D, etc.) and framed in terms of an incremental cost effectiveness ratio (ICER) [33].

Whilst costs are relatively straightforward to measure and report in CUAs, health outcomes are expressed in Quality-Adjusted Life Years gained (QALYs) to describe the health benefit of any technology, regardless of the disease it is being developed for. The ICER for Treatment A is thus the difference in costs divided by the difference in outcomes (expressed as QALYs) between Treatment A and Treatment B, the alternative). Cost-effectiveness thresholds provide an indication of health systems' willingness (not ability) to pay, have been static in England for example (i.e. do not change over time, despite inflation) and vary across different countries. An ICER falling under a given threshold for Treatment A vs B is deemed 'cost-effective'; however, an ICER for Treatment A that sits above a given threshold would be deemed 'not cost-effective' and thus Treatment A would not likely be recommended for reimbursement. Very few countries state an explicit threshold and a higher willingness to pay has been granted for rare and ultra-rare diseases.

With respect to economic evaluations, there are further methodological differences between countries in relation to the perspective adopted, the inclusion or not of indirect costs and choice of discount rates.

The limitations of economic modelling for innovative medicines are well documented because of uncertainties in estimating relative efficacy from non-comparative trials, identifying the most appropriate model structure to reflect the pattern and duration of response to treatment and the choice of extrapolation assumptions when long-term outcomes may be incomplete to predict quality adjusted survival and the most plausible costs and consequences associated with different health states [29,34-37].

A rapid review of the published and grey literature of HTA submissions was undertaken where economic modelling was employed to support HTA submissions for tisagenlecleucel and axicabtagene ciloleucel. Although the USA has no formal health technology assessment (HTA) body in place, CAR-T therapies have been evaluated by organizations such as the Institute for Clinical and Economic Review (ICER). ICER recently reviewed CAR-T cell therapies in an evidence report released on March 23, 2018 [3].

One ICER submission [38], 3 NICE HTA submissions [31,32,39] and 3 SMC HTA submissions [40-42] were identified. Out of the seven identified HTA and ICER submissions, two focused on pediatric and young adult patients (up to 25 years) [39,40], four concentrated on adult patients [31,32,40,42] and one focused on both populations [38]. All the pediatric submissions focused on relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), and the

adult submissions reported on diffuse large B-cell lymphoma (DLBCL). The submissions consisted of one from a US third-party payer perspective [38], three from the England and Wales National Health Service (NHS) and Personal Social Services (PSS) perspective [31,32,39] and three from the Scottish NHS perspective [40–42]. Six of the seven reported cost-utility analyses [31,32,40–42] and one was a cost-effectiveness study [38]. All of the HTA submissions used partitioned survival models with some also using a decision tree to handle considerations around pre-treatment with CAR-T therapy.

ICER used a two-part decision-analytic model, consisting of a short-term decision tree and long-term semi-Markov partitioned survival model [38]. The decision tree calculated the costs and consequences from treatment initiation to assessment of response. Its purpose was to stratify the cohort by which treatment they ended up receiving, because the model started at treatment initiation, however pre-treatment costs were included and allocated at the start of the decision tree. Furthermore, the decision tree allowed for allocation of upfront costs by treatment and the stratification of the cohort by response status, which becomes important when considering outcomes-based pricing. The long-term survival and outcomes derived from the long-term, partitioned-survival model were dependent on the treatment received in the short-term decision tree model and were simulated using parametric survival modeling from the direct extrapolation of PFS and OS curves for 5 years after therapy completion. Thus, the companies concerned used a partitioned survival model from assessment of response to 5 years after treatment completion, followed by a Markov model from 5 years until death.

All seven submissions used a lifetime time horizon within their economic models and had three health states: pre-progression, post-progression, and death. Comments from an HTA-agency appointed Evidence Review Group (ERG) relating to one of the

submissions, flagged that the model had a long-time horizon relative to the available data on the intervention (axicabtagene ciloleucel), and thus there would be uncertainty associated with the extrapolations used [41]. Regarding another submission, the ERG commented that: the long-time horizon was driven by the extrapolation and ‘cure’ assumptions within the company’s model, which the ERG considered to be subject to significant uncertainties [32].

As noted above, the QALY methodology (grounded on survival and quality of life data) poses some particular challenges for reliable HTA assessments of CAR-T therapies because of the uncertainties associated with accurately estimating (a) the likely survival of patients; (b) the HRQoL of patients; (c) the costs of any subsequent treatments received or avoided; and d) the broader impact (externality) of the treatment on patients, carers, family members and ability to fulfil paid/unpaid work when these have yet to be observed.

It is recommended that productivity gains and losses due to health care interventions are explicitly measured and valued in HTA assessments however QALYs do not capture well the effect of health improvement on productivity in the workplace or outside of it [20]. Furthermore, the QALY has been criticized for not incorporating individual or community preferences about the weight given to health gain for example, about disease severity, equity of access, unmet need, etc. [43], or preferences for potentially curative therapies.

Framing reimbursement decisions based on limited evidence that relies on statistical extrapolation of QALYs and costs that are unknown, does not necessarily reduce the uncertainty but rather exacerbates it. It is for this reason that Clay *et al.* [44] suggest that although standard economic evaluation approaches based on CUA are theoretically applicable to these types of therapies, they may in reality be of little use to decision makers and patients due to substantial uncertainty around the results.

Patient & carer value assessment

Evidence from patients and their involvement in HTA decision-making is growing in importance across Europe [45–49]. There are two issues here; first, the systematic engagement of patients/patient advocates in HTA processes and second, the generation of patient-relevance evidence to inform HTA submissions. Lee *et al.* evaluated the role of patient-reported outcome (PRO) data and patient testimonial evidence (e.g. patient advocacy) in reimbursement decisions in 10 countries and found substantial inter-country variability (from formal patient submissions/consultations and committee involvement [e.g. Scotland, England, Canada] to limited/unclear patient involvement [e.g. France, Japan]) [50].

As far as evidence is concerned, a recent study of 664 CAR-T trials found that the utilization of PROs to assess the impact on HRQoL and disease related symptoms to be well under the industry average with only 6.17% (41/664) of studies including a PRO measure [51]. Admittedly, there are some limitations in the validated health status/HRQoL instruments available to assess CAR-T therapies which likely do not capture the patient experience in an optimal manner. Standard generic utility measures (e.g. EQ-5D) may not be sufficiently sensitive to measure important changes in HRQoL. Even disease-specific patient-reported outcome measures such as the EORTC QLQ C30 may be unable to capture the unique characteristics of treatment because these questionnaires were constructed prior to the development of CAR-T therapies. Despite these challenges, it is important to capture insights from patients who have received the CAR-T therapy and their carers for the benefit of future patients and to ensure that this evidence plays a prominent role in regulatory and health technology appraisals [51].

Budget impact

Affordability is a combination of ability and willingness to pay – both of which will likely

vary by country, jurisdiction and payer. It also depends on who is the payer e.g. the health system, insurer or patient. Garrison *et al.* [21] describe the challenges that health system payers or insurers face when covering the costs (of a CAR-T therapy) because the benefits of CAR-T therapies (i.e. potential for future cost savings) may not be realized within the short time frame of the annual budget cycle. Due to the highly specialized nature of treatment, some healthcare providers have chosen to restrict the delivery of CAR-T treatment to a small number of hospitals which in turn, limits how many patients have the potential to receive a CAR-T treatment [52].

Barriers facing the acceptance & implementation of innovative payment models

The use of the term ‘innovative’ payment models that seek to spread the one-off treatment cost according to pre-determined milestones, provokes skepticism amongst the payer community. Such models are generally thought to add administrative burden and complexity, with payers often expressing a preference for simple discounts or rebates. To successfully implement outcomes-based payment models in a given country, it is important to have an infrastructure in place to capture high quality clinically meaningful real-world data using reliable sources that are trusted by both payers and innovators, where the administrative burden is minimized wherever possible.

Adoption/diffusion of CAR-T therapies once approved

A recent study carried out by PwC Strategy on behalf Gilead Sciences based on 18 interviews with CAR-T experts and representatives from large statutory health insurance companies found only a proportion of CAR-T eligible patients are receiving CAR-T therapy in Germany [53].

Cited reasons for this include:

- ▶ Different levels of knowledge about these innovative therapies;
- ▶ Lack of clarity about the definition of the patient profile;
- ▶ Nationwide heterogeneous standards and processes;
- ▶ Missing mechanisms for the management of the financial risk of the treating CAR-T centers; and
- ▶ Insufficient possibilities for scaling as well as systematic exchange.

More work is needed at the country-level in working collaboratively with multiple stakeholders to ensure that the appropriate measures are put in place to encourage wider adoption of innovation.

SOLUTIONS TO ADDRESS THE ACCESS CHALLENGES OF CAR-T THERAPIES

The ways in which innovators have attempted to overcome some of the access challenges has been to offer one of more of the following: a patient access scheme (i.e. a price discount), establishment of a registry to capture real-world evidence and/or a commitment to generate further evidence within a defined time period. In this section, we will explore some of the potential solutions that have been proposed in the grey and published literature, supplemented by the authors' own suggestions.

Clinical value assessment

Clinical outcome assessments should adopt a holistic perspective and incorporate all available evidence from as many stakeholders as possible. Assessments made at a single point in time should move towards iterative

processes of continual assessment, as more evidence becomes available on the longer-term safety and effectiveness of CAR-T therapies that emerge due to the maturity of data from clinical trials and post-authorization studies mandated by the regulatory agencies.

It is important, in order to maintain the integrity of the HTA processes, that assessments of the clinically meaningful benefits of CAR-T therapies and the quality of evidence are conducted independently to price negotiations with separate and distinct processes. There should be greater acceptance by HTA agencies of evidence generated by non-traditional methods including adaptive designs and non-comparative/single arm trials where randomization is problematic i.e.:

1. When clinical equipoise has waned – equipoise is particularly important for the ethical conduct of randomized trial and can affect feasibility and;
2. When studying treatments for late-stage disease in patients who have exhausted all effective treatment options and no 'standard' of care exists.

It is also imperative that the HTA agencies and Regulatory agencies come to an aligned position on the acceptance of surrogate/intermediate endpoints for the accelerated approval of innovative cancer therapies to avoid scenarios where one endpoint is accepted by EMA but then later challenged (or not accepted) by the HTA agencies [54,55]. Greater acceptance of clinical trial data from single arm studies supported with data from real-world/observational studies or indirect treatment comparisons and/or inclusion of meta analyses from existing trials should be encouraged, as these data generate valuable insights into the comparative safety and efficacy of CAR-T therapies.

Economic value assessment

Economic evaluations of CAR-T therapies need to focus strongly on the best available

evidence. While selective use of extrapolation techniques to examine likely overall longer-term benefits may be beneficial and appropriate in some instances, an over-reliance on long-term extrapolation of outcomes for CAR-T therapies should be avoided. A broad perspective is also warranted where inclusion of productivity gains and losses due to health care interventions are factored in. As far as the use of economic models for cost–effectiveness is concerned, improvements to existing modelling frameworks are needed to provide a more clinically meaningful representation of the disease and how it responds to CAR-T therapies. Suffice to say that alternative approaches to relying on the use of QALYs as well as the requirement to meet arbitrarily determined willingness to pay thresholds are warranted, given the considerable uncertainty around the input values and the limited value the resultant estimates offer in informing HTA decisions.

Patient & carer value assessment

Patients should have the opportunity to actively participate in all steps of the HTA process (including reassessments should they occur) e.g. priority setting, scoping, submitting evidence, commenting on draft reports and attendance at HTA appraisal meetings).

Hunter *et al.* [49] lists 4 key areas to implement recommended working methods for the inclusion of patient input into HTA processes in general (which are generalizable to CAR-T therapies):

1. Identifying and prioritizing which technologies to assess;
2. Scoping (developing a framework for an individual HTA);
3. Assessing and developing recommendations/guidelines;
4. Reviewing and disseminating HTA outcomes.

The authors consider that data on patients' experience of receiving CAR-T therapies in the clinical trial setting will be informative to decision-makers and future patients. For this reason, it should be mandated by both EMA and HTA agencies that these data should be more routinely captured in clinical trials. Finally, all types of evidence should be considered from patients e.g. qualitative interviews, videos, diaries, questionnaires, surveys, etc. [14].

Budget impact

Conversations around the likely budget impact of introducing a CAR-T therapy need to start earlier between innovators and payers. The budget impact of covering CAR-T therapies should extend beyond annual planning cycles in order to reap the potential for cost savings that these treatments offer, not only within the health system but also within society. The timely establishment of diagnosis-related groups (DRGs) has also been cited as an enabler to funding CAR-T therapies in Germany [3]. It is important that in those countries that use DRGs as the basis by which to reimburse hospitals that CAR-T therapies have been factored into these in a timely manner.

Solutions that overcome barriers facing the acceptance & implementation of innovative payment models

Alternative payment and financing strategies for cell and gene therapies may be needed to manage short-term affordability, while fairly rewarding value and providing the necessary incentives to maintain investment in future innovative therapies [28]. There are many different strategies that have been employed to manage expenditure for other types of high cost treatments. CAR-T therapies are not interchangeable – they are personalized therapies that are differentiated through distinct manufacturing processes and exhibit different

safety and efficacy profiles and outcomes. For this reason, financial agreements and tenders that focus on cost alone at the expense of outcomes, are inappropriate for CAR-T therapies and unlikely to help payers achieve ‘value-based’ outcomes for their patients.

Investment in electronic health records (EHR) systems and providing incentives to providers to capture high quality data would be a significant enabler in being able to track patient outcomes for outcomes-based reimbursement schemes for CAR-T. Outcomes-based schemes are “commercial arrangements where a treatment’s price is linked to the outcomes achieved for patients receiving the treatment in real-world clinical practice. Treatments that perform as expected and deliver pre-agreed outcomes are reimbursed at a pre-agreed price, while medicines that do not deliver on these outcomes are reimbursed at a lower price or not at all” (Cole *et al.*, 2019) [56]. If medicines exceed expectations, then a higher reimbursed price may be warranted. Table 3 list different outcome-based payment scheme categories suggested by Cole *et al.*

Coverage with evidence development schemes or outcomes-based agreements rely on the ability of the manufacturer to track the outcomes of patients in the real-world setting. CAR-T therapies lend themselves well

to outcomes-based agreements, since it is easy to identify patients in the first instance from the regulatory mandated post-authorization studies and the longer-term effectiveness of treatment is the main driver of uncertainty and these types of agreements ameliorate this (uncertainty) in the most part.

Table 4 outlines some of the outcomes-based agreements (based on publicly available sources) that have been successfully employed in some countries for the two approved CAR-T therapies [57] to enable patient access whilst at the same time addressing data uncertainty and managing financial risk.

Multi-stakeholder collaboration across Europe is critical to ensure alignment on registries used to capture data for the above regulatory studies and any additional data needed to support outcomes-based payment models for HTA agencies and payers. This will help achieve operational efficiencies reduce the administrative burden at the hospital level. What we need to avoid is a fragmented array of CAR-T datasets that differ in terms of how they define, capture and report outcomes and how they assess data quality and completeness; the latter will serve only to introduce barriers that prevent timely analyses of data to inform real-time studies of the safety, effectiveness and cost-effectiveness of CAR-T therapies in Europe.

► **TABLE 3**

Outcome-based payment scheme categories and definitions.

| Scheme category | Definition |
|---|---|
| Cost sharing arrangements | Price reduction for initial treatment cycles until it is clear whether a patient is responding to the medicine |
| Payment-by-results | Innovators reimburse the payer in full in instances where the patient does not respond to the treatment |
| Risk sharing | Innovators reimburse a proportion of the cost of the medicine for non-responders |
| Outcomes guarantees/ pay-for-performance | Innovators provides rebates, refunds or price adjustments if the medicine fails to meet pre-agreed outcome targets at the individual patient level |
| Coverage with evidence development | Access to a drug is initially provided on the condition that further population-level evidence is gathered. Based on this further evidence the payer then makes a decision whether to continue funding the treatment or not |
| Conditional treatment continuation | Payment for the continued use of a given drug is based on intermediate endpoints at the individual patient level |

Adapted from Cole *et al.* [56].

TABLE 4
 Select examples of outcomes-based payment schemes for CAR-T therapies.

| Country | Product | Description of outcomes-based scheme | Source document |
|---------|-----------|--|-----------------|
| Sweden | Yescarta® | A managed-entry agreement was negotiated at the national level which covers a refund of the cost by the manufacturer to the counties | [58] |
| Belgium | Kymriah® | Follow-up data on the response to treatment and the condition of the patient has been requested to be collected at 6 months, 12 months, 18 months and 20 months after the infusion of Kymriah® | [59] |
| Spain | Kymriah® | To address the uncertainty around the long-term efficacy and safety of Kymriah® in both indications, the following long-term and RWE generation projects are planned: A patient registry will be created; participation will be mandatory for all centers that provide Kymriah® (post-authorization study CCTL019B2401) A long-term follow-up study of patients who received Kymriah (study CCT-L019A2205B) has been requested | [60] |
| Italy | Kymriah® | There is a managed entry agreement that uses a conditional payment method (payment for outcomes), where payments are made in three instalments: at infusion and at 6 and 12-months' follow-up for responders only | [61] |
| France | Kymriah® | The Transparency Commission (TC) requested follow-up data from the JULIET trial, and data from the PAES studies and ATU, the establishment of a common register for medicinal products to collect short- and long-term efficacy and safety data, and identify predictors of treatment response (data should be collected from all eligible patients for Kymriah® in France, and not concern only patients actually treated) and the collection of clinical data of patients eligible for treatment under the post-ATU scheme | [62] |
| England | Kymriah® | Further data collection on long-term survival, post-progression survival, and immunoglobulin usage are required for funding Kymriah® through the Cancer Drugs Fund | [63] |
| Germany | Kymriah® | An outcomes-based payment model has been secured for Kymriah® where Novartis shares the risks of this arrangement by agreeing to partially reimburse these costs if the patient dies of their illness within a set period of time | [64] |

Adoption/diffusion of CAR-T therapies once approved

Authors of the CAR-T Zell-therapien in Deutschland report (2020) [53] suggest the following measures could be implemented in order to improve adoption of CAR-T therapies in routine clinical practice:

1. Clarification and creation of an innovation-friendly climate;
2. Adaptation of the qualification and financing process;
3. Scalability through centralization and creation of uniform standards;
4. Further development and application of innovative remuneration models;
5. Promotion of the exchange of practice experience (with CAR-T therapies).

CONCLUSIONS

The aim of this paper was to describe some of the challenges to value assessment of CAR-Ts in Europe and put forward potential solutions to remedy these; maintaining the principles of respecting the need to accelerate broad patient access, address affordability concerns and reward innovation to maintain a sustainable life sciences industry. We explored whether the value assessment criteria employed by HTA agencies is appropriate for CAR-T therapies, considering the unique characteristics of treatment and uncertainties in the evidence base and conclude that change is needed in this respect.

Uncertainty is inevitable if the goal of timely patient access to innovation is to be pursued. We advocate for a more systematic inclusion of evidence from patients and carers in the HTA decision-making process, a broader perspective of value to be adopted by

HTA agencies that take into account productivity gains from both patient and carers, and investment in data infrastructures to enable outcomes-based payment models.

We also maintain that an early and continuous dialogue between innovators, HTA agencies and payers is needed prior to, during and post-launch. The focus on eliciting scientific advice from regulators and HTA Agencies on the most appropriate evidence package for speedy HTA approval and adoption is insufficient by itself to ensure timely access to patient and widespread adoption.

We have highlighted the limitations of cost-per-QALY value frameworks for CAR-T in capturing productivity gains and handling uncertainty and flag the important role that outcomes-based payment models play in enabling faster access through addressing uncertainties from an HTA perspective and payer perspective. In conclusion, multi-stakeholder collaboration across Europe is critical to ensure alignment on registries used to capture data for the regulatory mandated post-authorization study commitments and any additional data needed to support outcomes-based payment models for HTA agencies and payers.

REFERENCES

- Blumenthal GM, Kluetz PG, Schneider J, Goldberg KB, McKee AE, Pazdur R. Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies. *Oncology* 2017; 22: 762–7.
- European Parliament (2007). Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2007_1394/reg_2007_1394_en.pdf
- Nguyen V, Kanaskar A, Sugarman R, Migliaccio-Walle K (2018). Valuing CAR-T therapies: Facing new challenges, fulfilling the potential. Xcenda: <https://www.xcenda.com/insights/htaq-fall-2018-valuing-car-t>
- Leech AA, Dusetzina SB. Cost-effective but unaffordable: The CAR-T Conundrum. *J. Natl Cancer Inst.* 2019; 111: 644–45.
- June CH, Sadelain M. Chimeric Antigen Receptor Therapy. *N. Engl. J. Med.* 2018; 379: 64–73.
- Kaiser Health News. Cascade of costs could push CAR-T therapy to \$1.5M per patient (2017): <https://khn.org/news/cascade-of-costs-could-push-new-gene-therapy-above-1-million-per-patient/>
- Grady D (2017). FDA approves first gene-altering leukemia treatment, costing \$475,000. *The New York Times*: <https://www.nytimes.com/2017/08/30/health/gene-therapy-cancer.html>
- Roland D, Loftus P. FDA approves pioneering cancer treatment with \$475,000 Price Tag. Novartis's Kymriah gets nod for some leukemia patients; uses body's own cells to fight cancer. *Wall Street J.* 2017.
- Privolnev Y, Webster R. CAR T-Cell Therapies In The EU5: What Can We Expect From Payers? *Cell & Gene Insight*. Guest Column | January 24, 2019: <https://www.cellandgene.com/doc/car-t-cell-therapies-in-the-eu-what-can-we-expect-from-payers-0001>
- Fiorenza S, Ritchie DS, Ramsey SD, Turtle CJ, Roth JA. Value and affordability of CAR T-cell therapy in the United States. *Bone Marrow Transplantation* 2020 (accepted for publication May 2020).
- EMA. First two CAR-T cell medicines recommended for approval in the European Union: <https://www.ema.europa.eu/news/first-two-car-t-cell-medicines-recommended-approval-european-union>
- Smith A. EMA validates Kite's CAR-T filing. *PharmaTimes*. 30 January 2020: http://www.pharmatimes.com/news/ema_validates_kites_car-t_filing_1323783
- Cook F, Slocomb T, Werner M. Regenerative medicine is here: New payment models key to patient access. *In Vivo* July/August 2018. Arm White Paper 3: https://46ax7g7nqm3di-vu13d9zsn1-wpengine.nerdna-ssl.com/wp-content/uploads/2018/07/ARM_WhitePaper3_IV1807_LRS.pdf
- Majhail NS, Chakraborty R, Shan GL, Hamilton BK, Scordo M, Sidana S. Patient-reported outcomes with chimeric antigen receptor-T cell therapy: challenges and opportunities. *Biol. Blood Marrow Transplant.* 2019; 25(5): e155–e162.
- EMA. Press Release. First two CAR-T cell medicines recommended for approval in the European Union. Development of Kymriah and Yescarta supported

- through PRIME (2008b): https://www.ema.europa.eu/en/documents/press-release/first-two-car-t-cell-medicines-recommended-approval-european-union_en.pdf. https://www.ema.europa.eu/en/documents/press-release/first-two-car-t-cell-medicines-recommended-approval-european-union_en.pdf
16. Levine BL, Kiskin J, Wonnacott K, Keir C. Global manufacturing of CAR T Cell Therapy. *Molecular Therapy. Meth. Clin. Dev.* 2017; 4: 92–101.
 17. O'Rourke B, Oortwijn W, Schuller T. Announcing the New Definition of Health Technology Assessment. *Value Health* 2020; 23: 824–5.
 18. Lewis JRR, Kerridge I, Lipworth W. Coverage with evidence development and managed entry in the funding of personalized medicine: Practical and ethical challenges for Oncology. *J. Clin. Oncol.* 2015; 34: 4112–7.
 19. Buxton MJ. Problems in the economic appraisal of new health technology: the evaluation of heart transplants in the UK. In: Drummond MF, *Economic appraisal of health technology in the European community*. Oxford Medical Publications, Oxford, UK 1987; 103–18.
 20. Lakdawalla DN, Doshi JA, Garrison LP, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care – a health economics approach: an ISPOR special task force report [3]. *Value Health* 2018; 21: 131–9.
 21. Garrison LP, Jackson T, Paul D, Kenston M. Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold. *J. Manag. Care Spec. Pharm.* 2019; 25: 793–99.
 22. IQVIA, EFPIA. Patients W.A.I.T Indicator Survey. 2019: <https://www.efpia.eu/media/554526/patients-wait-indicator-2019.pdf>
 23. EFPIA. The root cause of unavailability and delay to innovative medicines: Reducing the time before patients have access to innovative medicines. June 2020: <https://www.efpia.eu/media/554527/root-causes-unavailability-delay-cra-final-300620.pdf>
 24. Thomas M, Craddy P, Foxon G. PDG79. Was the evidence base for Yescarta and Kymriah sufficient to justify their cost and secure patient access across 5 markets? *Value Health* 2019; 22(s3): S610.
 25. Mathes T, Jacobs E, Morfeld J-C, Pieper D. Methods of international health technology assessment agencies for economic evaluations – a comparative analysis. *BMC Health Serv. Res.* 2013; 13: 371.
 26. Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. *Eur. J. Health Econ.* 2018; 19: 123–52.
 27. Zhang J, Junlong L, Ma Q, Yang H, Signorovitch J, Wu E. A review of two regulatory approved anti-CD19 CART-cell therapies in diffuse large B-cell lymphoma: why are indirect treatment comparisons not feasible? *Adv. Ther.* 2020; 37: 3040–58.
 28. Marsden G, Towse A, Pearson SD, Dreitlein B, Henshall C. Gene therapy: Understanding the Science, Assessing the Evidence, and Paying for Value. A report from the 2016 ICER Membership Policy Summit March 2017.
 29. Jonsson B, Hampson G, Michaels J, Towse A, von der Schulenburg JG, Wong O. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. *Eur. J. Health Econ.* 2019; 20: 427–38.
 30. Schuster SJ, Swoboda J, Chong EA *et al.* Chimeric antigen receptor T cells in refractory B-cell lymphomas. *N. Engl. J. Med.* 2017; 377: 2545–2554.
 31. National Institute for Health and Care Excellence (NICE). Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies: <https://www.nice.org.uk/guidance/ta567>
 32. National Institute for Health and Care Excellence (NICE). Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies: <https://www.nice.org.uk/guidance/ta559>
 33. Rudmik L, Drummond M. Health economic evaluation: important principles and methodology. *Laryngoscope* 2013; 1341–7.
 34. Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiple relapsed or refractory adult large b-cell lymphoma. *J. Clin. Oncol.* 2019; 37: 2015–9.
 35. Patel N, Farid SS, Morris S. How should we evaluate the cost-effectiveness of CAR T-cell therapies? *Health Policy Technol.* 2020.
 36. Raymakers, AJN, Regier, DA, Peacock, SJ. Modelling uncertainty in survival and cost-effectiveness is vital in the era of gene therapies: the case of axicabtagene ciloleucel. *Health Policy Technol.* 2019; 8(2): 104–104.
 37. Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, NcEwan P, Tahami Monfared AA, Yuan Y, Juarez-Garcia A, Tyas D, Lees M. Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. *ClinicoEconomics Outcomes Res.* 2018; 10: 139–54.

38. Institute for Clinical and Economic Review. Chimeric Antigen Receptor T-Cell Therapy for B-cell Cancers: Effectiveness and Value: https://icer-review.org/topics/?fwp_topic=car-t-therapies
39. National Institute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years: <https://www.nice.org.uk/guidance/ta554>
40. Scottish Medicines Consortium. tisagenlecleucel (Kymriah) full submission: <https://www.scottishmedicines.org.uk/medicines-advice/tisagenlecleucel-kymriah-fullsubmission-smc2129>
41. Scottish Medicines Consortium. axicabtagene ciloleucel (Yescarta): <https://www.scottishmedicines.org.uk/medicines-advice/axicabtagene-ciloleucel-yescarta-resubmission-smc2189>
42. Scottish Medicines Consortium. tisagenlecleucel (Kymriah) resubmission: <https://www.scottishmedicines.org.uk/medicines-advice/tisagenlecleucel-kymriah-resubmission-smc2200>
43. Garrison JP, Neumann PJ, Wilke RJ, Basu A, Danzon PM, Doshi JA, Drummond MF, Lakdawalla DN, Pauly MV, Phelps CE, Ramsey SD, Towse A, Weinstein MC. A Health Economics Approach to US Value Assessment Frameworks – Summary and Recommendations of the ISPOR Special Task Force Report [7]. *Value Health* 2018; 161–5.
44. Clay E, Kharitonova E, Ansari-pour A, Aballea S, Toumi M. Are specific methodological frameworks required for the economic evaluation of gene therapies? PHP102. *Value Health* 2018; 21: S1–S481
45. Health Technology Assessment international (HTAi). Patients’ perspectives in health technology assessment: a route to robust evidence and fair deliberation. *Int. J. Technol. Assess Health Care* 2010; 26: 334–40.
46. Health Technology Assessment international (HTAi). Good Practice Examples of Patient and Public Involvement in Health Technology Assessment. Report, HTAiC 2015: https://htai.org/wp-content/uploads/2018/02/Good_Practice_Examples_Feb_2015.pdf
47. Gauvin FP, Abelson J, Giacomini M, Eyles J, Lavis JN. “It all depends”: conceptualizing public involvement in the context of health technology assessment agencies. *Soc. Sci. Med.* 2010; 70: 1518–26.
48. European Patients’ Forum (EPF). Patient Involvement in Health Technology Assessment in Europe. Results of the EPF Survey. Report, EPF, Brussels 2013: <https://www.eu-patient.eu/globalassets/projects/hta/hta-epf-final-report2013.pdf>
49. Hunter A, Facey K, Thomas V, Haerry D, Warner K, Klingmann I, May M, See W. EUPATI Guidance for Patient Involvement in Medicines Research and Development: Health Technology Assessment. *Policy Practice Rev.* 2018; 5: 231.
50. Lee J, Kitchen H, Fletcher-Louis M. The role of patient-reported outcomes and patient engagement in health technology assessments and reimbursement decision making in 10 countries. *Value Health* 2017; 20: A693.
51. Messina AJ, Andrianov V, Mazzoleni D, Vidal-Fisher L. Emerging trends and utilization of patient-reported outcomes (PROs) in clinical trials of chimeric antigen receptor (CAR) T-cell therapies. *J. Clin. Oncol.* 2020; 38(15 Suppl.) e19142.
52. Williamson S (2019). Implementing CAR T cell therapy in the NHS. NHS England: <https://www.theattcnetwork.co.uk/wp-content/uploads/2019/06/Steve-Williamson-Commissioning-for-Advanced-Therapy-Medical-Products-NHS-England-Perspective.pdf>
53. CAR-T Zell-therapien in Deutschland. Übersicht über politische Handlungsfelder für besseren Patienten-zugang. June 2020: https://www.gilead-dialog.de/wp-content/uploads/2020/05/Strategy-und-Gilead-Sciences_CAR-T-Zell-therapien-in-Deutschland.pdf
54. Davis C, Naci H, Gurpinar E *et al.* Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European medicines agency: retrospective cohort study of drug approvals 2009-13. *BMJ* 2017; 359: j4530.
55. Sola-Morales O, Volmer T, Mantovani L. Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs. *J. Market Access Health Pol.* 2019; 7.
56. Cole A, Cubi-Molla P, Pollard J, Sullivan SD, Sussex R, Lorgelly P (2019). Making outcomes-based payment a reality in the NHS: https://www.cancerresearchuk.org/sites/default/files/obp_final_report_.pdf
57. Jorgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. *J. Market Access Health Pol.* 2020; 8:1.
58. Regionernas samverkansmodell för läkemedel: [https://janusinfo.se/download/18.2e2250bc-16d03ce47629547/1567756961040/Axikabtagenciloceucel-\(Yescarta\)-190906.pdf](https://janusinfo.se/download/18.2e2250bc-16d03ce47629547/1567756961040/Axikabtagenciloceucel-(Yescarta)-190906.pdf)
59. INAMI: <https://ondpanon.riziv.fgov.be/SSPWebApplicationPublic/fr/Public/ProductSearch>

60. Informe De Posicionamiento Terapéutico: <https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-tisagenlecleucel-kymriah-LAL-LCGB.pdf>
61. Valutazione Dell'Innovatività: https://www.aifa.gov.it/documents/20142/966686/KYMRIAH_13729_DLBCL_v1.0.pdf
62. HAS: https://www.has-sante.fr/upload/docs/application/pdf/2018-12/kymriah_ldgcb_pic_ins_avis3_ct17238.pdf
63. Cancer Drug Fund: <https://www.nice.org.uk/guidance/ta567/resources/managed-access-agreement-march-2019-pdf-6718513213>
64. GWQ: https://www.gwq-serviceplus.de/aktuelles/presse/2019-03-06-pm-novartis-gwq-car-t-zelltherapie_5177

AFFILIATIONS

Clare L Hague

Author for correspondence
Honorary Lecturer & Academic Supervisor, Department of Health Sciences and Medicine, University of Lucerne, Switzerland

Martin J Price

Vice President, Health Economics, Market Access & Reimbursement (HEMAR), EMEA Region, Janssen Pharmaceuticals (a Johnson & Johnson Company)
chague@its.jnj.com

AUTHORSHIP & CONFLICT OF INTEREST

Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgements: We would like to acknowledge the following Janssen employees that have contributed to characterizing the challenges and proposing the solutions described within this manuscript: Mike Spencer, Adrian Griffin, Satish Valluri, Martin Vogel, Kimberly Prior, Stacey Hickson, Ali Azough, Christina Vandoros, Jennifer Lee, Jamie Garside, Ahmed ElSada, Aleksandra Krygiel-nael, Arne Bartol, Daniel Wirth, Patrick Laroche, Joerg Mahlich, Jonathan Pentel, Amelie Scheffler, Blanca Gros Otero, Catharina Hjortsberg, Michel van Agthoven, Thomas Willert, Barbara Paleiko, Kristen van Nimwegen, Trevor Bacon, Yoann Rocaud, Alla Uhrlandt and Joerg Tomczkowski.

Disclosure and potential conflicts of interest: Clare Hague and Martin Price are employees of Janssen Pharmaceuticals.

Funding declaration: The authors received no financial support for the research, authorship and/or publication of this article.

ARTICLE & COPYRIGHT INFORMATION

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Attribution: Copyright © 2020 Hague C & Price M. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

Article source: Invited; externally peer reviewed.

Submitted for peer review: Jun 18 2020; **Revised manuscript received:** Aug 11 2020; **Publication date:** Aug 25 2020.

MARKET ACCESS: EVOLVING
COMMERCIALIZATION TRENDS & STRATEGIES

COMMENTARY

The heart of market access: opportunities and challenges for cell and gene therapy development for orphan and prevalent cardiovascular diseases

Faraz Ali

Heart disease is the leading cause of death globally, and there is a need for better medicines. No cell and gene therapies (CGTs) for heart disease are approved, but a new generation of companies are advancing promising science. The pipeline of CGTs is mostly focused on *in vivo* AAV-based therapies for prevalent cardiovascular (CVD) conditions, in contrast to broader trends favoring an initial focus on rare diseases seen in other therapeutic areas. CGTs for orphan heart disease indications have relevant benchmarks that could be used to justify the value and price for a one-time, potentially curative therapy. Significant challenges stand in the way of the development, approval, pricing, and adoption of even highly effective CGTs for prevalent CVD indications. Overcoming these will require scientific breakthroughs; heavy investment in CGT manufacturing technology and capacity; commercial and financial sophistication; and a focus on the needs of patients.

Cell & Gene Therapy Insights 2020; 6(7), 1141–1153

DOI: 10.18609/cgti.2020.124

A HEART-BREAKING INTRODUCTION

Heart disease exacts a tremendous toll on global human health and is the leading cause of death in the world, more than all oncology combined [1]. In the USA, >30 million adults are diagnosed with heart disease (or 12% of all adults), and an adult dies from a cardiovascular (CVD)-related health condition such as a heart attack every 40 seconds, a gruesome statistic that translates to 31% of all US deaths each year [2,3]. The picture is equally bleak at the other end of the age spectrum, as ~35,000 children are born in the USA every year with congenital heart disease (CHD), and CHD is the leading cause of birth defect-related morbidity and mortality [4-6]. While standards of care have improved with time, it is not keeping up; recent analysis has shown that after decades of reduction in the mortality rate due to heart failure, it started to increase again during the last decade [7-9]. And while there are >250 known genetically defined cardiomyopathies and monogenic disorders where the primary source of morbidity and mortality involves the heart, there are almost no approved products that target the underlying cause of such diseases [10].

There is clearly a need for improved treatments. Unfortunately, attempts at developing novel cell and gene therapies (CGTs) for heart disease have not been successful to date. Much effort was devoted to regenerative medicine approaches using autologous or allogeneic cell sources, but after >150 clinical studies involving thousands of patients over the last 2 decades those efforts have mostly ended in failure, and in some cases, scandal [11,12]. Of the original industry-driven cell therapy efforts, Revascor™ from Mesoblast – allogeneic mesenchymal precursor cells (MPCs) cell therapy for advanced chronic heart failure – is one of the few still ongoing and showing some promise in late stage trials [13,14].

There have been far fewer attempts at gene therapy for heart disease. The most well-known effort was advanced by Celladon, a company founded in 2000 to evaluate a one-time,

intracoronary infusion of the gene therapy agent Mydicar® (AAV1 to deliver SERCA2a). After promising pre-clinical and early clinical results, this effort was discontinued in 2015 after an unsuccessful Phase 2b study (CUPID 2) [15]. Celladon was sold in March 2016.

HEART DISEASE GENE & CELL THERAPY VERSION 2.0

Soon after Celladon conceded defeat, a new crop of biopharma innovators emerged to advance the next generation of CGTs for heart disease. **Table 1** captures important activities – company formation, financings, clinical and regulatory milestones – associated with a selected list of such companies in chronological order the last 4 years, starting with the founding of Tenaya Therapeutics in 2016.

Tenaya is advancing first-in-class product candidates from three separate platforms – Cellular Regeneration, Gene Therapy, and Precision Medicine. The Gene Therapy platform uses AAV vectors for the targeted delivery and expression of therapeutic payloads to specific cells in the heart, with an initial focus on the treatment of genetic cardiomyopathies. The Cellular Regeneration platform uses adeno-associated virus (AAV) vectors to deliver proprietary combination of transcription factors that can drive *in vivo* reprogramming of resident cardiac fibroblasts into cardiomyocytes, with an initial focus on chronic heart failure following a myocardial infarction. The Precision Medicine platform uses isogenic iPSC-derived cardiomyocytes as human disease models to identify and validate new heart failure targets and to screen for therapeutic compounds – including gene therapies and small molecules – with an initial focus on genetically-defined dilated cardiomyopathies (DCMs).

As **Table 1** reveals, most of these CGT companies are using AAV-based approaches where the target organ is the heart. It is beyond the scope of this article to consider the scientific merit of the different approaches represented by these companies. However, it is worth

▶ **TABLE 1**

Selected companies advancing cell or gene therapies for cardiovascular disease.

| Company | Modality | Target heart disease indication | Target organ | Population size | Recent milestones | Date |
|------------------------|--------------------------|--|-------------------------|-------------------------------|---------------------------------|--------------|
| Tenaya Therapeutics | Gene therapy (AAV) | Genetic HCM Genetic DCM Ischemic heart failure | Heart Heart Heart | Orphan Orphan Prevalent | Founded | 2016 |
| BlueRock Therapeutics | Engineered cell therapy | Ischemic heart failure | Heart | Prevalent | Founded Bayer acquisition | 2016 2019 |
| REGENXBIO | Gene therapy (AAV) | Familial hyper-cholesterolemia (FH) | Liver | Orphan | First patient dosed | 2017 |
| Renova | Gene therapy (Ad5) | HFrEF | Heart | Prevalent | Fast track designation | 2017 |
| Xylocor | Gene therapy (Ad) | Refractory angina | Heart | Prevalent | Founded First patient dosed | 2018 2020 |
| Sana Biotechnology | Engineered cell therapy | Ischemic heart failure | Heart | Prevalent | Founded | 2018 |
| Precigen | Gene therapy (non-viral) | Heart failure | Heart | Prevalent | First patient dosed | 2018 |
| Verve Therapeutics | Gene therapy (LNP) | Coronary artery disease (CAD) | Liver | Prevalent | Founded Series B | 2019 2020 |
| Renovacor | Gene therapy (AAV) | Genetic DCM | Heart | Orphan | Founded | 2019 |
| DiNAQOR | Gene therapy (AAV) | Genetic HCM | Heart | Orphan | Founded BioMarin partnership | 2019 2020 |
| Rocket Pharmaceuticals | Gene therapy (AAV) | Danon disease | Heart | Orphan | First patient dosed | 2019 |
| AskBio | Gene therapy (AAV) | Congestive heart failure (CHF) | Heart | Prevalent | First patient dosed | 2020 |

observing that while many have an early focus on orphan indications, a majority have an initial focus on prevalent indications (with Tenaya Therapeutics unique in its explicit pursuit of CGTs for both orphan and prevalent heart disease indications in parallel).

This reflects a broader trend: of the >1000 clinical studies evaluating regeneration medicines and advanced therapies, 45 are focused on cardiovascular indications, of which the majority are for prevalent forms of heart disease [16]. A recent analysis more specifically of *in vivo* gene therapies programs revealed that ~75% were focused on rare indications; of the remaining 25% focused on prevalent indications, cardiovascular programs were disproportionately represented, with programs intended to address atherosclerosis, coronary artery disease, angina, peripheral arterial disease, atrial fibrillation, and heart failure [17].

This insight is intriguing. In almost every other therapeutic area, the initial focus of

CGTs has been on orphan conditions. Early clinical, regulatory, and commercial success in rare diseases has provided the necessary validation and risk reduction required to consider pursuing CGTs for more prevalent indications. The field of heart disease appears to be unique in that the pursuit of CGTs for prevalent conditions has not been de-risked by prior success in rare diseases.

These insights beg the question: what kind of payer environment can the current generation of CGT companies focused on heart disease expect (if and) when their therapies are approved?

CGT VALUE, PRICING & REIMBURSEMENT, MARKET ACCESS CONSIDERATIONS

Debates about the price and market access for CGTs have been raging since before

Glybera® – the first AAV-based *in vivo* gene therapy approved in West in 2012 – broke a conceptual barrier by setting the price for their one-time therapy at €1MM. The debate has since only intensified with commensurate and increasing high prices for subsequently approved CGT therapies including Luxturna® (\$0.85MM) and Zolgensma® (\$2.1MM). Before receiving a Complete Response Letter from the FDA, BioMarin had suggested the price for Roctavian™ – a one-time gene therapy for Hemophilia A – would be around \$3MM, which would have made it one of the most expensive therapies in the world.

Debates about the appropriate value and price for CGTs for heart disease will also not be straightforward. The specifics will inevitably vary between products intended for orphan heart disease indications vs for more prevalent cardiac indications.

SCENARIO 1: CGTS FOR ORPHAN HEART DISEASE INDICATIONS

If a potentially curative, one-time CGT for a rare and severe genetic heart disorder was approved, there are several benchmarks that biopharma companies behind such a product could turn to support the value of their therapy and to attempt to justify a high, one-time price to recoup their investment. These benchmarks are captured in [Table 2](#), and described below.

Heart transplants

Heart transplants are the only existing ‘curative’ therapy for individuals experiencing end-stage heart failure, whether due to a rare genetic disease or due to more traditional causes of heart disease associated with age and lifestyle. These procedures are very rare – mainly due to a severely limited supply of donor hearts – with only ~3500 procedures performed in the USA in 2019 [18]. At \$1.6MM+ in total billed charged per procedure, heart transplants are also one of the

most expensive medical treatments of any kind current covered by payers [19]. Long-term outcomes are variable, particularly for children who may require multiple transplants over their lifetime as they grow up. A CGT that could replace the need for a heart transplant and/or that had a magnitude of effect commensurate with a heart transplant with fewer long-term side effects would be well-positioned to use that as a justification for value – and therefore, price – that is similar or higher, and that could still be considered cost-effective.

LVADs

Implantation of left ventricular assist devices (LVADs) is the only option available to patients with end-stage heart failure who are not able to obtain a heart transplant. Data supports improved survival and quality of life, but these procedures are not considered cost-effective [20]. The total cost of a LVAD can be in the \$250K–300K range when accounting for both the cost of the surgery and the device [21,22]. In situations where the LVAD provides a bridge to a heart transplant, the cost of the LVAD will be additive to that of the transplant. Long-term outcomes are variable and there are substantially increased lifetime costs because of frequent readmissions and costly follow-up care, including LVAD replacements. A CGT that could replace the need for a LVAD or that had a magnitude of effect and safety profile superior to several rounds of LVAD replacements would be well-positioned to use that as a justification for value – and therefore, price – in the \$0.5MM–\$1MM range or higher, and that could still be considered cost-effective.

Chronic therapies for orphan heart disease

Only a few therapies have been developed for orphan disease where the source of morbidity and mortality is primarily due to the heart.

Of the more than 770 orphan therapies approved, only an estimated ~3% were for cardiac indications [23]. The most relevant example is the pair of therapies Vyndaquel® and Vynda-max™ (both from Pfizer) that were approved in recent years for transthyretin amyloid cardiomyopathy (ATTR-CM), an ultra-orphan genetic cardiomyopathy with less than 5K estimated patients eligible for treatment in the USA [24]. The annual cost for this lifetime therapy is approximately \$225K/year [25]. A biopharma innovator commercializing an approved gene therapy for a genetic cardiomyopathy would make the case that a one-time, potentially curative therapy should be valued at levels similar to 3–5 years of therapy of chronic therapy for a similarly sized indication. Such a logic could translate to a price of \$0.7MM–\$1.1MM. It is worth acknowledging that the logic of this argument would not be as convincing to a payer or a Health Technology Assessment (HTA) agency as would be in the case if the gene therapy was truly displacing an expensive chronic therapy (e.g. as is the case for CGTs under development for hemophilia A and B, or for lysosomal storage disorders like MPS I, MPS II, and Pompe where the standard of care involves high cost protein replacement therapies).

Non-cardiac gene or cell therapies

Approved therapies for non-cardiac orphan diseases mentioned earlier are priced in the \$1MM–\$2MM range. It could be reasonable to assume that a future gene or cell therapy approved for a rare heart disease will follow the commercial and market access playbook already established by similar products for non-cardiac orphan indications. Such products would of course not be accepted by payers and HTA agencies as direct comparators for cost or value for a cardiac orphan disease product. But the fact that such agencies have increasingly had to consider and adopt value frameworks and innovative payment models (such as annuities and risk-sharing agreements) for other gene and cell therapies for

orphan conditions presumably better prepares them to engage in such discussions with the biopharmaceutical innovators in **Table 1** in the coming years.

Taken together, this suggests that CGTs for orphan heart disease could strive for prices in the \$0.5MM–\$2MM range, presuming high and durable efficacy and an overall strong health evidence and outcomes research (HEOR) package that includes analysis on cost offsets and comparative effectiveness vs relevant benchmarks.

SCENARIO 2: CGTS FOR PREVALENT HEART DISEASE INDICATIONS

The frame of reference changes dramatically for the potential value proposition, price, and adoption of CGTs for more prevalent heart disease indications. The challenges fall into three broad categories:

High product performance expectations & regulatory uncertainty

- ▶ Cardiovascular drug development has mostly been the realm of large outcome studies where a survival benefit must be demonstrated over and above standard of care, and where there is very low tolerance for safety risks. Endpoints focused on functional improvements – such as ejection fraction (EF), 6-minute walk tests (6MWT) – alone have generally not been acceptable for FDA approval. This translates to a need for very large, long, and expensive randomized and placebo-controlled clinical studies. To put this in perspective, one report found that the average size of a clinical study used to support recommendations for heart failure treatments involved more than 2,300 patients, with one study including as many

8,400 patients [26]. Studies for therapies intended to treat diabetes may require very safety trials involving 5,000–15,000 patients to rule out cardiovascular risk [27].

- ▶ This phenomenon at least in part explains why drug development in cardiovascular disease has been so challenging. Between 2000 and 2009, Food and Drug Administration (FDA) approvals for new cardiovascular drug therapies declined by approximately 33% compared with the prior decade [28]. Several studies have determined that the overall probability of successful drug development from Phase I through commercial launch is in the 4–7% range for CVD, among the lowest of all therapeutic areas [29,30]. A recent analysis demonstrated that, on average, biopharmaceutical companies spent \$1B in clinical development per cardiovascular product approval, the highest ratio compared to any other therapeutic area [31]. Some experts believe that “clinical trials in cardiovascular medicine have grown in size, scope, and complexity ... [resulting in] shifts away from the cardiovascular arena by some pharmaceutical companies” [32].
- ▶ The FDA – acknowledging these concerns – issued draft guidance on endpoints for drug development for heart failure in 2019 “to make it clear that an effect on symptoms or physical function, without a favorable effect on survival or risk of hospitalization, can be a basis for approving drugs to treat heart failure”. Unfortunately for CGTs, this draft guidance also makes clear that “drugs with novel mechanisms of action are more likely to require mortality data” [33].

Low cost benchmarks for standard of care treatments

- ▶ First line therapies for heart failure has mostly been the realm of generic

small molecules, including angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), beta blockers (BBs), aldosterone antagonists (AldA), and diuretics [34].

These medications are very well accepted as safe and effective, with proven long-term survival benefits. They are also very inexpensive. One of the most widely prescribed ACEi drugs (enalapril) has an annual cost of less than \$500 per year, and this combination of generic first line therapies has a collective annual cost less than \$2,000 per year [35,36]. These therapies are considered very cost effective, and in some scenarios these medications save costs (i.e. where heart-failure patients’ lives were prolonged at lower costs to the healthcare system) [37].

High price sensitivity

- ▶ In addition to being the leading cause of death, heart failure is one of the largest and most expensive categories for payers. The USA spends \$317 billion per year on CVD (including heart disease and stroke) – or nearly 17% of all US healthcare spending – representing the most expensive category of chronic diseases to treat [38]. The total direct and indirect costs of heart failure alone is expected to increase to \$70 billion by 2030 [39]. This makes it a therapeutic area of very high focus for cost control for both private and public payers.
- ▶ When genetics or congenital defects is not the underlying cause, then heart failure is most common in individuals aged 65 or older, as aging can weaken the heart muscle, and older people also may have had diseases for many years that led to heart failure. This means that most heart failure patients in the USA are covered by Medicare, the primary public option.

Indeed, heart failure is a leading cause of hospital stays among people on Medicare [40]. Many older adults live on an average income of less than \$25,000 per year, and therefore are most price sensitive and less able to afford out-of-pocket (OOP) costs and co-pays associated with essential medicines. The effect of Medicare beneficiary price sensitivity on product utilization has been well documented, with one study demonstrating that even a \$10 increase in monthly premiums translated to measurable differences in the market share of a plan [41,42].

LESSONS LEARNED FROM RECENT PRODUCT LAUNCHES FOR PREVALENT CVD INDICATIONS

The experience of the most recent product launches intended for broad use in prevalent heart disease indications – also captured as relevant cost benchmarks in Table 2 – are illustrative of the challenges that new CGTs in this category may encounter in the future:

PCSK9i therapies for hypercholesterolemia

Repatha® (Amgen) and Praluent® (Sanofi/Regeneron) were both approved in 2015 and launched at a price of \$14,000 per year. Consensus sales estimates for peak sales were greater than \$3 billion per year for each therapy [43,44]. But insurers imposed strict controls against their adoption; one study found that less than 50% of patients who were prescribed a PCSK9i received insurance approval for the therapy [45]. An analysis by the Institute for Clinical and Economic Review (ICER) in 2017 suggested Repatha® could not be considered cost effective unless priced 80–90% lower i.e. in the range of \$1,700–2,200 per year [46]. Amgen riposted with their own cost–effectiveness analysis suggesting that number was more like \$9,700; a number higher than ICER’s but that nonetheless undercut their own sales price [47]. The same year, Amgen announced a first-of-its-kind risk-sharing agreement for Repatha® with Harvard Pilgrim Healthcare under which Amgen offered a rebate for the cost of Repatha® for an eligible patient who has a heart attack or stroke while on the product. However, this appears to have been a one-off

TABLE 2 Potential comparators for cell or gene therapies for heart disease.

| Therapy | Modality | Indication | Provider | US price |
|---------------------------------------|---|---|---|---|
| Zolgensma® | Gene therapy (<i>in vivo</i> AAV) | Spinal muscular atrophy (CNS) | Novartis/AveXis | \$2,100,000 (one time) |
| Heart transplant | Surgical procedure | End-stage heart failure | Heart transplant centers | \$1,670,000 (per procedure) |
| Left ventricular assist device (LVAD) | Implantable device + surgical procedure | End-stage heart failure | Device: Medtronic, Abbott, etc. Surgery: heart failure Clinics | Device: \$80,000–90,000 (per procedure) Surgery: \$175,000 (per procedure) |
| Vyndaqel®/Vyndamax™ | Small molecule | Transthyretin amyloid cardiomyopathy (ATTR-CM) | Pfizer | \$225,000/year |
| Repatha®/Praluent® | Monoclonal antibody (PCSK9i) | Patients with high LDL that cannot be controlled by statins | Amgen/Sanofi-Regeneron | \$5,850/year |
| Entresto® | Small molecule (ARNi) | Patients with chronic heart failure and reduced ejection fraction | Novartis | \$4,500/year |
| Enalapril | Small molecule (ACEi) | Patients with high blood pressure and/or congestive heart failure | Multiple (generic) | <\$500/year |

agreement as no other such agreements were announced [48]. The results of a large outcome study involving more than 27,000 patients demonstrated that Repatha® significantly reduced major adverse cardiovascular events (MACE) but unfortunately did not move the needle with payers and did not increase product adoption [49]. Amgen and Sanofi/Regeneron have been locked in a price war, with both products taking at 60% price reduction in 2018, bringing their prices to the \$5,000–6,000 range [50]. Yet despite the positive clinical data, cost–effectiveness analysis, willing to share risk, and competitive forces at work, sales for both products have only modestly improved, and expectations for peak sales are dramatically less than they were 5 years ago.

ARNi therapy for heart failure with reduced ejection fraction (HFrEF)

Entresto® (Novartis) was also approved in 2015 and launched at a list price of \$4,500 per year [51]. Analysis by ICER was mostly supportive of Entresto®'s value at this price, suggesting a modest 9% decrease would make it cost effective; however, the same analysis also focused on a potentially very high budget impact of \$15 billion over a 5-year horizon if Entresto® uptake was 'unmanaged' [52]. Many payers indeed imposed control on the adoption of this product, including use of clinical criteria (e.g. cutoffs for treatment eligibility based on ejection fraction values) that were not supported by available clinical evidence [53]. To support adoption, Novartis entered into risk-sharing agreements with major insurers including Cigna and Aetna in 2016, but other payers and pharmacy benefit managers (PBMs) have been openly skeptical of such arrangements [54]. It has also emerged more recently that senior citizens who are on a Medicare Part D plan may have to pay \$1600 year in OOP costs for Entresto®, making it unaffordable for some [55].

It is informative to note the differences in the way that payers approach the budget impact of therapies for prevalent vs orphan disorders. Pfizer's Vyndaqel® for ATTR cardiomyopathy

is intended for an orphan heart disease, and by some estimates annual global sales could grow to \$1.5 billion in 2021 and to \$3.5 billion by 2025 [56]. At these levels, the budget impact of Vyndaqel® would be comparable to Entresto®'s \$1.7 billion in sales in 2019 and would be greater than the <\$1 billion in combined sales for Repatha® and Praluent® in 2019 [57–59]. While payers will undoubtedly try to impose some restrictions on the use of Vyndaqel®, those efforts will likely not rise to the level experienced by Repatha®, Praluent®, and Entresto®. This is possibly because the long-term budget exposure of unmanaged treatment is perceived to be far higher with products intended for more prevalent populations, even for cost-effective therapies. This is likely to be true for CGTs as well.

The clinical, regulatory, and commercial considerations described in this section represent important challenges at multiple level for the biopharmaceutical innovators advancing CGTs for prevalent heart disease conditions:

- ▶ Most, if not all, are working on product candidates with novel mechanism of actions (MOAs) that may require large outcome studies where a survival benefit must be demonstrated and where there will be very low tolerance for safety risks.
- ▶ Such clinical studies are likely to be long and expensive and will require considerable long-term financing needs from private and public investors.
- ▶ The expenses involved with such studies may be dramatically higher vs historical benchmarks considering the uniquely high cost of goods (COGs) for CGTs that can be in the range of hundreds of thousands of dollars for a single dose using current technology (vs pennies per dose of a small molecule) [60].
- ▶ The volume of drug required to support larger Phase 2 and registration clinical

studies (and eventual commercial supply) will be orders of magnitude larger than what is required for orphan diseases. This would stretch the limits of the current manufacturing paradigm of dependence on CDMOs, many of which are already facing severe limitations on capacity to support the growth in CGTs for orphan drug development [61].

- ▶ Even if the COGs of CGTs were to decrease an order of magnitude from where they are today (i.e. in the range of tens of thousands of dollars), that may still translate to unacceptably high prices for such products vs generic small molecules that currently represent the standard of care. Such products may be unlikely to be considered cost-effective by ICER in the USA (or by HTAs ex-US).
- ▶ Considering the high and growing prevalence of heart failure, the budget impact of even modestly priced, cost-effective CGTs would be high and would face challenges to broad adoption by payers.

One limitation of the preceding analysis is that the data presented are US-centric. However, recommendations for pharmacological interventions to prevent and to treat heart failure are generally consistent between the US and EU [62]. The lower cost of health-care spending and the higher sensitivity to drug prices outside the US is very well-documented. Therefore, it is likely that the value, pricing, and market access considerations documented here will be commensurately challenging ex-USA for novel CGTs intended for prevalent heart diseases.

PRESCRIPTIONS FOR CGT SUCCESS

Several recommendations follow from this analysis for biopharmaceutical companies contemplating development of innovative CGTs for heart disease:

Product selection

An initial product focus on orphan heart diseases may overall make more strategic sense for most companies, whether entrepreneurial start-ups or established biopharmaceutical companies, where technical hurdles and market access barriers are likely considerably lower vs for more prevalent heart conditions.

Product design

It is important to continue to invest in innovation to improve the risk-benefit ratio of CGTs intended for prevalent heart disease. What this means for AAV-based gene therapy products in particular:

- ▶ The field needs capsids with higher tropism for the heart (to reduce dose levels and COGs) and that also de-target other organs, especially the liver (to improve potential safety profile).
- ▶ While promoters already exist to limit the expression of proteins to the heart (e.g. for cardiomyocytes), these need to be improved to enable higher expression per cell, and to work in other abundant cell types (e.g. cardiac fibroblasts).
- ▶ There also needs to be more exploration of the use of delivery devices (e.g. direct injection and/or infusion-based catheters) that can provide therapy closer to where it is needed vs traditional IV infusion-based therapies. This can improve efficacy; reduce the potential off-target safety concerns associated with systemic administration; and lower the overall product (and COGs) required of a one-time dose.

Product profile

Gene and cell therapies for prevalent conditions must be prepared to demonstrate high

overall efficacy – including an overall survival benefit – on top of SOC therapies, plus very strong safety profiles. Companies working on such product candidates need to start with that end in mind even early in drug development. This needs to be formally factored into early thinking on Target Product Profiles (TPPs) and needs to be explored during non-clinical development.

Development strategy

Depending on the specific target and MOA of the gene or cell therapy product candidate, it may be advisable to first establish the efficacy and safety profile in a relevant rare condition or in a well-defined sub-population of heart disease patients first before expanding to more prevalent conditions. Such a strategy has potential to reduce development time and costs, and to ‘de-risk’ the investment in large outcome studies.

Manufacturing

For CGTs focused on prevalent heart conditions, it is critical for the field to invest in manufacturing technology breakthroughs and infrastructure early in drug development in order to reduce reliance on CDMOs, to achieve COGs at commercial scale that is dramatically lower than current benchmarks, to support commercially viable and societally responsible prices, and to ensure reliably consistent global supply.

Commercial models

CGT companies need to be prepared to address the price-sensitivity of future customers. While that is true in general, it is especially the case for products intended for prevalent heart diseases. Product innovation may need to be paired with innovative financial models to share risk and/or to address budget impact [63].

Partnerships

Strategic partnerships with large biopharmaceutical companies are already an area of focus for many biotech start-ups. Some early innovators in the field of gene and cell therapy – including Spark Therapeutics and bluebird bio – have demonstrated it is possible to become a fully-integrated company and commercialize their first products intended for rare diseases on their own. However, for products intended for prevalent heart disease indications, strategic partnerships with larger biopharmaceutical companies who have the experience with cardiovascular outcome studies; the resources to invest in manufacturing infrastructure; and the commercial know-how to navigate the complexity of global value, pricing and reimbursement and market access considerations may be essential for product launch and adoption.

CONCLUSION

Biopharmaceutical companies are often guilty of taking a ‘build it and they will come’ approach towards drug development for innovative therapies. This paper makes the case for a very different approach to drug development for CGTs for heart disease, particularly for therapies intended for prevalent heart conditions, where most biopharma innovator efforts appear to be currently focused.

As an emerging leader in next-generation gene therapies, regenerative medicines, and precision-medicine approaches for both rare and prevalent heart disease conditions, Tenaya Therapeutics has already been expending thought, effort, and investment in many of the areas described above, years before starting first-in-human studies. This is consistent with our mission to discover, develop, and deliver potential curative therapies that target the underlying causes of heart failure. We are motivated by a vision to transform the lives of individuals and families fighting heart disease and will keep the needs of these patients at the forefront as we navigate the challenges ahead and create the treatments that these patients urgently need.

REFERENCES

- WHO, The top 10 causes of death: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>
- CDC Fast stats, Heart disease: <https://www.cdc.gov/nchs/fastats/heart-disease.htm>
- Top 10 Most Expensive Chronic Diseases for Healthcare Payers: <https://healthpayerintelligence.com/news/top-10-most-expensive-chronic-diseases-for-healthcare-payers>
- Hoffman JIE, Kaplan S. The incidence of congenital heart disease. *J. Am. Coll. Cardiol.* 2002; 39(12): 1890–900.
- Tennant PWG, Pearce MS, Bythell M, Rankin J. 20-year survival of children born with congenital anomalies: a population-based study. *The Lancet* 2010; 375(9715): P649–56
- Vetter VL, Covington TM, Dugan NP *et al.* Cardiovascular deaths in children: General overview from the National Center for the Review and Prevention of Child Deaths. *Am Heart J.* 2015; 169(3): 426–437.e23
- Selim A, Zolty R, Chatzizisis YS. The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going? *Pharmacol. Ther.* 2017; 178: 67–82.
- Sidney S, Go AS, Jaffe MG *et al.* Association Between Aging of the US Population and Heart Disease Mortality From 2011 to 2017. *JAMA Cardiol.* 2019; 4(12): 1280–6.
- McClellan M, Brown N, Califf RM, Warner JJ. Call to Action: Urgent Challenges in Cardiovascular Disease: A Presidential Advisory From the American Heart Association. *Circulation* 2019; 139: e44–e54.
- Tenaya analysis on file.
- He L, Nguyen NB, Ardehali R, Zhou B. Heart Regeneration by Endogenous Stem Cells and Cardiomyocyte Proliferation. *Circulation* 2020; 142: 275–91.
- Tenaya analysis of clinical studies as of October 2019 on file.
- Borow KM, Yaroshinsky A, Greenberg B, Perin EC. Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure. *Circulation Res.* 2019; 125: 265–81.
- Mesoblast's Phase 3 trial of revascor in advanced chronic heart failure surpasses the number of primary endpoint events for trial completion: <http://investorsmedia.mesoblast.com/static-files/ed48adf6-b47c-490c-bf3b-8dd7d272915f>
- Greenberg B. Gene therapy for heart failure: time to go back to the drawing board. *Eur. J. Heart Fail.* 2017; 19(11): 1542–4.
- Advancing Innovation During COVID-19: <https://alliancerm.org/sector-report/h1-2020-report/>
- In Vivo* Gene Therapy: Personalizing The Ultra-Rare And Scaling-Up For Chronic Disease. BioFuture Virtual Salon Series: https://cello-healthbioconsulting.com/wp-content/uploads/2020/07/Gene-Therapy-Webinar-Slides-7.29.2020presented_1.pdf
- UNOS transplant trends: <https://unos.org/data/transplant-trends/>
- 2020 U.S. organ and tissue transplants: Cost estimates, discussion, and emerging issues: <https://www.milliman.com/en/insight/2020-us-organ-and-tissue-transplants>
- Shreibati JB, Goldhaber-Fiebert JD, Banerjee D, Owens DK, Hlatky MA. Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure. *Clin. Res.* 2017; 5(2): 110–9.
- HeartMate 3 gets FDA approval for extended use: <https://apnews.com/c3915182c1ad48b0991785fc935eb-7f2#:~:text=Hospitals%20pay%20a%20range%20of,North%20American%20headquarters%20in%20Massachusetts>
- Shreibati JB, Goldhaber-Fiebert JD, Banerjee D, Owens DK, Hlatky MA. Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure. *Clin. Res.* 2017; 5(2): 110–9.
- Miller KL, Lanthier M. Investigating the landscape of US orphan product approvals. *Orphanet. J. Rare Dis.* 2018; 13(1): 183.
- ICER, Inotersen and Patisiran for Hereditary Transthyretin Amyloidosis: Effectiveness and Value: https://icer-review.org/wp-content/uploads/2018/02/ICER_Amyloidosis_Draft_Report_072018.pdf
- 'Outrageous' \$225,000 per Year List Price for Tafamidis Draws Outcry: <https://www.tctmd.com/news/outrageous-225000-year-list-price-tafamid-is-draws-outcry>
- Docherty KE, Campbell RT, Jhund PS, Petrie MC, McMurray JJV. How robust are clinical trials in heart failure? *Eur. Heart J.* 2017; 38(5): 338–45.
- The Future of Clinical Trials in Cardiovascular Medicine: <https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.115.020723>
- Kaitin KI, DiMasi JA. Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade,

- 2000–2009. *Clin. Pharmacol. Ther.* 2011; 89(2): 183–8.
29. Kaitin KI, DiMasi JA. Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009. *Clin. Pharmacol. Ther.* 2011; 89(2): 183–8.
30. Clinical Development Success Rates 2006–2015: <https://www.bio.org/sites/default/files/legacy/bioorg/docs/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf>
31. Trends in clinical success rates and therapeutic focus: <https://www.nature.com/articles/d41573-019-00074-z>
32. EvaluatePharma® World Preview 2019, Outlook to 2024: https://info.evaluate.com/rs/607-YGS-364/images/Evaluate-Pharma_World_Preview_2019.pdf
33. The Future of Clinical Trials in Cardiovascular Medicine: <https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.115.020723>
34. Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/treatment-heart-failure-endpoints-drug-development-guidance-industry>
35. Medications Used to Treat Heart Failure: <https://www.heart.org/en/health-topics/heart-failure/treatment-options-for-heart-failure/medications-used-to-treat-heart-failure>
36. GoodRx: <https://www.goodrx.com/enalapril>
37. Voigt J, John MS, Taylor A *et al.* A Re-evaluation of the Costs of Heart Failure and Its Implications for Allocation of Health Resources in the United States. *Clin. Cardiol.* 2014; 37(5): 312–21.
38. Banka G, Heidenreich PA, Fonarow GC. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure. *J. Am. Coll. Cardiol.* 2013; 61(13): 1440–6.
39. Top 10 Most Expensive Chronic Diseases for Healthcare Payers: <https://healthpayerintelligence.com/news/top-10-most-expensive-chronic-diseases-for-healthcare-payers>
40. Heidenreich PA, Albert NM, Allen LA *et al.* Forecasting the Impact of Heart Failure in the United States. *Circ. Heart Fail.* 2013; 6(3): 606–19.
41. NIH, Heart Failure: <https://www.nhlbi.nih.gov/health-topics/heart-failure>
42. Frakt AB, Pizer SD. Beneficiary price sensitivity in the Medicare prescription drug plan market. *Health Economics* 2010; 19(1): 88–100.
43. Rahul Shenolikar R, Schofield Bruno A, Cantrell C, Eaddy M. Sensitivity of Medication Use to Formulary Controls in Medicare Beneficiaries: A Review of the Literature. *Am. Health Drug Benefits* 2011; 4(7): 465–74.
44. A \$5 Billion Cholesterol Bet May Be an Overreach: <https://www.bloomberg.com/opinion/articles/2019-11-19/novartis-risks-overpaying-for-medicines-co-cholesterol-drug>
45. PCSK9 price-cut matchup is on, as Regeneron and Sanofi slash Praluent list tag 60%: <https://www.fiercepharma.com/pharma/pcsk9-price-cut-matchup-as-regeneron-and-sanofi-slash-praluent-list-tag-60>
46. Navar AM, Taylor B, Mulder H *et al.* Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy. *JAMA Cardiol.* 2017; 2(11): 1217–25.
47. Evolocumab for Treatment of High Cholesterol: Effectiveness and Value: https://icer-review.org/wp-content/uploads/2017/06/ICER_PCSK9_NEU_091117.pdf
48. Fonarow GC, Keech AC, Pedersen TR *et al.* Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. *JAMA Cardiol.* 2017; 2(10): 1069–78.
49. Amgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha® (Evolocumab): <https://www.amgen.com/media/news-releases/2017/05/amgen-and-harvard-pilgrim-agree-to-first-cardiovascular-outcomesbased-refund-contract-for-repatha-evolocumab/>
50. FDA Approves Amgen’s Repatha® (evolocumab) To Prevent Heart Attack And Stroke: <https://www.amgen.com/media/news-releases/2017/12/fda-approves-amgens-repatha-evolocumab-to-prevent-heart-attack-and-stroke/>
51. PCSK9 price-cut matchup is on, as Regeneron and Sanofi slash Praluent list tag 60%: <https://www.fiercepharma.com/pharma/pcsk9-price-cut-matchup-as-regeneron-and-sanofi-slash-praluent-list-tag-60>
52. Interventions for Management of CHF: Final Report: https://icer-review.org/material/chf_final_report/
53. Psotka MA, Fiuzat M, Solomon SD *et al.* Challenges and Potential Improvements to Patient Access to Pharmaceuticals: Examples From Cardiology. *Circulation* 2020; 142(8): 790–8.
54. Novartis defies naysayers with new-fangled pay-for-performance deals on Entresto: <https://www.fiercepharma.com/pharma/novartis-defies-naysayers-with-new-fangled-pay-for-performance-deals-on-entresto/>

- com/sales-and-marketing/novartis-defies-naysayers-newfangled-pay-for-performance-deals-on-entresto
55. Critical heart drug too pricey for some Medicare patients: <https://www.healthcarefinancenews.com/news/critical-heart-drug-too-pricey-some-medicare-patients>
 56. Pfizer's EU Vyndaqel okay 'sets up \$1.5bn sales next year': <https://pharmaphorum.com/news/pfizers-eu-vyndaqel-okay-sets-up-1-5bn-sales-next-year/>
 57. Amgen Reports Fourth Quarter And Full Year 2019 Financial Results: <https://www.prnewswire.com/news-releases/amgen-reports-fourth-quarter-and-full-year-2019-financial-results-300996505.html>
 58. Sanofi delivers strong 2019 business EPS growth of 6.8% at CER: <https://www.globenewswire.com/news-release/2020/02/06/1980751/0/en/Sanofi-delivers-strong-2019-business-EPS-growth-of-6-8-at-CER.html>
 59. Novartis Full Year 2019 Product Sales: <https://www.novartis.com/investors/financial-data/product-sales>
 60. Breaking Down Pricing Of Cell & Gene Therapies: <https://www.cellandgene.com/doc/breaking-down-pricing-of-cell-gene-therapies-0001>
 61. Capacity Analysis for Viral Vector Manufacturing: Is There Enough?: <https://bioprocessintl.com/manufacturing/emerging-therapeutics-manufacturing/capacity-analysis-for-viral-vector-manufacturing-is-there-enough/>
 62. der Meer P, Gaggin HK, Dec GW. ACC/AHA Versus ESC Guidelines on Heart Failure: JACC Guideline Comparison. *J. Am Coll. Cardiol.* 2019; 73(21): 2756–68.
 63. Curative Regenerative Medicines: Preparing Health Care Systems For The Coming Wave: <https://invivo.pharmaintelligence.informa.com/IV004955/Curative-Regenerative-Medicines-Preparing-Health-Care-Systems-For-The-Coming-Wave>

AFFILIATION

Faraz Ali

Chief Executive Officer, Tenaya Therapeutics

AUTHORSHIP & CONFLICT OF INTEREST

Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgements: None.

Disclosure and potential conflicts of interest: Dr Ali is the CEO of Tenaya Therapeutics mentioned in the article, and holds stock in Tenaya Therapeutics.

Funding declaration: The author received no financial support for the research, authorship and/or publication of this article.

ARTICLE & COPYRIGHT INFORMATION

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Attribution: Copyright © 2020 Ali F. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

Article source: Invited.

Revised manuscript received: Sep 7 2020; **Publication date:** Sep 23 2020.

INTERVIEW

HTA evolution in Canada: considerations for cell and gene therapy



SUZANNE MCGURN joined CADTH in July 2020 as its President and Chief Executive Officer. She brings to the role a deep understanding of the complex issues surrounding the management of pharmaceuticals, medical devices, and clinical interventions in Canadian health systems. Prior to joining CADTH, Ms McGurn's distinguished career spanned clinical practice, patient support, and senior roles in government. Within the Ontario Ministry of Health, she served as the Assistant Deputy Minister of the Drugs and Devices Division and the Executive Officer of the Ontario Public Drug Programs. She also led the implementation of the pan-Canadian Pharmaceutical Alliance and served as its first chair. Ms McGurn holds both a Bachelor of Nursing Sciences and a Master of Public Administration from Queen's University.

Cell & Gene Therapy Insights 2020; 6(7), 985–992

DOI: 10.18609/cgti.2020.108

Q With both your new role leading a national health technology assessment agency (CADTH) and your former role heading Canada's largest government payer (Ontario Drug Programs Branch) in mind, can you compare the HTA challenges assessing the clinical and cost-effectiveness of cell and gene therapies with the drug plan

mandate to ensure timely access to innovative treatments, but within a limited budget?

SG: The first point of comparison I would make is to state that the importance of these decisions is considerable from both HTA and payer perspectives.

Similarities include the need to define what constitutes a timely decision on such important products, careful consideration of the evidence, and the need for diligence that accompanies all significant investments in health while being thoughtful regarding the significant repercussions for patients and their families. Another area of commonality relates to implementation.

Implementing a drug, even an innovative drug, into a community (e.g. a person consuming the drug at home) is in many ways quite straightforward. But once you start offering therapies including pharmaceuticals that require hospital settings (in-patient or out-patient), perhaps involving a more invasive procedure, and potential for more significant before or after care, it adds a lot of complexity. Implementation considerations are an important area where CADTH has started to support the jurisdictions/funders, and it is one where HTA organizations and jurisdictions are finding common ground, as they strive to identify potential concerns at as early a stage as possible.

Implementation concerns can cover a wide range of considerations, from the location where the treatment is offered, to the nature of the care needed including in some cases the other drugs that may be used in combination with the treatment. It's important for HTA bodies, such as CADTH, to be aware of these and include them as considerations in the HTA review process. This enhances the ability of the HTA work to inform both decisions, and if funded, greater likelihood of implementation success.

There are also ethical considerations and again, from both HTA and payer points of view, thinking about individuals and how they have access is important. For example, an approved complex therapy that might only be offered in a small handful of sites throughout Canada may raise important implementation sensitivities in terms of who can and cannot benefit from it.

I think one of the strengths that CADTH brings to these discussions is its reputation and strength as a convenor, a facilitator, that can bring the right people together to work through thorny issues. We certainly saw this in Canada with the introduction of CAR T cell therapy – CADTH played a really important role there in assisting funders (including myself in a former job) to understand what this new type of treatment could look like in Canada, and how we might be successful in using the best available evidence in a new way to inform our decisions.

Q What's your perspective in your current role at CADTH on outcomes-based risk-sharing agreements as a means of funding cell and gene therapies?

SM: I would firstly say that HTA assessment is based on the value of the evidence and of the opportunity cost based upon what we know at a given moment in time. CADTH has adopted a lifecycle approach to looking at these products, so when we

consider longer-term funding models, we also have to be cognizant of the fact that what we know about the product may change over that period.

When it comes to risk-sharing and outcomes-based agreements, there are many cost management options that payers have to consider. In Canada, the pCPA (pan-Canadian Pharmaceutical Alliance) has certainly played an important role in helping to identify which options are feasible, and looking at how they could be managed, in order to support jurisdictions in making their decisions.

At the macro level, I think the challenge isn't the individual agreement, it's the complexity of the pipeline as a whole and the multiple different agreements that will be likely be involved or required. It's perhaps not an ideal analogy, but when I was first learning about outcomes-based agreements, or agreements that might be amortized over many years, one of the patient stakeholder group representatives I spoke with shared with me that in a former job, they adopted the same sort of model for building bridges and roads. Every year, municipalities make choices about which roads or bridges will get built and which ones won't. For payers in the healthcare system, those are even more difficult discussions and in the cell and gene therapy space, where there may be new treatments coming through for very small patient populations, just one or two additional individual patients may have a substantial impact on decision-making, even in a model where the funding risk is spread over years.

So there's no simple answers here. I can say with confidence that the payers in Canada are already well versed in a variety of options, and regarding outcomes-based agreements specifically, my experience to date is that there have been some very effective examples entered into, both in Canada and internationally. CADTH and other HTA organizations around the world will need to play a key role in helping payers with the evidence and analysis over time, helping identify further economic and other considerations that may be important to payers.

Q CADTH has established a separate review process for cell and gene therapies that requires sponsors/manufacturers to complete an implementation plan. Can you describe CADTH's objectives in seeking this information, how it will be used by CADTH, and the implications for CADTH recommendations for reimbursement?

SM: CADTH has established this process to gather the necessary information to ensure that cell and gene therapy products get screened in the right place to provide the best possible type of assessment, and for efficiency.

Sponsors are asked to provide information that helps CADTH understand the complexity of their therapies. This helps to determine whether a product is more suited to what is deemed a standard drug review process at the

“..one of the strengths that CADTH brings ... is its reputation and strength as a convenor, a facilitator, that can bring the right people together to work through thorny issues.”

present time, or the new process for a cell and gene therapy. It is envisaged that there will be circumstances where the first couple of approved new types of therapies in a given modality might go through the new process, but once the technology becomes more familiar, then subsequent products will move into the more standardized drug review process.

A new therapy that is complex to administer and brings with it lots of concerns around implementation would be anticipated to go through our cell and gene therapy process.

The information that is gathered during this process allows us to engage and prepare the jurisdictions early on for issues that could arise from the health technology assessment. This proactive engagement is aimed at ensuring the review does meet the jurisdictions' needs in helping inform their decisions. It also provides the opportunity for industry to benefit from these early-stage conversations. When I started in my new role, the CADTH team shared with me that the evolution of this new process for cell and gene therapy followed an internal review. What they came to realize was that for cell and gene therapies, they wanted to leverage the strength of the two existing programs. The program for cell and gene therapy will offer stakeholders the benefits of a firm performance target and well-established processes for conducting the review and issuing recommendations – all things that are familiar to the industry and to patient groups, and that have timelines that people already understand. However, it also introduces the sort of ethical and implementation considerations that have always been an important strength of CADTH's medical device process.

Gathering information at the front-end allows for the best possible assessment of these important products as they're being brought to Canada, and to make sure that we're giving the provincial jurisdictions the specific information they need to inform their decisions around how to fund and integrate these new technologies.

For reference, below is our review process for cell and gene therapies:

- ▶ **Descriptor:** <https://cadth.ca/cart>
- ▶ **Process:** https://www.cadth.ca/sites/default/files/cdr/process/CADTH_Gene_Process.pdf

Q When should manufacturers of cell and gene therapies first approach and inform CADTH and government payers about new cell and gene therapies? What information should manufacturers be prepared to share and what advice can be provided by CADTH and government payers pre-assessment?

SM: This is another area where CADTH has done a tremendous amount of work. We would say that manufacturers should come and discuss their new therapies with us as early as possible. Even before a product is in the regulatory approval process, there are opportunities for engagement that may help – to have discussions that alleviate uncertainty for the developer and potentially help them refine their plans for generating evidence. This is key because we have learned that once a submission is prepared and the work has been done, it's much harder to address any uncertainty questions that may arise.

For example, the scientific advice program is something that many sponsors have considered in other technology areas and it may be of value to cell and gene therapy developers. From the

“...manufacturers should come and discuss their new therapies with us as early as possible. Even before a product is in the regulatory approval process, there are opportunities for engagement that may help – to have discussions that alleviate uncertainty for the developer and potentially help them refine their plans for generating evidence.”

Canadian HTA perspective, the early stages of drug development provide a real opportunity for valuable dialogue, hence the fact CADTH supports parallel scientific advice both with Health Canada and with NICE in the UK.

Typically, if you were proceeding to consider the scientific advice process, applications should be filed prior to the finalization of your pivotal trial protocol so that the feedback can be incorporated if necessary. Developers are required to submit a briefing book outlining the clinical development plan together with some questions for the HTA and regulatory agencies involved.

One notable part of the scientific advice program process that CADTH goes through is outreach to patients with the condition of interest. This helps us to understand from the patients' perspective what's important with regard to the drug and the drug development program.

I would say you cannot reach out to us at too early a stage. There is no harm in doing so: if it transpires you are too early, we will let you know and indicate when is the right time to return. And this 'the earlier the better' mantra is particularly valid when you have a product that carries a high degree of uncertainty, as many novel cell and gene therapies do.

It's important to note that our scientific advice program has been paused during the COVID-19 pandemic so that we could redirect our scientific resources towards assisting with the generation of COVID-related evidence. However, we are currently looking at resuming the scientific advice program in late September, early October.

Q You mentioned a collaboration with NICE there – can you go deeper on CADTH's international activities, and describe any initiatives that may lead towards harmonization of HTA methods and procedures for cell and gene therapies?

SM: While there is no formal international collaboration underway that is specific to cell and gene therapy at this time, it is obviously a top-of-mind conversation between all major HTA bodies at the moment. And CADTH does have a very significant

presence and works hard to enhance collaboration within the global HTA community. We're looking at sharing information, at defining and implementing best practices, and at enhancing our ability to build capacity for HTA. We are also following any regulatory harmonization that may be occurring between different jurisdictions.

Looking to the future, the sort of work we're doing with NICE in offering parallel scientific advice is something that could help facilitate discussions around efficient evidence generation, and potentially meeting the needs of more than one market at the same time. I also think that our collective experience with COVID-19 has encouraged and allowed individuals to talk with each other in new ways. So I remain optimistic that the strength of the relationships that have been built over the last few years with other HTA agencies does provide a real opportunity for greater international collaboration, regardless of whether it's specific to cell and gene therapy or pharmaceuticals in general. I think there are a lot of things that we can do better together.

Q CADTH has a structured process for patient groups to contribute a perspective to the assessment of all technologies – are there any special or unique considerations for patient input into assessments of cell and gene therapies, and do you have any advice for manufacturers who may offer financial assistance/support to patient groups?

SM: The first thing I would say is that in my last role, working on the pharmaceutical file, I truly enjoyed and valued the input of the patient community. And having arrived at CADTH, I see more of the same important recognition of, and gratefulness to, the patient community for the work they do in preparing patient input for submissions. They make a difference, and they are an important part of a good assessment.

For CADTH, the patient input received allows the organization to gain insight into the lived experience of people with a particular condition. And as I've said, it becomes a really important part of the discussion as the team works through their assessment.

For cell and gene therapy specifically, patient input is invited and if patient groups have questions about the process, or how they may be able to contribute the patient submissions themselves, we welcome them to contact the patient engagement team at CADTH.

“...our collective experience with COVID-19 has encouraged and allowed individuals to talk with each other in new ways.”

With regard to financial assistance, we simply ask all groups who are submitting patient input to clearly declare their funding as part of the conflict of interest disclosure. This request has been in place for some time for all patient groups, not simply submissions that relate to cell and gene therapy. Of course, while we are looking for the disclosure of that information, we are also looking for the valuable content of what that patient group provides to us.

Q As you embark on this new role, can you share any personal goals for your work at CADTH?

SM: Firstly, I'm certainly very excited to join the team here. I obviously learned about CADTH as a payer in a jurisdiction, and I really recognized the importance of health technology assessments and their value in helping you think through your options as a payer. I always described CADTH's input as one of the most significant pieces of advice that you would get as a drug plan manager. I also sat on the CADTH board as a jurisdictional representative, so I had the opportunity to see the agency at an organizational level. I was always very impressed with the thoughtfulness of the organization and its responsiveness.

In terms of my personal goal in coming to CADTH, I believe there are opportunities for the important evidence work that CADTH is so well known for to have greater impact and influence. Not just with funders, but on healthcare systems as a whole – on decision-makers within hospitals and other organizations, and on frontline clinicians.

I think this greater impact will come from us continuing to focus on how we can effectively communicate our evidence findings in a way that's consumable to the various audiences that are interested in, or rely upon, the work that CADTH does. Whenever there's discussion around the funding or non-funding of a drug, I want CADTH to be known as a trusted place that people will go to easily find information that helps them understand the evidence that has influenced a given funding decision, and the dialogue that may be going on around it in the public realm at that time. I'd like it to be a source of truth.

The current COVID-19 environment has really raised awareness of how important it is to have accurate information and evidence to inform healthcare decisions in as timely a way as possible, and to communicate clearly to people to help them understand why they should do or not do something. I want to be part to creating and effectively conveying evidence-based products that help people understand the available evidence and make informed choices about their own health, about the health system they work in, or as jurisdictions, about the choices they have to make as payers.

That latter piece of taking evidence to the next level, of building on the strength of CADTH, is key. I know for a fact that many jurisdictions rely on CADTH, for their drug programs and in other areas, I believe strongly that there's more that we can do to make HTA a more understandable process for people, to communicate the value and impact of the really important work that's done by the staff here so it can be utilized to the fullest. They are a bright, brilliant team, with so much to offer the health system.

AFFILIATION

Suzanne McGurn

President and Chief Executive Officer, Canadian Agency for Drugs and Technologies in Health

AUTHORSHIP & CONFLICT OF INTEREST

Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgements: None.

Disclosure and potential conflicts of interest: The author declares that they have no conflicts of interest.

Funding declaration: The author received no financial support for the research, authorship and/or publication of this article.

ARTICLE & COPYRIGHT INFORMATION

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Attribution: Copyright © 2020 McGurn S. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

Article source: Invited.

Interview conducted: Aug 3 2020; **Publication date:** Aug 26 2020.

COMMENTARY

Joint collaborations and future perspectives for gene therapies

Monique Dabbous, Eve Hanna, Boris Borislav, Claude Dussart & Mondher Toumi

High cost innovative medicines increasingly seeking market access and reaching the market are further challenging national healthcare systems already dealing with finite, constrained budgets and resources. Since 2012, European countries have begun to establish joint collaborations to conduct information sharing, horizon scanning, joint assessments, joint negotiations, and joint procurements in healthcare. More than 30 European countries have partnered together in 13 joint collaborations, 11 targeting innovative medicines, 1 targeting biosimilars, and 1 targeting vaccines. The aim of these joint collaborations is to increase bargaining and purchasing power while ensuring patient access and maintaining sustainable healthcare systems. As of today, only 2 joint collaborations, BeNeLuxA and FINOSE, have published the outcomes of their joint activities - joint assessments of innovative gene therapies. While such joint collaborations are still young, an examination of their establishment and outcomes may be insightful as to their implications for market access of gene therapies, healthcare systems, and future perspectives.

Cell & Gene Therapy Insights 2020; 6(7), 965–983

DOI: 10.18609/cgti.2020.107

INTRODUCTION

In the European Union (EU), the central regulatory body, the European Medicines Agency (EMA), established in 1995, pools together

participating member states' regulatory procedural efforts into one process resulting in a centralized marketing authorization granted by the European Commission valid in all EU

member states. This centralized route aims to improve the quality of market authorization and products entering the EU as well as to reduce costs, conserve resources and avoid delays, otherwise commonly incurred via individual member state regulatory appraisals and processes [1]. The single-entry point via the EMA into the EU market, however, does not automatically translate to direct and successful market access. The single European market has forced health technology developers to adopt international pricing strategies and to shift away from previously price-differentiated strategies due to issues such as parallel trade within the market, compounded by the effects of international referencing pricing [2,3]. At the same time, individual member states still subscribe to their individual, traditional health technology assessment (HTA) bodies and frameworks to appreciate and value health products in order to ensure market access and, ultimately, patient access. HTA bodies vary greatly depending on their frameworks and valuation criteria for pricing and reimbursement. However, before a medicine is made available to patients, decisions about pricing and reimbursement take place at the national and regional level in the context of the national health system of each country. These tailored market access strategies require large resources, both financial and capital, and may result in the delay of access in some countries.

Innovative therapies, such as gene therapies, require even further resources and unique consideration when compared to traditional pharmaceuticals. Gene therapies are characterized by their one-time treatment targeted at addressing disease causation. By targeting disease causation, gene therapy developers are able to make the claim that their health technologies are able to provide long-term, even lifelong benefits, if not cure patients. However, due to their inherent nature, prices associated with such treatments are extremely high and there remain uncertainties surrounding their benefits, which require a much longer timeline than traditional pharmaceuticals to be observed. Traditional

frameworks applied by health authorities are struggling to quickly adapt procedures relating to the valuation, appraisal, pricing, and negotiation of such unique therapies.

In order for national healthcare authorities to increase their purchasing power while making efficient, effective, and strategic decisions related to pricing and reimbursement of such new, innovative products as gene therapies that are presenting with high price tags and limited evidence, joint collaborations have been established. This increasing European trend can be observed with joint, cross-country collaborations pooling resources together in order to conduct joint HTAs, joint negotiations, and joint procurement as well as to collectively engage in horizon scanning and the exchange of information for innovative medicines, including gene therapies. The first of these efforts was the Baltic Partnership Agreement [4] established in May of 2012 between Estonia, Latvia, and Lithuania for the joint procurement of vaccines and the most recent collaboration is the Norwegian-Danish Initiative established in September of 2018 between Norway and Denmark for the joint procurement of medicines [5]. Thirteen joint collaborations have been established within the last 8 years, with 11 dedicated to addressing the challenges of innovative therapies, including gene therapies.

Most interestingly, a cross-collaboration for HTA, FINOSE [6], has recently jointly assessed Zynteglo® [7], an orphan designated drug for the treatment of a genetic blood disorder known as beta thalassaemia. With an increasing number of these initiatives and innovative health technologies (especially gene therapies) in the pipeline, seeking market access, and reaching the market, an analysis and closer look at the accomplishments and shortcomings of such joint collaborations thus far may provide insight as to the future aims and future projects in assessing innovative health technologies, including gene therapies. As a recent, evolving area in healthcare, this manuscript details the inception and evolution of joint collaborations, their application to innovative health technologies, and provides

insight into potential future perspectives for their role. Although some joint collaborations address specific pharmaceutical products, such as biosimilars and vaccines, the majority of joint collaborations have been established to address the challenges associated with innovative medicines [2], therefore, the scope of this manuscript is restricted to the consideration of joint collaborations targeting innovative health technologies.

JOINT COLLABORATIONS

What are joint collaborations?

Despite their recent inception, with the first joint collaboration established in 2012, these initiatives manifest in many forms. As of today, joint collaborations have no single, standardized definition nor term that is widely accepted. Joint collaborations may be bilateral or multilateral and may be dedicated to conducting a single activity or may be engaged in several activities facilitating market access for new health technologies, especially innovative medicines, including gene therapies. Common activities conducted by such initiatives include joint assessment, joint procurement, joint price negotiations, horizon scanning, and information sharing. These cross-collaboration projects ultimately seek more efficient ways to increase the purchasing power of participating members and to obtain sustainable prices, while facilitating secured market access in the face of an increasing number of innovative therapies seeking to enter the market [2]. Participating member countries recognize the importance in understanding and addressing the imbalances and challenges in the current healthcare processes and systems and believe that joint collaborations will allow them to address these as they aim to drive down the costs of highly expensive, innovative medicines, such as gene therapies, while increasing access to these products.

Joint assessment, as defined by the World Health Organization (WHO)'s International Health Partnership + Related Initiatives, is “a shared approach to assessing the strengths

and weaknesses of a national strategy, which is accepted by multiple stakeholders, and can be used as the basis for technical and financial support [8].” The European Network for Health Technology Assessment (EUnetHTA) defines joint assessments as “HTAs jointly performed by 4 or more EUnetHTA partners in different European countries, EUnetHTA processes, guidelines, and the HTA Core Model are used for the production of assessments that are subject to extensive review procedures in order to ensure high quality. [Joint assessments] are centrally coordinated by the WP4 Co-leads and comprise a broad stakeholder involvement, including the use of a EUnetHTA submission file in addition to a scoping (e)meeting with industry [9].” It is interesting to note that joint collaborations engaged in joint assessments detailed in the following sections of this manuscript do not fall under EUnetHTA's definition of joint assessments as several collaborations consist of less than 4 participating member countries.

EUnetHTA, the EU-established European network for HTA bodies, was founded in the support of efficient HTAs across Europe [10]. EUnetHTA itself does not conduct joint assessments – however, it primarily provides a platform where European HTA agencies can exchange information on developing HTAs and their methodologies. EUnetHTA, therefore, is an important step towards an all-encompassing joint HTA for the EU, but unlike the EMA for regulation and marketing authorization, EUnetHTA's decisions and outcomes are not decision-making processes themselves. It may be argued that there is redundancy with the co-existence of EUnetHTA and joint collaborations engaging in joint assessments. However, it is important to observe once again that while EUnetHTA's assessments should inform decision-making, they are not decision-making processes themselves [11]. Technically, and dependent on the joint collaboration body, participating members may not be obliged to adopt the outcomes. Joint assessment, essentially, may apply one assessment framework or the conducting of an agreed upon assessment on

behalf of participating member countries, previously established and approved, with its outcomes to be potentially adopted by and applicable to all member countries of the joint collaboration.

Other joint collaborations also engage in joint procurement. According to the European Commission Green Public Procurement Toolkit, joint procurement occurs when two or more procurement processes of the contracted parties, or participating countries of the joint collaboration, are combined into one process conducted on behalf of all participants with the distinct characteristic that only one tender is published on behalf of them all [12]. Although this definition was published within the GPP for environmental efforts, the definition is applicable to pharmaceuticals. In fact, in 2010 following the outbreak of the H1N1 pandemic influenza, the European Council appealed for an agreement adopting this definition and for the joint procurement of vaccines, which ultimately precipitated in the formation of the joint procurement of medical countermeasures with its provisions outlined in Article 5 of Decision 1082/2013/EU [13]. Ultimately, Directive 2014/24/EU addresses public procurement and clearly allows for joint procurement and for different member states to engage collectively in contracting [2].

Joint negotiations, horizon scanning, and information sharing are also important activities joint collaborations may engage in. Joint negotiations occur when two or more contracted parties negotiate together as one negotiating entity with the health technology supplier to secure better prices and access for therapies. One of the parties may negotiate on behalf of all involved in the joint collaboration, or a negotiating committee may be established representing the participating countries. In order to effectively conduct such joint negotiations, joint collaborations may also, in parallel, engage in horizon scanning and information sharing to better anticipate and prepare for important products and developments in their healthcare systems. This is in order to better position themselves in

negotiation settings, and to create and maintain sustainable healthcare systems. Horizon scanning is key when anticipating the pipeline of innovative health technologies, such as gene therapies, which are costly yet provide tremendous benefits for patients in need. Conducting horizon scanning while information sharing (including but not limited to information regarding prior experience, methodologies, expertise, and skills) can facilitate more effective and efficient joint collaborations.

Countries' engagement in joint collaborations may vary from simple information sharing to horizon scanning ultimately leading to joint assessments and joint procurement, which require more commitment and participation. Espin *et al.* put forward a joint collaboration model detailing the levels of collaboration in procurement as ranging from informed buying to coordinated informed buying, group contracting, and central contracting and purchasing [2]. Espin *et al.* further elaborate on defining characteristics of joint collaborations, such as the type of ownership, financing mechanism, procurement activities, timeframe, range of products or services involved, and purchasing mechanism [2]. Joint collaborations, although young, can be found in a plethora of forms engaging in various degrees of activities.

As of today, there are currently 13 formal joint collaborations established in Europe with 39 European countries participating (Table 1) [8]. Of the 13 identified established joint collaborations, 11 are dedicated to innovative and expensive medicines, 1 is dedicated to vaccines, and 1 is dedicated to generics and biosimilars.

Why are countries engaging in joint collaborations?

Challenges, such as constrained and finite healthcare budgets, are further exacerbated by innovative health products targeting rare diseases with small populations presenting with limited evidence, with mounting concern

▶ **TABLE 1****Joint collaborations.**

| Joint collaboration | Date established | Member countries | Scope | Activities | Major assessments |
|---|------------------|--|---|---|---|
| Baltic Partnership | May 2012 | Estonia, Latvia and Lithuania | Vaccines | Joint procurement | Vaccines |
| BeNeLuxA-I | April 2015 | Belgium, Netherlands, Luxembourg, Austria, Ireland and France (observer status) | Medicines, innovative and expensive therapies | Joint HTA/REA, joint price negotiations, horizon scanning, information sharing | Lumacaftor/ivacaftor (Orkambi®) for cystic fibrosis (failed) Nusinersen (Spinraza®) (positive) Obeticholeic acid (Ocaliva®) for of primary biliary cholangitis (negative) |
| Romanian+Bulgarian IFA | June 2015 | Romania and Bulgaria | Medicines, innovative and expensive therapies | Joint HTA/REA, joint price negotiation, joint procurement | |
| Nordic Collaboration | June 2015 | Denmark, Finland, Iceland, Norway and Sweden | Medicines, innovative and expensive therapies | Joint HTA/REA, information sharing | Gentamicin is mentioned as pilot |
| Nordic Pharmaceuticals Forum (NLF) | 2015 | Denmark, Iceland, Norway and Sweden | Medicines, innovative and expensive therapies | Joint procurement, horizon scanning | To focus on security of supply: ampicilline, benzylpenicilline, piperacillin/ tazobactam, calciumfolinate, methotrexate, ondansetron, furosemide, meropenem, gentamicin, anagrelide, paracetamol (IV) |
| Sofia Declaration | February 2016 | Romania, Bulgaria, Croatia, Estonia, Hungary, Latvia, Macedonia, Serbia, Slovakia and Slovenia | Medicines, innovative and expensive therapies | Information sharing | N/A |
| Visegrad+ Collaboration | March 2017 | Poland, Slovakia, Hungary, Lithuania and Czech Republic (observer status) | Medicines, innovative and expensive therapies | Joint price negotiations, information sharing | Expected pilot project to start within HIV/hepatitis C therapeutic area |
| Southern European+ | May 2017 | Greece, Cyprus, Italy, Malta, Portugal and Spain | Medicines, innovative and expensive therapies | Joint price negotiation, joint procurement, horizon scanning, and information sharing | N/A |
| Valletta Declaration | May 2017 | Italy, Cyprus, Greece, Malta, Portugal, Spain, Ireland, Romania, Croatia and Slovenia | Medicines, innovative and expensive therapies | Joint price negotiation, joint procurement, horizon scanning, and information sharing | Ocrelizumab (Ocrevus®) indicated for the treatment of multiple sclerosis. Nusinersen (Spinraza®) |
| Iberia Partnership | April 2017 | Portugal and Spain | Generics and biosimilars | Joint HTA/REA, joint price negotiation, information sharing | Flu vaccine |
| France - Portugal Declaration of Intent | December 2017 | France and Portugal | N/A | Joint price negotiation, information sharing | N/A |
| FINOSE initiative | March 2018 | Sweden, Finland and Norway | Medicines, innovative and expensive therapies | Joint HTA/REA, information sharing | Pilot on 'simple' products to be completed Summer 2020, set to assess onasemnogene abeparvovec (Zolgensma®) |
| Norwegian-Danish Initiative | September 2018 | Norway and Denmark | Medicines, innovative and expensive therapies | Joint price negotiations, joint procurement | Nusinersen (Spinraza®) |

stemming from widespread anticipation of an increasing number of highly costly gene therapies reaching market. Current frameworks and regulations applied to the valuation, appraisal, pricing, and reimbursement of innovative therapies, including gene therapies, despite adapting dedicated pathways for such therapies, seem to continue to face challenges due to such health technology's inherent characteristics. In a recent publication by Qiu *et al.*, a review and international comparison of various regulatory policies of regenerative medicines (RMs), including gene therapies, has revealed that out of the EU and the 9 countries investigated (USA, Japan, South Korea, Australia, Canada, New Zealand, Singapore, China, and India) only the EU, USA, Japan, South Korea, and Australia had specific legislation already in place for the regulation and consideration of RMs [14]. While it is encouraging that the EU and these several countries have adopted specific pathways for the regulation of such therapies as gene therapies in accordance with their unique characteristics, the authors note that harmonization and international standardization of such regulations would alleviate administrative burdens on innovative health technology developers as well as health authorities, and would facilitate patient access more quickly [14]. Another review conducted by Qiu *et al.*, on advanced therapy medicinal products (ATMPs), which includes gene therapies, revealed that addressing uncertainties surrounding the value, pricing, and reimbursement of such therapies remains challenging for national healthcare authorities in Europe and for healthcare authorities in the USA [15]. Qiu *et al.*'s work further emphasizes discrepancies between HTAs and the weighting they assign to attributes assessed. However, it is interesting to note that the review reports that the EU countries considered and the USA all requested in one form or another further reviews upon the collection of additional data (due to lack of evidence at the time of assessment and uncertainties surrounding the proclaimed long-term benefits of such therapies) [15]. All the EU countries

in the review and the US facilitated prompt market access by adapting pathways specific to gene therapies and ATMPs in general without impairing healthcare affordability [15].

Although discrepancies can be seen on the regulatory and HTA levels in relation to RMs or ATMPs, health authorities, innovative health technology developers, and patients all seek to facilitate their market access. However, this proves difficult and may lead to unsuccessful or delayed market access due to variations in institutions and their respective frameworks. If such efforts were pooled or standardized, it could not only alleviate the administrative burden on both developers and health authorities, but could also help improve health authorities positioning in negotiation and procuring such costly therapies, and improve the quality of health technologies entering their markets.

Further challenges arise when considering smaller countries with small purchasing power and/or even smaller target patient populations, which may lead to a health technology developer pulling their product from such a market if the actual uptake is not as anticipated. This could certainly be the case with a gene therapy targeting a rare disease with a very small number of patients in certain countries. By pooling together several countries, a larger population, market size, and volume can be presented during negotiations with health technology developers [2]. Larger countries also benefit by pooling their resources and creating a larger market when conducting joint collaboration activities targeting innovative therapies and such small populations. Participating members in joint collaborations are able to exchange information, experience, and skills as well as potentially improve the quality of products seeking and entering market access.

Through such collaborations, these countries not only benefit by obtaining more sustainable prices through economies of scale, but are also able to enjoy reduced costs associated with transactions and can redirect resources previously associated with individual national processes. Participating countries

enjoy the comfort of secured access to these therapies as do health technology developers, who may also benefit from one streamlined market access strategy and process for similar reasons, such as reduction in costs and invested resources. Joint collaborations further hope to increase transparency around pricing and strengthen information sharing – particularly information and knowledge on the efficacy, safety, and quality of the innovative technologies seeking market access.

The first joint collaboration established, the Baltic Partnership Agreement, was initiated as a response to the H1N1 Swine Flu pandemic. Latvia, Lithuania, and Estonia all have the same immunization schedule and effectively established a collaboration to procure vaccines multilaterally [4]. Although the first procurement project fell through when no tender was submitted, the establishment of the collaboration is significant in that vaccines procured through the Baltic Partnership Agreement can be lent and transferred between the participating member countries, ensuring optimization of market access and avoiding potential shortages of vaccines as was experienced during the H1N1 pandemic [2]. Such an establishment sought to secure access to a critical health technology while leveraging their position to create a larger market when engaging with health technology suppliers. Since 2012 and the Baltic Partnership Agreement, joint collaborations have continued to emerge to address challenges which may become crippling for the future of sustainable healthcare.

What does it take to establish & conduct joint collaborations?

Joint collaborations, ranging from simple information sharing entities to full bodies conducting joint assessments, negotiations, and procurement, all require dedicated cooperation in order to run efficiently. The complexity of establishing and executing such agreements and activities renders it necessary for solid and transparent foundations to be laid

out. Such collaborations require clear roles and responsibilities to be outlined and trust to be built between participating countries. Governance and roles must be detailed with open communication to ensure transparency, accountability, and fairness. A critical component, especially in joint procurement activities, will be the financial management aspect. Tracking the financial responsibilities, including the funding and payments, will require detailed and intimate outlining and monitoring to ensure funds are available and purchases and payments are made in a timely manner. If agreements or deals are conducted via the joint collaboration, timelines must be clear and partnerships must be stable enough to maintain continuity through long contracting, and to ensure secured access to resources and, ultimately, the health technologies they seek to introduce to the market.

However, major obstacles remain when establishing joint collaborations. Governance remains an issue when deciding if one of the participating countries should govern, or a committee should be established representing all participants and ensuring everyone's responsibilities and accountability is upheld. As mentioned earlier, although these joint collaborations are unique in that they consider two or more countries in the processes, at the end of the conducted activities there are no obligations required for the participating countries to adopt the outcomes of the reports unless legally bound by a joint agreement: for example, for procurement where specific participating parties may be contractually obligated to execute specific financial responsibilities. Such contractual agreements and activities require well-defined and robust legal frameworks and some joint collaborations may even require extensive legislative implementation and adaptations to engage in these joint collaborations, which further requires time and legal investment. Furthermore, these joint collaborations have only just been established within the last 8 years with limited real-life experience and many, as detailed in the next section, are so burdened with the establishment of the actual joint

collaboration that they have yet to conduct pilot projects or any activities. Due to their recent inception, there is a lack of clarity regarding the degree to which they may influence the market, such as the risk in distorting the supply, purchase, as well as trade, and regarding the impact their activities may have on the healthcare system, even horizon scanning. Lastly, larger countries in the EU have increasingly voiced their interest in establishing or becoming participating members of joint collaborations, which although it may initially seem appealing for greater bargaining power, may result in these larger countries overshadowing smaller ones.

JOINT COLLABORATION BODIES

BeNeLuxA

In April 2015, BeNeLuxA was established between Belgium and Netherlands with the announcement to engage in joint price negotiations of orphan drugs [16]. Luxembourg and Austria later joined the joint collaboration in September 2015 and June 2016, respectively. In 2018, Ireland expressed its interest to also join the collaboration [17]. The collaboration together covers 42 million citizens and represents 8% of the EU's population. BeNeLuxA was one of the first, prominent European experiences in joint collaborations. Following the launch and difficult negotiations of the highly priced sofosbuvir (Sovaldi®) for the treatment of Hepatitis C, BeNeLuxA was established to combat such high prices and in the anticipation of the increasing arrival of highly costly gene therapies among other innovative therapies. It is dedicated to enhancing patient access to medicines with a focus on high-cost, orphan products. The BeNeLuxA initiative aims for sustainable access to, and appropriate use of, medicines in the participating countries. The joint collaboration strives to increase patients' access to high quality and affordable treatments [18]. The joint collaboration's activities consist of information sharing, optimization of

patient access, focus on public policy issues development, harmonized evaluation methods and joint assessment, and increased bargaining power. The joint collaboration has also engaged in building an international horizon scanning initiative with BeNeLuxA partners and other interested countries as well. Information sharing has also been an ongoing activity with the joint collaboration holding meetings on patient registries in November of 2017 with Hungary and the UK. Interestingly, those discussions did not capture the interest of health technology suppliers who may seek to set up registries in the future.

Its pilot joint HTA and pricing negotiations with the industry began in 2017. BeNeLuxA assessed the combination of lumacaftor/ivacaftor (Orkambi®) for the treatment of cystic fibrosis. The combination was assessed by 2 out of the 4 member countries, with the leading countries being Belgium and Netherlands. The assessment ultimately ended with the absence of consensus on the product price, the product was not considered cost-effective, and the price was overestimated by 80% [19]. The second assessment and negotiation undergone by BeNeLuxA targeted the highly priced nusinersen (Spinraza®) for Spinal Muscular Atrophy (SMA) [20]. Nusinersen, assessed by the Netherlands and Belgium, received a positive reimbursement decision and the joint collaboration was able to reach an agreement on the pricing and reimbursement of the product successfully with only one negotiation process conducted instead of two separate ones. The Belgian Ministry of Health took the lead and weighed in on the process heavily to ensure its securement and demonstrate that joint procurement was feasible [19,21]. However, in 2018, BeNeLuxA did give another negative decision for the orphan drug obeticholeic acid (Ocaliva®) for the treatment of primary biliary cholangitis following a joint HTA assessment [22].

Most Recently, on May 19th, 2020, BeNeLuxA announced it will engage in a joint

assessment for onasemnogene abeparvovec (Zolgensma®) [23]. The joint collaboration body is also in talks with other countries such as Italy, Romania, the Czech Republic, and Switzerland, with exploratory talks launched with France, and potential non-EU entities considered for partnership (European Commission, EUnetHTA, WHO, and the Organization for Economic Cooperation and Development [OECD]). To ensure the joint collaboration is effective in improving patient access to innovative treatment options, the process applied for the successful assessment and price negotiations should be implemented in future joint collaborations to ensure that the process can be replicated and yield valid outcomes [19].

Romanian-Bulgarian IFA

The Romanian-Bulgarian International Framework Agreement (IFA) was established on November 9th, 2016 to conduct joint HRA, joint price negotiations, and joint procurement between Romania and Bulgaria [24]. The agreement was ultimately established to ensure that patients in both Romania and Bulgaria have access to medicines, especially during instances where they have lacking pharmaceutical resources. The concept was initially presented at the Work Meeting of the Health Ministers from Central and Eastern European on the growing challenges in the field of medicine policy, on June 2nd and 3rd of 2016 in Sofia, after which other European countries besides Romania and Bulgaria, interested in joining signed a joint statement of intent. These other countries included were Croatia, Estonia, Latvia, Macedonia, Serbia, Slovenia, Hungary, with Poland as an observer. The Romanian-Bulgarian IFA has yet to conduct activities due to the changing political climate and the required ratification of two parliaments as an international treaty. Legislation in both Romania and Bulgaria will also need to be adapted for the pricing and reimbursement of medicines considered in their joint collaboration.

Nordic Collaboration

Denmark, Finland, Iceland, Norway, and Sweden are members of the Nordic Collaboration, which already addresses improvement and coordination of business and energy policy [25]. In June of 2015, it was determined that medicines and addressing their increasing costs would be added to the target of this joint collaboration and was addressed as the extended Nordic pharmaceutical cooperation for greater cost-effectiveness and safety [26]. It was formally adapted in November 2016. A closer cooperation has been started on pharmaceutical pricing policies and procurement [27]. Further development has led toward a provision of mandatory framework for exchange of information and experience on price and procurement of pharmaceuticals, as of March 2017. In 2017, the joint collaboration gained momentum, firstly with a pilot for joint purchasing of medicines (between Norway and Denmark), and then a Memorandum of Understanding (MoU) being signed by Finland, Norway, and Sweden in order to strengthen joint collaboration on HTA. Denmark, Norway, and Iceland announced a tender for spring 2018 with Sweden and Finland unlikely to participate. Gentamicin has been mentioned as a pilot for the joint collaboration's consideration. However, legal framework has yet to be established and final criteria to be identified.

Nordic Pharmaceuticals Forum (NLF)

Another Nordic joint collaboration, the Nordic Pharmaceuticals Forum (NLF), consisting of Denmark, Iceland, Norway, and Sweden, was established by Amgros, the Danish regional pharmaceutical procurement service in 2015 [28]. The NLF was founded to explore and develop joint tendering for pharmaceuticals and collaborations on horizon scanning. Its focus is targeted to four areas: horizon scanning, security of supply, new expensive pharmaceuticals, and manufacturers [29]. The objective

of its pilot project was to gain experience in completing joint tendering procedures and explore whether joint efforts can influence the pharmaceutical market, particularly in the acquisition of cheaper prices and more secure supply [30]. In September of 2018, an agreement of political intent on increased cooperation for joint tendering procedures and negotiations was signed between Norway and Denmark [29]. To date, the Joint Collaboration has conducted several important meetings and has been engaging in critical activities to firstly identify drivers and obstacles in their participating country members, legal options, and proposition of appropriate pharmaceuticals.

Sofia Declaration

The Sofia Declaration was founded with the following participating countries: Romania and Bulgaria as the leading countries and Croatia, Estonia, Hungary, Latvia, FYR Macedonia, Serbia, Slovakia, and Slovenia. The announcement of this cooperation came in May of 2015 and the declaration was finalized and signed by all country members in June of 2016 [2,31]. The ultimate goals of the Sofia Declaration are to increase their bargaining power as well as to engage in joint tendering of medicines. The joint collaboration is aiming to secure patient access to expensive, innovative medicines whilst maintaining a sustainable healthcare system [31]. As of today, the Sofia Declaration has not produced any joint tenders.

Visegrad+ Collaboration

Poland, Slovakia, Hungary, Lithuania and Czech Republic (observer status) began the Visegrad+ Collaboration in March of 2017 and the Memorandum of Understanding was signed in Warsaw within the context of high-priced medicines [32]. (Slovenia had considered joining – however, this country opted to join the Valletta Declaration instead, which is

described later). The Visegrad+ Collaboration was established with the aim to develop procedures and guidelines for negotiations in order to secure fairer prices for high-priced medicines, including innovative and orphan drugs, and to engage in information sharing [32]. The joint collaboration founded a Coordination Committee, charged with the responsibility for outlining and detailing the specific procedures and guidelines for negotiations as well as to organize negotiations. In November of 2017, all the participating countries of this joint collaboration, with the exception of Lithuania, signed and committed to cooperating on long-term medicines subsidies as well as in the production and acquisition of vaccines in order to achieve more affordable prices and ensure supply security. Having no clear structure and a heterogeneous group of country members in terms of size and populations, this joint collaboration has yet to produce any outcomes or conduct activities. However, as of November 2019, interest and enthusiasm for joint price negotiations was reiterated by the “V4,” also known as Poland, Slovakia, Hungary, and the Czech Republic [33].

Southern European+

In June of 2016, Greece, Bulgaria, Spain, Cyprus, Malta, Italy, and Portugal expressed the establishment of a Southern European+ joint collaboration targeting joint assessment with information sharing on clinical data and databases. The joint collaboration set out to establish a platform where the participating countries could further share expertise and experience in negotiations, pricing, and reimbursement in order to ultimately develop a transparent and effective collaboration. The Southern European+ joint collaboration aims to target innovative medicines as its main scope.

Valletta Declaration

The Valletta Declaration was signed on March 21st, 2017 in Valletta, with Italy,

Cyprus, Greece, Malta, Portugal, Spain, Ireland, Romania, Croatia, and Slovenia as the signees, and Estonia as an observing member [34]. Together, these countries represent 32% of the EU's population with 160 million citizens all together [35]. The declaration defines and establishes a joint collaboration aimed to improve patients' access to innovative medicines, while maintaining a sustainable health-care system. Its activities include joint price negotiation, joint procurement, horizon scanning, and information sharing. The joint collaboration's Technical Committee is charged with organizing and conducting meetings for further development of the collaboration's infrastructure, processes, and guidelines as well as for other discussions and activities relating to their objectives. The Valletta declaration has so far conducted two notable assessments, with Roche and Biogen, both for innovative products. The Valletta declaration group conducted its first confirmed pilot negotiations for ocrelizumab (Ocrevus®) for the treatment of Multiple Sclerosis. A second innovative health technology to be assessed by the Valletta Declaration joint collaboration was nusinersen (Spinraza®) for SMA.

As of 2019, the Technical Committee and Valletta Declaration Group has conducted 6 meetings dedicated to several topics, including the administrative establishment regarding objectives, scope, and cooperation in the joint collaboration [36]. Meetings also centered around the discussion and decisions of products for pilot assessments, the tracking, political analysis, and technical analysis of the declaration, the reinforcement of information sharing, exploration of new areas of activities, and the creation of a clear legal framework for the joint collaboration. Most interestingly and distinct to other joint collaborations is that the Valletta Declaration Group is particularly interested in and engaged in activities to influence political decisions. At their 5th meeting in Athens in July 2018, the joint collaboration explicitly stated that they would join forces to influence political decisions as the pharmaceutical industry does as well [36]. The following year, at their meeting in Zagreb

(March 2019) the Valletta Declaration Group presented a drafted resolution seeking to promote increased transparency for pricing, research and development (R&D) costs, clinical trial data, and patent information. More specifically, the draft sought the requirement for results and costs from human clinical trials regardless of outcome or whether the results would support an application for marketing approval, and also the publication of annual reports on sales revenue, prices, units sold, marketing costs for individual products, and costs of each trial used in the support of marketing authorization applications. Additionally, details on financial support received during the development of the drug from public sources were included. The draft went further by calling on the WHO Director-General to put forth a model for a web-based tool to facilitate information sharing on medicines prices, revenues, units sold, patent landscapes, R&D costs, public sector investments and subsidies for R&D, marketing costs, and other related information [36]. A forum to develop alternative incentive frameworks to patent or regulate monopolies for new medicines and vaccines was also proposed by the draft, in order to incentivize innovation whilst promoting universal health coverage.

It is suspected that the number of country members may increase in the Valletta Declaration Group, although this may actually prove to be counterproductive due to a resulting increase in heterogeneity in the joint collaboration, which may render cooperation more complex and complicated to achieve. The group is also further interested in analyzing the therapeutic areas of growing expenditure, such as oral antidiabetics and oral anticoagulants, and reinforce the exchange of information in areas of common interest such as biosimilars [35]. Despite the Valletta Declaration Group engaging in several meetings and reiterating commitment and interest in conducting their activities, it has not yet confirmed the completion nor published the results of its two assessments of ocrelizumab and nusinersen.

France–Portugal Declaration of Intent

The France–Portugal Declaration of intent was signed in 2017. However, to date, there is no additional information accessible on the progress of this joint collaboration.

FINOSE

FINOSE, another Nordic joint collaboration, unites Finland, Norway, and Sweden. FINOSE represents the three national HTA agencies of each country, including the Finnish Medicines Agency (Fimea), the Norwegian Medicines Agency (NoMA), and Sweden's Dental and Pharmaceutical Benefits Agency (TLV) [6,37]. The project started in 2017 and culminated with the MoU signed in March 2018 officially establishing the joint collaboration [28,38]. FINOSE aims to conduct joint assessments of medicines, for both relative effectiveness and health economics. In addition, the joint collaboration aims to facilitate information sharing for knowledge gain about products, increase efficiency in production and assessment reports, discourage divergence in HTA methods and evidence requirements, and to reduce the complexity in industry submissions [39]. The FINOSE collaboration is not aiming for joint decision making, but rather focuses on joint assessments. Any health technology developer with a new but not yet authorized product may contact any of the three HTA bodies to inquire as to how to begin the joint assessment process [39]. The developer is required to sign a waiver to enable information sharing between the three HTA bodies of the joint collaboration and they are required to submit simultaneously to all three HTA bodies comprised in the joint collaboration [39]. An additional and distinct characteristic of FINOSE to other joint collaborations is that it may use an available joint relative effectiveness assessment report from EUnetHTA as a ground for joint health economic analyses

between Fimea, NoMA, and TLV [39]. The joint collaboration is specifically interested in joint assessments across European HTA agencies and how real-world evidence (RWE) can be integral to assessment decision-making processes [6,37]. FINOSE also appreciates efficiency and seeks to maintain a shorter assessment time than the individual national processes involved in the joint collaboration.

Initially, in June 2018, FINOSE stated it would assess simple drugs in their pilot joint assessments and would run these assessments until summer 2020 with the intent that if successful, the joint collaboration would become permanent. More interestingly and recently, FINOSE has assessed betibeglogene autotemcel (Zynteglo®) with Fimea and TLV as the authoring bodies and NoMA as the reviewer. The joint collaboration stated that with such a joint assessment for a therapy targeting such a small population, patient access to an innovative health technology could be secured [7]. The joint collaboration went further to highlight that an assessment on the benefits and costs could aid in practical coordination for patients who may have previously needed to travel between countries to gain access to such a product [7]. FINOSE also recognized the importance of such an assessment and its potential role in future joint negotiations despite joint procurement not being a core activity of the collaboration, as its main focus is joint assessments. In addition, the joint collaboration introduced a new chapter on post-launch evidence generation through their assessment report by requiring a follow-up. It was also noticed in their assessment report that joint assessment submission could reduce administrative burdens for smaller companies with limited resources and organizations in each of the participating countries in the collaboration. Ultimately, FINOSE recognized the demonstration of Zynteglo®'s benefits in comparison to blood transfusions. However, there were no results on iron-related morbidity and survival due to limited follow-up time

in clinical trials. FINOSE further noted the lack of health-related quality of life reported from the clinical trials, and noted that the number of patients treated with Zynteglo® is very small, given that there is substantial geographic, ethnic and genetic variation among β -thalassaemia patients [7]. In terms of Zynteglo®'s cost-effectiveness, FINOSE also recognized uncertainties in the number of patients eligible for treatment, whether the success rate is sustained, and whether the survival gains based on the assumption that complications associated with high iron levels are reduced. The model was found to be very sensitive to the disutility associated with chelation therapy affecting long-term utility gains [7]. The assessment report further and explicitly states that the generation of RWE can mitigate uncertainties identified by the joint collaboration. The report also mentions the importance of RWE in establish Managed Entry Agreements (MEAs), despite MEAs being out of scope of the joint collaboration's activities. As of today, this is the third assessment conducted by FINOSE.

Norwegian-Danish Initiative

This joint collaboration established between Norway and Denmark on September 18th, 2018 with the signing of its agreement is based on the previously existing Nordic Collaboration and remains welcoming to other countries wishing to participate [5]. Norway and Denmark's joint collaboration aims to enhance cooperation for joint procurement and joint negotiations to secure lower prices for innovative medicines while ensuring continuous, secured access in the context of potential shortages [5,40]. The joint collaboration was specifically interested in obtaining a lower, more affordable price for nusinersen (Sprinraza®) [40]. Currently, nusinersen is reimbursed in Denmark for patients with SMA types I and II as well as pre-symptomatic infants and it is reimbursed in Norway for patients under the age of 18 years old.

FUTURE PERSPECTIVES OF JOINT ASSESSMENTS

Despite being young, these joint collaborations are targeting the issue of ever-evolving health technologies, decreased purchasing power, finite budgets, and limited evidence and uncertainties surrounding the efficacy and cost-effectiveness of innovative health technologies, especially gene therapies. Out of the 11 joint collaborations identified targeting innovative medicines, only 2 have completed and published the results of their activities – BeNeLuxA and FINOSE – both in the area of joint assessments, which requires the integration of other joint collaboration activities (specifically, information sharing) (Table 2). BeNeLuxA was one of the first joint collaborations to be established and is only 5 years old, while FINOSE established in 2017 is only 2 years old. Both joint collaborations are relatively small with BeNeLuxA being a collaboration between 4 countries and FINOSE being a collaboration between 3 member countries. Both of these joint collaborations assessed innovative health technologies: BeNeLuxA assessed nusinersen and FINOSE assessed betibeglogene autotemcel, which are both innovative therapies targeting genetic disorders. BeNeLuxA granted a positive decision for nusinersen and was able to negotiate and procure the health technology, while FINOSE recognized the importance of betibeglogene autotemcel's benefits relative to its comparator and explicitly stated the need for additional follow-up and for RWE integration and implementation in this follow-up. BeNeLuxA did give the next orphan product it assessed, obeticholeic acid (Ocaliva®), a negative decision. The success of these 2 initiatives so far could lie in their small size, yet BeNeLuxA is already in talks with additional countries which may wish to join. Furthermore, their success could lie in the structures and open communication with emphasis on information sharing, as well as their close cultures and related understanding of one another.

▶ **TABLE 2**

Joint collaboration assessments and outcomes.

| Joint collaboration | Activity | Health technology | Outcome |
|---------------------|------------------------------|---|---|
| BeNeLuxA | HTA and pricing negotiations | Combination of lumacaftor/ivacaftor (Orkambi®) for the treatment of cystic fibrosis | Absence of consensus on the product price, the product was not considered cost-effective, and the price was overestimated by 80% |
| | HTA and pricing negotiations | Nusinersen (Spinraza®) for the treatment of Spinal Muscular Atrophy | A positive reimbursement decision was given and an agreement on the pricing and reimbursement of the product was reached successfully, with one negotiation process conducted, instead of 2 separate ones |
| | HTA and pricing negotiations | Obeticholeic acid (Ocaliva®) for of primary biliary cholangitis | Negative decision |
| FINOSE | HTA | Betibeglogene autotemcel (Zynteglo®) for the treatment of transfusion-dependent β -thalassaemia | Recognition of demonstration of benefits, but also recognized the uncertainties especially surrounding the eligible patient population and the lack of health-related quality of life. The importance of real-world evidence in the mitigation of uncertainties and for the use in MEAs was highlighted in the report |

With their publicized assessments, these two joint collaborations may quickly emerge as setting the standard for health technology developers seeking entry into their markets and for their health technologies' assessments. This may especially be the case with gene therapies, as BeNeLuxA will next be assessing onasemnogene abeparvovec (Zolgensma®), the most expensive advanced therapy on the market today. Overall, this may be positive for innovative health technology developers as they can secure a greater market and both developers and joint collaborations can ensure secured patient access. These processes may be more efficient with a one-point, one contact, one-time submission process, resulting in saved time and resources. However, these joint collaborations may have a negative impact on current products or the first to be assessed by such collaborations, as their structures and frameworks are still being established and will need to be tried, tested, and adapted. This may result in direct impact on pricing of current products, especially highly-priced gene therapies like onasemnogene abeparvovec (Zolgensma®) coming up for assessment next, and will depend on whether the joint collaborations clearly outline and establish appropriate legal frameworks to be able to negotiate the prices they seek.

The Valletta Declaration Group is also an interesting and potentially influential joint collaboration as it seeks not only to conduct joint collaborations and activities, but to also directly politically influence health technology developers' access to the market through requirements related to data submission, transparency, costs in R&D and trials, and costs of marketing amongst others. The Valletta Declaration Group's draft propositions, if enacted, could have a degree of direct influence on the pharmaceutical industry in terms of transparency, information sharing, price negotiations, and procurement and may therefore challenge traditional frameworks and processes in place, as well as shape the political environment and future of healthcare systems. Given their high R&D cost and the complexity of their pricing negotiations, gene therapies and their developers may in such a situation experience a particularly direct and large impact on how they present themselves during market access as well as their requirements for market access. However, this joint collaboration impact on the market access of innovative health technologies remains unclear as it is still being established and lacks legal framework. In comparison with BeNeLuxA and FINOSE, this joint collaboration also has a higher number of member

countries, which may delay the maturation of this group due to lack of consensus and growing heterogeneity amongst its members. Yet, once again, if the Valletta Declaration Group is well-established and its proposition is adopted, it may have a high level of impact by creating a large market representing 32% of the EU's population (160 million citizens in total).

The remaining 8 joint collaborations identified, which represent the potential to harmonize processes in their regions, create larger markets, create additional budget, and guarantee supply of innovative products, are still in the establishment stages. As frameworks, and institutions for the regulation of and assessment of gene therapies, remain limited and are challenged, the number of joint collaborations established points towards the need for harmonization and standardization, which may facilitate optimal market access for all stakeholders involved in the process. The remaining 8 joint collaborations for innovative therapies vary in the range of participating member countries as well as in the activities they seek to conduct. However, the potential risks for all joint collaborations still apply: the lack of legal framework, clear administration, regulation, and accountability will threaten the success of all these joint collaborations. Ultimately, joint collaborations will experience their greatest challenge when faced with situations requiring legislative changes and implementations. For example, in joint collaborations, it must be highlighted that national regulations and legislation remains in place and precedes joint collaboration procedures, which should be supplementary and noncontradictory to national legislation and procedures [2,41].

In order for joint collaborations to succeed, there must be a solid, clear foundation beginning with a legal framework and agreements outlining roles and responsibilities for accountability and for their outcomes to be accepted at national levels without potential dispute. Joint collaborations must operate as single markets with a unique price and simultaneous access for all. Joining forces with

like-minded and similar cultured countries may lead to further success, as seen with BeNeLuxA and FINOSE. Joint collaborations must select the appropriate products (with proven efficacy and robust evidence; targeting populations with high unmet needs) for their initial activities to test their models in preparation for evaluating complex, highly priced gene therapies with limited evidence. There remains the question of whether or not health technology developers will be interested in negotiating with a group of countries at the cross-border level as the ultimate goal of these joint collaborations is to lower prices to an affordable price. Small and large countries in joint collaborations may have different priorities and perceptions of the goals and aims of the collaboration and how to achieve them. Large countries inherently have higher bargaining power and may succeed in securing better discounts outside of joint negotiations, for example, whilst small countries may expect one unique price negotiation and one price for all countries. Expectations must be managed by setting clear goals and outlining methodologies and processes, as FINOSE did. There are many challenges yet to be overcome by joint collaborations. However, they will mature and if they are able to overcome and adapt to these obstacles, they may be successful in obtaining their goals. Both BeNeLuxA and FINOSE stand testament to their potential success.

DISCUSSION CONCLUSION

Joint collaborations have begun to be established with the aim to increase participating member countries' bargaining and purchasing power while ensuring patient access and maintaining sustainable healthcare systems in the anticipation of an increasing number of innovative therapies, especially highly priced gene therapies, seeking market access. Joint collaborations' activities may include information sharing, horizon scanning, joint assessments, joint negotiations, and joint procurement. EUnetHTA, also established as a

platform for joint assessment, is certainly a progressive step forward in terms of joint assessments, however, its definition that limits collaborations to those consisting of 4 or more country members discredits and does not consider initiatives established between 2 and 3 member countries. It is also dedicated solely to HTA activities and is not considered a decision-making process. EUnetHTA and its efforts have yet to gain increasing momentum.

Two joint collaborations, BeNeLuxA and FINOSE, have been successful in executing their joint assessments in the area of innovative therapies for genetic disorders. These joint collaborations are gathering countries of reasonably similar sizes and GDPs with close cultures, making the individual countries' will to efficiently and effectively work together more important than the overall political and governance matters. Large joint collaborations, such as Valletta, are gathering very heterogeneous countries with dissimilar populations along with dissimilar GDPs and health expenditures, making a joint procurement complex to achieve. Such joint collaborations may only work if the richest countries subsidize the price for the poorest

EU countries through an internal compensation mechanism invisible to external third parties. This would assume a single EU price (with access to 580 million EU citizens) with a differential price per country and an internal subsidy mechanism. This may well be the way forward to establish EU equity in accessing gene therapies. If joint collaborations continue to mature and adapt, they may be able to influence the way innovative health technologies, especially the most highly priced treatments such as gene therapies, seek market access and may influence pricing and reimbursement. Joint collaboration activities require trust, communication, and a legal framework outlining roles and responsibilities in order to hold member countries accountable and ensure activities are being executed as intended. If joint collaborations are able to overcome their inherent obstacles, they will shape the future of innovative health technology and gene therapy market access in Europe, with the assumption that new regulations are put in place to allow a new governance within most member countries to delegate price negotiations to a joint body instead of national pricing committees.

REFERENCES

1. Agency EM. European Medicines Agency, Science Medicines Health - What we do Online: European Medicines Agency: <https://www.ema.europa.eu/en/about-us/what-we-do>
2. Espín J, Rovira J, Calleja A *et al.* European Observatory Policy Briefs. In: Richardson E, Palm W (Eds). *How can voluntary cross-border collaboration in public procurement improve access to health technologies in Europe?* European Observatory on Health Systems and Policies, Copenhagen, Denmark © World Health Organization 2016 (acting as the host organization for, and secretariat of, the European Observatory on Health Systems and Policies); 2016.
3. Kanavos P. A Prospective View on European Pharmaceutical Research and Development. *PharmacoEconomics* 1998; 13(2): 181–90.
4. LV L. Partnership Agreement between the Ministry of Health of the Republic of Latvia, the Ministry of Social Affairs of the Republic of Estonia and the Ministry of Health of the Republic of Lithuania on Joint Procurements of Medicinal Products and Medical Devices and Lending of Medicinal Products and Medical Devices Procurable Centrally Online: LIKUMI LV; 2012: <https://likumi.lv/ta/id/248008-partnership-agreement-between-the-ministry-of-health-of-the-republic-of-latvia-the-ministry-of-social-affairs-of-the-republic-of-estonia-and-the-ministry-of-health-of-the-republic-of-lithuania-on-joint-procurements-of-medicinal-products-and-medical-devices-and-lending-of-medicinal-products-and-medical-devices-procurable-centrally>
5. BELLIS VB. Agreement between Denmark and Norway to Negotiate Jointly Procurement of Medicines Online: VAN BAEL & BELLIS; 2018: <https://www.vbb.com/insights/corporate-commercial-regulatory/agreement-between-denmark-and-norway-to-negotiate-jointly-procurement-of-medicines>
6. FINOSE T-. FINOSE, a Nordic cooperation Online: TLV: <https://www.tlv.se/>

- in-english/international-collaboration/finose---a-nordic-cooperation.html
7. FINOSE. FINOSE joint assessment report: Zytenglo (autologous cd34⁺ cells encoding β A-T87Q-globin gene). Online: FINOSE TLV, 2020 11 May 2020. Report No.
 8. The World Health Organization and International Health Partnership + Related Initiatives. Joint Assessment of National Health Strategies and Plans Online: WHO and International Health Partnership + Related Initiatives; 2011: https://www.who.int/workforcealliance/knowledge/toolkit/24_1.pdf?ua=1
 9. EUnetHTA. What are Joint and Collaborative Assessments? Online: EUnetHTA: <https://eunethra.eu/assessments/>
 10. EUnetHTA. About EUnetHTA Online: EUnetHTA: <https://eunethra.eu/about-eunethra/>
 11. EUnetHTA. An Understanding of EUnetHTA HTA Online: EUnetHTA 2018: <https://eunethra.eu/an-understanding-of-eunethra-hta/>
 12. Commission E. European Commission Green Public Procurement (GPP) Training Toolkit - Module 1: Managing GPP Implementation. In: *European Commission DE-G*. Online: European Commission; 2008: 14.
 13. Commission E. Joint Procurement of medical countermeasures Online: European Commission; 2010: https://ec.europa.eu/health/preparedness_response/joint_procurement_en
 14. Qiu T, Hanna E, Dabbous M, Borislav B, Toumi M. Regenerative medicine regulatory policies: A systematic review and international comparison. *Health Pol.* 2020; 124(7): 701–13.
 15. Qiu T, Hanna E, Dabbous M, Borislav B, Toumi M. Health Technology Assessment of Gene Therapies in Europe and the USA: Analysis and Future Considerations. *Cell Gene Ther. Ins.* 2019; 5: 1043–59.
 16. Alliance EPH. Beneluxa: First results of multi-country cooperation on medicine price negotiations 2017: <https://heatinformatcs.com/sites/default/files/images-videosFileContent/EPHA-Reflection-Paper-Beneluxa-A2M.pdf>
 17. Ireland DoH. Ireland to open negotiations with Belgium, the Netherlands, Luxembourg and Austria on drug pricing and supply – Minister Harris Online: gov.ie; 2018 [updated 27 May 2019]: <https://www.gov.ie/en/press-release/bd03b7-ireland-to-open-negotiations-with-belgium-the-netherlands-luxembourg/?referrer=http://www.health.gov.ie/blog/press-release/ireland-to-open-negotiations-with-belgium-the-netherlands-luxembourg-and-austria-on-drug-pricing-and-supply-minister-harris>
 18. Beneluxa – Initiative on Pharmaceutical Policy. Beneluxa initiative online: Beneluxa; 2020: <https://beneluxa.org/collaboration>
 19. Pisarczyk K, Rémuzat C, Hajjeji B, Toumi M. PCP8 - BENELUXA INITIATIVE: WHY THE FIRST ATTEMPT OF JOINT ASSESSMENT FAILED? *Value Health* 2018; 21: S83.
 20. Beneluxa. Beneluxa Archive Online: Beneluxa; 2018: <https://beneluxa.org/archive>
 21. Pisarczyk K, Hajjeji B, Rémuzat C, Espín J. HT3 – DESCRIPTION AND COMPARISON OF EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT. *Value Health* 2018; 21: S8–S9.
 22. Schmidt M. SG. Emerging Collaboration in EU Drug Pricing and Reimbursement: A Beneluxa Case Study Online: PharmExec.com; 2018: <http://www.pharmexec.com/emerging-collaboration-eu-drug-pricing-and-reimbursement-beneluxa-case-study>
 23. Beneluxa. Joint HTA assessment of Zolgensma Online: Beneluxa; 2020: <https://beneluxa.org/news3>
 24. O’Clock N. Romania and Bulgaria, agreement on the patients’ access to medicines Online: Nine O’Clock; 2016: <https://www.nineoclock.ro/2016/11/11/romania-and-bulgaria-agreement-on-the-patients-access-to-medicines/>
 25. Authority DB. Nordic Collaboration Online: <https://danishbusinessauthority.dk/nordic-collaboration>
 26. Konberg B. The Future Nordic Co-operation on Health. Online: Noden, 2014.
 27. Ryan E. Nordics inch toward cooperation on drug purchasing, but don’t expect early developments Online: IHS Markit; 2017: <https://ihsmarkit.com/research-analysis/nordics-inch-toward-cooperation-on-drug-purchasing-but-dont-expect-early-developments.html>
 28. Grubert N. A landmark for international collaboration on HTA and pharmaceutical pricing Online: LinkedIn; 2018: <https://www.linkedin.com/pulse/landmark-international-collaboration-hta-pricing-neil-grubert/>
 29. AMGROS. International Cooperation Online: AMGROS: <https://amgros.dk/en/about-amgros/cooperation-partners/international-cooperation/>
 30. AMGROS. Joint Nordic Procurement (Denmark, Norway, and Iceland) - Information and dialogue meeting. Online: AMGROS, 2018.
 31. Partnership PA. Ministers of health of CEE countries discuss how to improve access to medicines Online: Patient

- Access Partnership: http://eupatientaccess.eu/page.php?i_id=73
32. Group V. VISEGRAD BULLETIN 5 (2/2017) Online: Visegrad Group: <http://www.visegradgroup.eu/visegrad-bulletin-5-2>
 33. REMIX. The V4 to negotiate on drug prices together Online: REMIX; 2019: <https://rmx.news/article/article/the-v4-to-negotiate-on-drug-prices-together>
 34. Michalopoulos S. Southern EU states present unified front in drug talks Online: EURACTIV; 2017: <https://www.euractiv.com/section/health-consumers/news/southern-eu-states-present-unified-front-in-drug-talks>
 35. Innovations G-GP. Taking stock: European cross-border cooperation on medicines' value-assessment, and Pricing & Reimbursement negotiations Online: GPI; 2018: <https://globalpricing.com/news/taking-stock-european-cross-border-cooperation-on-medicines-value-assessment-and-pricing-reimbursement-negotiations/>
 36. Grubert N. Is the Valletta Declaration Group the most disruptive cross-border market access collaboration in Europe? Online: LinkedIn; 2019: <https://www.linkedin.com/pulse/valletta-declaration-group-most-disruptive-market-access-neil-grubert>
 37. FIMEA. Nordic collaboration (FINOSE) Online: FIMEA: https://www.fimea.fi/web/en/development/therapeutic_and_economic_value_of_medicines/nordic-collaboration-finose-
 38. FIMEA N, and TLV, Memorandum of Understanding. Online: Fimea; 2017, 6.
 39. FIMEA N, and TLV, FINOSE – PROCESS FOR JOINT ASSESSMENT. Online: FIMEA, NoMA, and TLV; 2019.
 40. Bruce F. Norwegian-Danish Procurement Deal Targets Biogen's Spinraza Online: Pink Sheet – Informa Pharma Intelligence; 2018: <https://pink.pharmaintelligence.informa.com/PS123958/NorwegianDanish-Procurement-Deal-Targets-Biogens-Spinraza>
 41. Grubert N. Challenges of cross-border collaboration on market access – lessons from the Beneluxa experience Online: LinkedIn; 2019: <https://www.linkedin.com/pulse/challenges-cross-border-collaboration-market-access-lessons-grubert/>

AFFILIATIONS

Monique Dabbous

Public Health Department, Research Unit EA 3279, Aix-Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille, France

Eve Hanna

Creativ-Ceutical, 215 Rue du Faubourg Saint-Honoré, 75008 Paris, France

Boris Borislav

Prescriptia Ltd., Sofia, Hristo Botev Blvd. № 28, Bulgaria

Claude Dussart

Université Claude Bernard, Laboratoire Parcours Santé Systémique, EA 4129, Faculté de Médecine Laennec, 7-11 rue Guillaume Paradin, 69372 Lyon Cedex 08, France

Mondher Toumi

Author for correspondence
Public Health Department, Research Unit EA 3279, Aix-Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille, France
mondher.toumi@univ-amu.fr

AUTHORSHIP & CONFLICT OF INTEREST

Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgements: None.

Disclosure and potential conflicts of interest: Dr Toumi is a consultant for a vendor providing services for Industry and governmental bodies.

Funding declaration: The authors received no financial support for the research, authorship and/or publication of this article.

ARTICLE & COPYRIGHT INFORMATION

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Attribution: Copyright © 2020 Dabbous M, Hanna E, Borislav B, Dussart C & Toumi M. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

Article source: Invited.

Revised manuscript received: Aug 7 2020; **Publication date:** Sep 1 2020.

COMMENTARY

Challenges in the adoption of regenerative medicine therapies, meeting summary

**Maya Chaddah, Allison Brown, Siofradh McMahon,
James Kusena, Karen Bremner, Ann Perry & Murray Krahn**

Currently, there is scant evidence of policies that adequately outline the process for therapies and technologies in the regenerative medicine (RM) field, known in the EU as Advanced Therapy Medicinal Products (ATMPs). Areas such as payment mechanisms, pricing and reimbursement schemes still remain largely elusive. Clear policies are pertinent due to ATMPs such as KYMRIA[™] and YESCARTA[®] that have been approved, but how they and future ATMPs will be sustainably paid for remains unclear for many healthcare systems globally. Also, their long-term effects are not yet known, and social, ethical and legal issues have not always been adequately considered.

The scarcity in defined reimbursement and adoption policies for ATMPs prompted the development of an international workshop on the 'Challenges in the Adoption of Regenerative Medicine Therapies (CHART)'. Co-hosted by Medicine by Design (a regenerative medicine initiative at the University of Toronto and funded by the Canada First Research Excellence Fund), CCRM, Toronto Health Economics and Technology Assessment (THETA) Collaborative, and the Centre for Biological Engineering at Loughborough University UK, CHART focused on the post-market approval challenges associated with economic evaluation, reimbursement and adoption of regenerative medicine products. The challenges were explored in the context of the Canadian and UK healthcare systems as provision of health in both countries is largely via publicly funded systems. The workshop was attended by 37 experts from institutions and companies from Canada, the UK, and the USA that included representatives of the Ontario government, National Institute for Health and Care Excellence (NICE), Canadian Agency for Drugs and Technologies in Health (CADTH), Takeda Canada, Gilead Sciences Canada, Inc., Office of Health Economics (OHE), Centre for Health Economics (CHE), University of York, and Oxford Academic Health Science Network (OAHSN) amongst others.

Proceedings from the workshop demonstrated that challenges regarding ATMP adoption are not unique to the regenerative medicine field. (1) Current methods of evaluation are applicable to ATMPs, but the biggest challenge for these novel therapies is providing evidence that reduces the uncertainty of their long-term effects. (2) The generation of evidence of clinical effectiveness needs to be improved by ensuring clinical trial designs employ robust controls and increase their sample sizes while collecting data in the relevant setting. (3) Incentives for real-world evidence capture should be established to ensure that data are gathered and can be used to further evaluate the therapies for long-term clinical effectiveness and adverse effects. (4) The implementation of ATMPs will require concerted efforts from multiple stakeholders to ensure that the adoption pathway for ATMPs is efficient, effective and aligned with social values. (5) There needs to be greater interaction with policy makers, as political will is essential for research to progress into meaningful efforts. (6) There is a need to improve patient management and data management to aid in evidence generation and facilitate outcome-based payment mechanisms. (7) Payment mechanisms remain a challenge; the sustainability of current payment methods for expensive therapies will need to be evaluated, prior to the approval of more ATMPs. The next steps outlined from the workshop included: targeted policy maker engagement, relevant stakeholder engagement, addressing the evidence generation issues, and understanding future payment system mechanisms.

Cell & Gene Therapy Insights 2020; 6(7), 887–921

DOI: 10.18609/cgti.2020.099

PRESENTATION HIGHLIGHTS

Session 1: Evidence of Clinical Effectiveness

Speakers

- ▶ Pilar Pinilla Dominguez, Senior Scientific Advisor, National Institute for Health and Care Excellence (NICE; UK)
- ▶ Dr John Kuruvilla, Hematologist, Princess Margaret Cancer Centre, University Health Network (Canada)

Discussants

- ▶ Tania Bubela, Dean, Faculty of Health Sciences, Simon Fraser University (Canada)
- ▶ Alex Klarer, Biomedical Engineer, Hitachi Chemical Advanced Therapeutics Solutions, LLC (USA)

National Institute for Health and Care Excellence (NICE) experience on evaluation of cell and gene therapies

NICE was established as a legal entity in 1999 and for the past 20 years has been providing national guidance to improve the outcomes for those using the National Health Service (NHS) and other public health and social

care services in the UK. In the context of regenerative medicine products, ATMPs are not new and assessing their clinical effectiveness is pivotal to informing payors and patients as to their clinical benefits.

The first NICE technology appraisal was in December 2000 for autologous cartilage transplantation for full thickness cartilage defects in knee joints. Since then there have been many product development failures, either due to clinical reasons or feasibility of commercialization. Many ATMPs have now been evaluated at NICE and seven have been recommended to date. For all new cases, the NICE framework addresses six key questions that together explore the clinical effectiveness of a therapy, and its added value, benefits and additional costs compared with established practice (**Box 1**).

These are exciting times, with the promise of major benefits stemming from novel ATMPs including CAR T and other gene therapies, as well as therapies targeting biomarkers, and combination therapies. CAR T therapy has grown out of decades of immunologic research, with the first CAR T clinical trial in 2006 for adult patients with ovarian or renal cancer, and the first pediatric patient, Emily

▶ BOX 1

Key questions from NICE appraisals.

1. What is the evidence supporting the benefit and safety of ATMPs?
2. What is the structure of the data/evidence?
3. How do we ascertain the clinical benefits of ATMPs? Does their promise of cure/long-term effect make them different?
4. What is the strength of the evidence?
5. How can these technologies be evaluated when the sample size is very small?
6. How can both payors and regulators be satisfied by producing adequate data?

Whitehead, successfully treated for lymphoma in 2012. With the hope of treating cancer, CAR T has become a highly disruptive therapy that poses important challenges from a health technology assessment (HTA) perspective.

In HTA, the goal is to evaluate whether a technology is clinically- and cost-effective in order to inform whether it should be adopted in the health system. Timely patient access is also important for early HTA of emerging technologies. For single-arm trials, where a sample of individuals with a medical condition is given an experimental therapy and observed over time, NICE's technology appraisals of CAR T trials have uncovered some key issues relating to their clinical- and cost-effectiveness:

1. Inability to make a direct and robust comparison between trial and comparator groups;
2. Limited evidence where randomized controlled trials are not always possible, and sample sizes are small, limiting generalizability and external validity;
3. Short (or not yet reached) median follow-up involving a high degree of censoring;
4. Assumptions required about the curative effect and uncertain adverse effects of CAR T therapies;
5. Uncertainty around the number of patients who subsequently have a transplant (particularly relevant for acute lymphoblastic leukemia, ALL);


6. Uncertainty around the location in the treatment pathway with the most value;
7. Uncertainty around cost of long-term adverse effects and treatments that can extend the life of patients at end of life; and
8. No clear window into patient-relevant outcomes at the time of HTA evaluation; only data on surrogate or intermediate rather than final/clinical outcomes available.

In light of these limitations, the NICE committee agreed that while the trials are promising, the short-term follow-up and the many clinical uncertainties are still a major concern.

Many ATMPs have been developed by academic researchers or small and medium size enterprises (SMEs) where lack of funds means that HTA-relevant data may not always be generated from the outset. To help address this issue, NICE, through the Scientific advice programme, advises companies on their clinical and economic development program, HTA requirements and evidence needed to prepare for HTA evaluation. Companies most often have questions around single-arm trials, historical controls, matching adjusted indirect comparisons, trial design, patients as own controls, and questions related to extrapolation and follow-up. Many developers are more familiar with regulatory data requirements than HTA-related data requirements and are unaware that alignment between the two is an important consideration and

► **FIGURE 1**

Alignment between Health Technology Assessment Bodies (HTABs) and regulators.



A retrospective analysis of 31 different procedures from 2010 to 2015 assessed the level of agreement between HTABs and regulators across five domains (population, comparator, endpoints, design, efficacy and safety data package). Blue indicates full agreement, red partial agreement and green no agreement. Across the five domains, the clearest misalignment is in the comparator domain [1].

impacts how HTA is conducted. As shown in **Figure 1 [1]**, there has been an improvement in alignment between Health Technology Assessment Bodies (HTABs) and Regulators. The clearest misalignment between the two groups is in the comparator domain. This is a clear signal to companies that they need to think about HTA requirements earlier on.

Anti-CD19 CAR T cells for diffuse large B cell lymphoma (DLBCL) as a model

John Kuruvilla used the specific example of DLBCL to provide insight into the evidence development process for ATMPs, with the example of CAR T therapy. His group previously worked with Celgene and is working with Kite, a Gilead Company, as one of the Canadian sites, and will also be working with Novartis and Juno/Celgene/BMS.


In Canada, the expertise to transplant CAR T cells is concentrated in three to four centers that participated in the early-phase studies, but has since broadened to include

approximately 15 centers across the country. Princess Margaret Cancer Centre at the University Health Network (UHN) is one of the largest bone marrow transplant practices in North America, with more than 600 transplants conducted every year. Due to this high volume of procedures, hematologists there are very familiar with the principles of CAR T in clinical practice (**Figure 2**).

All the first-in-human CAR T studies, done in academic centers, provided proof-of-concept for CAR T therapy but important lessons have emerged around feasibility, platform development, efficacy and safety. In terms of feasibility, the CAR Ts were manufactured in a single setting; an important question that arises is whether they can be scaled for multicenter trials and for a global setting. Lymphodepletion, cell dose, and product composition are also areas where current processes need to be improved. Lymphodepletion is particularly important because CAR T cells are a 'living drug' and without

▶ FIGURE 2

How CAR T therapy works in clinical practice.



The generation of CAR T cells from a patient's T cells is a lengthy process involving many steps (1–4). Chemotherapy to delete resident lymphocytes (5) is crucial for preparing the niche for the CAR T transplant. CAR T cells infused into the patient (6) are able to recognize specific antigens on the surface of cancer cells and initiate their destruction (7).

lymphodepletion, the transplanted cells do not expand. While there was a practical dose that led to the observed results in the early studies, the optimal dose has yet to be determined. In addition, the product composition varies by manufacturer, with only one company having looked at the ratio of CD4⁺ to CD8⁺ T cells. In the high-risk patient population that was studied, there were signs of efficacy but there are still unknowns about whether the responses are durable and the mechanisms of resistance or failure. One of the important lessons learned from these early studies was that two toxicities were identified: cytokine release syndrome (CRS), largely an interleukin (IL) 5-driven phenomenon leading to a cytokine storm, and capillary leak syndrome which requires intensive care.

To date, the trial with the longest follow-up is the ZUMA-1 study treating patients with refractory DLBCL with a CAR T therapy (axicabtagene ciloleucel) [2]. The Phase 1 portion of the study was a limited sample size and demonstrated that the cells could be manufactured and distributed to sites in the USA and Canada effectively. The expansion cohort of the Phase 2 trial included refractory DLBCL and two other subtypes of aggressive lymphoma. The trial was designed to assess the overall response rate, which was 82% (complete response rate 54%) with a 15 month progression-free survival (PFS) of 41%. The key toxicities generally occurred early but were manageable with a grade 3 or greater rate of cytokine release syndrome (CRS) and neurotoxicity rate of 13 and

28%, respectively. The late-event toxicities, including infectious toxicity, and sequelae of long-term B cell aplasia, suggest that CAR T cells are still present and active leading to prolonged B cell aplasia and hypogammaglobulinemia. Longer-term follow-up of the ZUMA-1 study with data follow-up at the 2-year mark was quite reassuring and there were no additional safety signals seen with later events [3].

For current Phase 2 trials, there is demonstrated proof-of-concept in terms of being able to do large, multicenter, global CAR T cell trials. But Kuruvilla cautioned that one cannot compare the roster of Phase 2 trials head to head as they may use different CRS grading systems, and the starting patient populations are not always identical. There are additional data coming from these trials that will inform whether chemotherapy can be given to patients while the CAR T cells are being manufactured.

One of the interesting questions that arises from current Phase 2 studies is whether CAR T cells need to be in the system forever or whether persistence may be a moving target in terms of the disease that is being treated. In many patients who are in remission, CAR T cells disappear but that doesn't mean impending relapse. There is a recovery of immunoglobulins and recovery of B cells in the peripheral blood so it may be sufficient for the CAR T construct to be in the system for as little as 6 months.

Going forward, many companies are opening randomized Phase 3 trials around the world. The Food and Drug Administration (FDA) has approved very similar designs in terms of the patient population and the standard, accepted surrogate end point of event-free or progression-free survival. Variations will be in cell dose, hospitalization or not, the subset of lymphoma and the Eastern Cooperative Oncology Group (ECOG) Performance Status, which scores a patient's level of function.

In summary, Kuruvilla stressed that compared to other therapies, CAR T is managed in the clinic as a 'one and done' treatment.

That means that there isn't the same data collection that one sees in other studies where treatment is ongoing until progression. Although the CAR T therapy process is similar to other drug therapies, Kuruvilla noted that regulators and payors are pausing over the complexity of the products as well as the magnitude of the cost; the need for timely decision-making is huge.

Insight from discussants: session 1

Complicated therapies

We are victims of our own hype and this is accelerating ATMP products into the market at a rate that we would not otherwise see for other types of technologies.

"We need to innovate in this space; however, we need to be very careful about our incentives and keep our decisions informed by empirically-grounded evidence."

– Tania Bubela

Headroom analysis

It is important to consider whether there is a sufficient unmet need for candidate ATMPs to support a price consistent with an acceptable return on the investment.

"We see very limited target product profiles based on preclinical studies and surrogate analytical measures and they are not always tied to patient efficacy in the long term."

– Alex Klarer

Informing costs

We need to invest more in cell processing, manufacturing, and scale up, and economic models can help to inform developers in bringing down the costs.

Risk sharing

As a society we have not yet had a discussion about the extent to which we want public-sector dollars to pay for things that are currently

in the research and development budgets of pharmaceutical and biotechnology companies. If developers are expecting these kinds of products to be coming through with conditional approvals, and if they are forced onto our public payor systems with a lower evidence threshold, then the developers should be expected to participate in risk sharing on the funding of these types of therapies.

Patient variability & product analysis

Many product profiles don't measure patient variability and there is limited incoming product analysis. For example, Juno Therapeutics, (now a Celgene company) is looking to reformulate its final product so that there is a one-to-one CD4/CD8 T cell ratio for the final product and to select for naïve markers in the starting product to reduce product variability.

Strong product profiles

Clinical stage companies heading to commercialization need to prepare for the Investigational New Drug (IND) phase or pre-IND by building a strong product quality profile that allows production of a consistent and efficacious product. With very accelerated clinical timelines and conditional approvals, there is little time to put more stringent measures in place and re-evaluate the product profile; that will affect long-term outcomes and drive long-term revenue from within whatever payor model companies are selling.

Highlights from open discussion: session 1

1. Lowering the bar for evidence generation is not the answer as we have a duty to patients to have some certainty around our recommendations. However, it is not yet clear how to complement sub-optimal evidence while understanding the manufacturers' difficulties in running the studies. Collecting clinical and patient-relevant outcomes will provide confidence to decision-makers that real-world

evidence will be generated and can be looked at again.

2. Although randomized controlled trials (RCTs) are the gold standard, there are justifiable circumstances (e.g., treatments for rare diseases) in which the collection of gold standard evidence is very difficult. In such cases, it will be necessary to coordinate data internationally. This poses a problem in Canada because to date we are unable to easily share data among health authorities within and across provinces.
3. Canada needs a national registry and database to manage the follow-up of ATMPs. We lag behind other countries and are not well-funded provincially to manage these types of disparate data sets across national and international borders. The long-term follow-up is even more problematic with retrovirally-modified products which often require follow-up for 25 years.
4. Market access in Canada includes engagement with health systems. We need to promote to developers that they can have parallel engagement with both the HTAs (Canadian Agency for Drugs and Technologies in Health, CADTH, and Institut National d'Excellence en Santé et Services Sociaux, INESSS), and Health Canada.

Session 2: Health Economics

Speakers

- ▶ Ana Duarte, Research Fellow, Centre for Health Economics (CHE), University of York (UK)

Discussants

- ▶ Grace Hampson, Senior Principal Economist, The Office of Health Economics (OHE; UK)

- ▶ Pilar Pinilla Dominguez, Senior Scientific Advisor, National Institute for Health and Care Excellence (NICE; UK)
- ▶ William Wong, Assistant Professor, School of Pharmacy, University of Waterloo (Canada)

Challenges in economic evaluation of ATMPs

In 2014, the UK Department of Health set up the Regenerative Medicine Expert Group (RMEG) to develop an NHS regenerative medicine readiness strategy and assess the effect of regulation on the development of regenerative medicines in the U.K. In advancing this goal, the RMEG recommended that an exploratory study of the appraisal of regenerative medicine products be commissioned and published by NICE to highlight key issues in the evaluation of regenerative medicines and explore the suitability of current methods. Towards this goal, the University of York conducted an assessment of a hypothetical CAR T therapy. The mock technology appraisal was conducted by the Expert Panel, mimicking a NICE technology appraisal committee, which was informed by the University of York assessment and by the views of the expert panel members. The mock appraisal of a CAR T cell therapy explored two potential profiles of this technology: i) as a bridge to hematopoietic stem cell transplant (HSCT) or ii) with curative intent, using a hypothetical data set for acute lymphoblastic leukemia (ALL) in young adults and children. The benefits and costs of the two hypothetical target product profiles (TPPs) in **Table 1** are taken from the report Exploring the Assessment and Appraisal of Regenerative Medicines and

Cell Therapy Products [4]. The incremental quality-adjusted life year (QALY) benefit of either of the two explored hypothetical profiles far exceed that of conventional cancer treatments.

The general conclusions were that while the methodology of NICE and the decision framework were applicable to regenerative medicine and cell therapies, for technologies with high costs, limited evidence and benefits being accrued over long time-horizon, the exploration of uncertainty is key to inform decision-making. The York group devised a novel framework to assess this uncertainty that is not part of the standard NICE methods guidelines. Another concern was the extrapolation of benefits as a key driver of cost effectiveness and the risks of irrecoverable capital costs as therapies are rolled out. The appropriate discount rate to apply to costs and benefits was also an important point of discussion. The key recommendations for NICE were:

1. To continue to develop a framework to quantify and present consequences of uncertainty to decision-makers, building from the framework proposed by York;
2. To collaborate with other stakeholders to develop novel practical payment methods, such as leasing;
3. To consider the implications of this study when reviewing the criteria for the application of lower discount rates on costs and outcomes.

In the UK, NICE has conducted two appraisals on CAR T therapies (axicabtagene ciloleucel and tisagenlecleucel) that are now funded through the UK Cancer Drugs Fund (CDF) [5] via well-defined managed-access

▶ TABLE 1 Hypothetical target product profiles (TPP) [4].

| | Bridge to HSCT TPP | Curative intent TPP |
|---|--------------------|---------------------|
| Assumed individual patient level incremental quality adjusted life year (QALY) gain | 7.46 | 10.07 |
| Assumed price (acquisition cost of the therapy) | £356,100 | £528,600 |

▶ BOX 2

The Cancer Drugs Fund (CDF) [5].

Established in 2011 and managed by NICE since 2016, the CDF is a tool for recommending cancer drugs with high clinical uncertainty that would not otherwise be recommended in NHS England. The new CDF framework is a managed-access scheme with clear entry and exit criteria that aims to:

1. Provide patients with faster access to promising cancer drugs;
2. Drive value for money for taxpayers in drugs expenditures; and
3. Offer pharmaceutical companies that price their products responsibly an accelerated NICE appraisal process and a new CDF managed-access scheme.

agreements (MAAs) (Box 2). For therapies to qualify for the CDF, all the plausible scenarios must be under the cost-effectiveness threshold. The manufacturer of axicabtagene ciloleucel agreed to an MAA, the details of which are confidential. In Canada, CADTH is the independent, not-for-profit organization responsible for providing Canada's healthcare decision-makers with objective evidence to make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in the healthcare system. Following the review of tisagenlecleucel and axicabtagene ciloleucel by CADTH, the Health Technology Expert Review Panel (HTERP) advisory board recommended the provision of both therapies in Canada, with conditions, including a substantial reduction in price.

The University of York, as the evidence review group for the NICE technology appraisals on CAR-T, identified key issues across all the CAR-T appraisals.

1. Target population and proposed positioning is critical in that the population defined by the marketing authorization is broader than the trial populations, and there are also concerns over finding the relevant comparator/standard of care in the treatment pathway.
2. Violation of the intention-to-treat (ITT) principle has implications on cost and health outcomes.
3. Extrapolation of overall survival is critical to cost-effectiveness, but assumptions

need to be made around potential curative effect, longer-term excess mortality, and possible late relapse.

4. Resource and cost uncertainties arise because:
 - a. not all appraisals considered bridging versus lymphodepleting chemotherapy;
 - b. there were differences in administration and monitoring requirements (inpatient versus ambulatory); and
 - c. there were differences in incorporating relevant costs from managing adverse events (e.g., CRS and B-cell aplasia, intensive care, readmission).
5. Implementation issues for introducing CAR T therapy into the UK included:
 - a. lack of expertise and capacity to expand from other similar services like stem cell transplantation;
 - b. how to phase in implementation; and
 - c. the need for new training requirements.

Real-world evidence published post-appraisal identified other key issues.
6. The efficacy data for CAR T cells was reasonably consistent for fitter patients but less so for those with ECOG performance status greater than or equal to 2.
7. There were greater rates of drop off between the point of leukopheresis and

▶ TABLE 2
Current approval status of CAR-T therapy [6].

| | Tisagenlecleucel (Kymriah™) | Axicabtagene ciloleucel (Yescarta®) | Brexucabtagene autoleucel (Tecartus™) |
|--------|---|--|---|
| Canada | Health Canada Sept 2018 CADTH Jan 2019 (pediatric ALL and DLBCL) | Health Canada Feb 2019 CADTH Aug 2019 (adult r/r LBCL) | |
| USA | FDA Oct 2017 (adult LBCL, DLBCL, primary mediastinal) | FDA May 2018 (adult DLBCL, high-grade CLL) | FDA July 2020 (adult r/r mantle cell lymphoma) |
| UK | EMA Aug 2018 NICE Dec 2018* (r/r ALL up to 25 years) NICE March 2019* (r/r adult DLBCL) | EMA Aug 2018 NICE Jan 2019* (adult DLBCL and primary mediastinal LBCL) | |

* Recommended for use on the CDF only.

CAR T cell infusion than suggested by the trials.

- 8. The use of bridging chemotherapy in the population was considerable, whereas for some of the previous trials (e.g., ZUMA-1) bridging chemotherapy was not allowed.
- 9. Resource use associated with treatment of adverse events and rates of readmission were much higher than observed in trials.

These differences suggest that some of the costs of CAR T therapy may have been underestimated in the NICE appraisals, but the key driver for the estimate of cost-effectiveness was the choice of comparator data and the extrapolation of overall CAR T cell survival. And even though there is now more

follow-up data, there are areas of uncertainty that remain; namely, the possibility of late relapse, and the duration of B cell aplasia and the need for treating it over time. The current approval status of CAR T therapies in Canada, the UK and USA is shown in **Table 2** [6].

In summary, CAR T cells are highly innovative and have the potential to improve patient outcomes, but they are expensive and require infrastructure changes that might not be captured in the cost-effectiveness analysis. The group at York University, UK, still posits that the uncertainties and their consequences may not be fully considered in the NICE methods. The use of more innovative pricing arrangements, insofar as they are linked to a quantification of uncertainty and what that uncertainty

▶ TABLE 3
BioCanRx modelling exercise [7].

| CAR T wait time | ΔCost (CAR T vs chemo) | ΔQALY (CAR T vs chemo) | ICER (CAR T vs chemo) |
|-----------------|------------------------|------------------------|-----------------------|
| No delay | \$392,230 | 3.54 | \$110,799 |
| 1 month | \$352,015 | 2.97 | \$118,524 |
| 2 months | \$315,469 | 2.34 | \$134,816 |
| 3 months | \$282,015 | 1.56 | \$180,779 |
| 4 months | \$232,043 | 0.91 | \$254,992 |
| 5 months | \$183,463 | 0.36 | \$509,619 |
| 6 months | \$142,033 | -.02 | Dominated |

means in terms of opportunity costs elsewhere in the health system, still remains an important area of further investigation. Going forward, it is difficult to predict what shape the NHS England commercial deals will take after access within the CDF has expired.

Insight from discussants: session 2

Getting all the stakeholders in the room

In the UK, NICE looks at value through HTA, and NHS England is the main stakeholder in the commercial deliberations. We need to move away from having two sequential debates to instead having both stakeholders in the room.

Hypothetical wait time for CAR T therapy for DLBCL patients

A modelling exercise funded by BioCanRx, Canada's Immunotherapy Network, used the ZUMA-1 trial for the CAR T arm and the SCHOLAR-1 trial for the chemotherapy arm. (The SCHOLAR-1 trial was the first patient-level analysis of refractory DLBCL and pooled data from two Phase 3 clinical trials and two academic databases). This BioCanRx study showed that mortality increases with a wait times of longer than 3 months. At wait times of 9 months, the 1-year mortality rate for CAR T hits the standard chemotherapy arm. The impact of CAR T wait time on cost-effectiveness, QALY and incremental cost-effectiveness ratio (ICER) for CAR T versus chemotherapy in the BioCanRx Modelling Exercise is shown in [Table 3 \[7\]](#).

Highlights from open discussion: session 2 (see also [Box 3](#))

1. Improving methodology: Little is new or different about trying to conduct a proper economic evaluation of an ATMP. However, there are specific issues that arise in trying to operationalize a conventional HTA; for example, immaturity of the data, extrapolation both with respect to survival and health-related quality of life effects, small sample sizes, single-arm and short-term trials, and surrogate outcomes. The current methods also require assumptions that the data are not always able to support so there is room for methodological improvement.
2. Randomized data: The lack of randomized data to populate these models creates a host of problems: estimating treatment effect correctly, estimating uncertainty associated with treatment effect, and correctly specifying lack of randomization with some parameter in the model. In addition, using non-randomized data means that one must potentially set differential start times for two cohorts.
3. Re-evaluating costs: In England, CAR Ts in the CDF will be re-evaluated after 5 years and that will provide an opportunity to look at data from the long-term clinical trials and the incidence of adverse events plus real world data collected through the CDF. It will also be important to assess program costs, population-level screening programs


▶ **BOX 3**

Questions for further consideration: session 2.

- ▶ Trial design: For single-arm trials, do we need more data for comparisons and new methods to make the comparisons or should we simply require RCTs?
- ▶ Impact on the ICER: Do we need new methods for dealing with the complexity of ATMPs or should we take a pragmatic approach based on the data we have?
- ▶ Uncertainty: How do we mitigate risk if we need to make the decision immediately? Are MAAs answering the question that we really need them to answer? Even if we wait to collect the data to mitigate risk, there are other uncertainties that play a big role.

► **FIGURE 3**

Advanced therapeutics product pathway – proposed regulatory sandbox.



The regulatory sandbox is a new triage process for Health Canada to authorize unique advanced therapeutics. Health Canada provides a concierge service to help clients assess whether their products can be considered for the advanced therapeutics pathway and to design rules for market access via individual licences or orders of permission [8].

and training costs, such as resetting a stem cell transplant unit to provide CAR T cell therapy treatments.

Session 3: Social Values in the Evaluation of Regenerative Medicine

Speakers

- Jennifer Gibson, Director, Joint Centre for Bioethics, University of Toronto (Canada)

Discussants

- Fiona Miller, Professor, Institute of Health Policy, Management and Evaluation, University of Toronto (Canada)
- Tania Bubela, Dean, Faculty of Health Sciences, Simon Fraser University (Canada)

Bioethics is considered the third pillar of HTA and often comes last in the discussions around evidence-based medicine and policy. Jennifer Gibson invited the audience to move

away from this paradigm and to think upstream about the values that apply to emerging technologies.

In July 2019, as part of Bill C-97, Health Canada opened a consultation on clinical trial regulations and a newly proposed pathway for approval of “advanced therapeutic products”. This new regulatory pathway, referred to as a ‘regulatory sandbox’, allows the regulator to work with the developer to appropriately regulate products that do not otherwise fit within existing definitions of medicines or devices (Figure 3) [8]. The regulatory sandbox provides a path to market for even the most complex and innovative therapeutic products and allows for controlled regulatory science experimentation, ensuring innovative products can be regulated appropriately and made available to patients who need them.

In the last few years, Canada, the UK and the USA have all approved to a greater or lesser extent CAR T cell therapies for particular populations (Table 2). The promise of these and other personalized medicines is driving


the discourse around which technologies are explored at an individual level. However, as shown in **Figure 4 [9]**, there can be tension between balancing the needs of individuals with the needs of the population across policies and practice. Health systems must also balance the principles of autonomy and non-maleficence with solidarity, equity and distributive justice.


While the Canadian system has done a good job of implementing standards as they apply to drugs and devices, it is still exploring whether there is something unique about ATMPs that will require a different balance.

In collaborating with Cancer Care Ontario (CCO) to explore the ethics of CAR T therapy, Gibson was struck by the complex policy uncertainties around CAR T therapies, from classification, to regulatory, evidentiary, clinical, funding, and public values, and how the uncertainties could be approached in a publicly defensible way that would be evidence-informed, values-based and flexible enough to respond to an evolving context. She highlighted some of the key questions that capture the emerging uncertainties.

1. Should we be applying a research ethics paradigm or a clinical ethics paradigm?
2. Are the regulatory protocols fit for purpose to address policy and governance challenges?
3. What is the right balance between benefits for novel therapies versus the risk, and who ought to decide?
4. Who should have access to CAR T therapies given the risk and how and where should the therapy be delivered given that delivery within specialized centers will raise constraints on geographical access?
5. Are CAR Ts affordable? Who should pay for them, and what is the true cost of their implementation when factoring in the costs (e.g., travel) that patients will have to bear?
6. Which public values should inform the choices about ascribed risks and delivery of CAR T therapies?

In framing the complex policy uncertainties as different types of problems (technical,





process and social values), one can begin to flesh out some possible solutions. Technical solutions might include retrofitting current regulations, better use of data, developing better economic models based on that data, and refining HTA methods and tools. Process solutions could involve managing in a participatory way the institutions that are involved with decision-making (transparency), training, negotiation and post-market surveillance. Social values solutions could include public engagement, broad sampling of perspectives, contextual understanding and values.

Gibson emphasized that apart from the technical solutions that give the right answer or the process solutions that give a reasonable

answer, it is critical in this rapidly evolving ecosystem of ATMPs to foster public trust. In Canada, recent polls have shown that public trust is highest for not-for-profit institutions such as healthcare providers and universities, and lowest for life and health insurance companies, politicians and the media.

Gibson also reviewed the principles of responsible innovation [10]. These came, in part, out of the Ethical, Legal and Social Implications (ELSI) program, founded as part of the Human Genome Project. Broadly speaking, responsible innovation means “taking care of the future through collective stewardship of science and innovation in the present” [9]. As it applies to health, the Responsible

Innovation Framework (RIH) (Figure 5) [10] is “a collaborative endeavor where stakeholders are committed to clarify and meet a set of ethical, economic and social and environmental principles, values and requirements when they design, finance, produce, distribute, use and discard sociotechnical solutions to address the needs and challenges of health systems in a sustainable way” [11]. The value domains (population health, health system, economic, organizational, and environmental) of a responsible innovation in health framework are considered throughout the life cycle of health innovations. Gibson concluded that the particular values within each domain need to be further explored with the view to building population-relevant versus individual-relevant values into an iterative process. This discourse should engage patients, who need to be added to the regulatory sandbox as the primary stakeholders that inform complex policy uncertainties.

Insight from discussants: session 3

Questioning the high cost of CAR T therapies

There is a conflation of interest among researchers, industry, media and patients in getting good news stories out to the public. But in all the stories about CAR T, no one questions why they are high-cost despite the fact that CAR T was developed using National Institutes of Health (NIH) funding at the University of Pennsylvania, which is on the patents, and that there are requirements on rights of use for the USA federal government.

“A full suite of partners needs to be at the table for participatory governments to enhance trust in our institutions and decision-making bodies.”

– Tania Bubela

Hype in the media

There is a definite bias in how stories are reported in the media, which is where a majority of people get their health information. For

example, few stem cell products have been approved beyond bone marrow transplantation, a fact that gains little media traction, and rarely is it discussed that gene therapy is not curative where degeneration has already started. Similarly, because the results from stem cell clinical trials (e.g., cardiac stem cell trials) may not be reported, the public may not learn about the efficacy of regenerative therapies. These shortcomings lead to a hype-bubble of expectation that regenerative medicine will have a real clinical impact in a host of diseases for which we do not have treatment options and for which patients are desperate for any treatment, let alone a cure.

“We shouldn’t just assume adoption. We should evaluate. We need to think much more creatively at the adoption stage about how we are going to deal with this innovation system because what happens here at adoption isn’t just neutral, it has an effect.”

– Fiona Miller

The hype-bubble has spawned thousands of clinics in the USA and Canada that are promising stem cell cures, using supposed treatments that are not benign. In sifting through the database of ongoing clinical trials to understand the landscape, it is important to note that clinicaltrials.gov, a database of privately and publicly funded clinical studies from around the world, is simply a registry and does not include any quality control. Regulators such as the FDA and Health Canada are now stepping in to try to shut down fraudulent clinics by clarifying the regulatory stance that cell therapies are in fact drugs; at the end of the day, the enterprise of science should be based on credible evidence of safety and efficacy for patients and identify issues that diminish the public’s trust in regulatory and reimbursement agencies.

Strengthening our regulatory environment

We are functioning in a regulatory environment where people doing HTA and

reimbursement are dealing with decisions about what qualifies as adequate evidence to allow access to market, and where there is a stronger emphasis on market access than on public health. There has been some pushback to this, and in 2013 Health Canada raised the bar on transparency under Vanessa's Law to protect Canadians from unsafe drugs and devices. We need to be asking why statutory/regulatory review is emphasizing market access.

Innovation in finance

Finance for our innovation system is extraordinarily expensive and has a large number of players – from dominant enterprises that self-finance innovation and R&D, to start-ups and venture capital firms that want to get paid vast amounts of money. For this reason, we need to think more creatively at the adoption stage and innovate at the HTA reimbursement stage, particularly around transparency of R&D costs, transparency of where taxation is being paid, the acceptable return on investment for a company, and the price government will pay. It is not just about the ICER; it is a bigger upstream question.

Highlights from open discussion: session 3 (see also Box 4)

1. Engaging the public: We have to be careful to avoid falling into the deficit

model of public understanding of science, which infers that if the public knew more about science, they would think more like scientists. In fact, people's judgments and values and heuristics about how they think through problems are generally defined from a suite of social characteristics that have little to do with how much more information they receive. We need to let unanticipated questions from the public rise to the surface and to be more innovative about where we engage in public discourse and go to the locations, like yoga studios and church basements, where people have conversations that matter.

2. Innovations in Canadian CAR T patent development: In Canada, we are using regulatory filings as a tailorable exclusivity period to provide developers with a fixed term, relative to their innovativeness, of exclusivity on the market after which time generics or biosimilars can have a rapid entry. We need to bring more innovation to our toolkit that applies to the intersection of intellectual property, data exclusivity and patent terms. For example, some suggest that an extended market exclusivity period could be granted commensurate to the degree to which companies agree to share their data in the public domain.

▶ **BOX 4**

Questions and comments for further consideration: session 3.

- ▶ Some argue that HTA expresses social values related to our respect for science and for the wise use of healthcare resources. To what extent can we respect these values in this context by taking our HTA methods and our activities seriously? Transparency of rules and following them is one of the best ways to do that. But one of the problems with HTA is that it brings a distinct and arbitrary logic to the allocation system. It brings a value for money judgement that is absent from all other allocative decisions, which are based on a business model and return on investment. An HTA logic is not present in most of those allocative decisions and so we have an HTA system that is set up to be a front door for certain industries and products, but an enormous amount of the allocative decision-making is not going through that front door and is not subject to HTA reasoning. But social values reflected in HTA processes are important meaningful values that assess broad questions of social concern. They address questions of solidarity, equity and belief in science, which is something we want to foster and something that Canadians want to believe in.

Session 4: Health Technology Assessment Overview

Speakers

- ▶ Heather Logan, Senior Advisor, Pharmaceutical Reviews, Canadian Agency for Drugs and Technologies in Health (CADTH; Canada)
- ▶ Pilar Pinilla Dominguez Senior Scientific Advisor, National Institute for Health and Care Excellence (NICE; UK)

Discussants

- ▶ Suzanne McGurn, Assistant Deputy Minister, Drugs and Devices, and Executive Officer, Ontario Public Drug Programs Government of Ontario (Canada)
- ▶ Rebecca Yu, Vice-President, Market Access & External Affairs, Takeda Canada (Canada)

HTA perspectives from the National Institute for Health and Care Excellence (NICE)

NICE’s evaluations pertain to clinical and economic evidence for new technologies or existing technologies for new indications. The Department of Health and Social Care, UK, formally refers topics for NICE evaluation. By 2020, NICE will expand its scope to review all new drugs approved by drug licensing agencies in addition to most new uses of approved drugs. For updates, see [12].

Key elements that NICE values in its appraisals are clinical effectiveness, cost-effectiveness, end of life care, innovation, degree of need, equity and non-health objectives. The two key questions for NICE when doing health technology evaluations pertain to cost and benefit.

Benefit: How well does the technology work when compared with established practice in the health service?

Cost: How much does this course of action cost compared with


established practice in the health service?

One of the distinctions of the NICE appraisal process is that recommendations carry a funding mandate as acknowledged in the NHS constitution. This means that if NICE recommends a drug for routine use, it must be made available by NHS England within three months of NICE publishing final guidance. To use NHS resources cost-effectively, NICE’s threshold is between £20,000 and £30,000 pounds per QALY gained. However, there is some room for flexibility in that NICE is also able to recommend treatments that extend the life of patients at end of life (EOL) up to a threshold of £50,000 per QALY, with QALYs given more weight for certain health benefits (Figure 6) [13].

Importantly, affordability is not one of the criteria that NICE values in its decision-making. This leads to the practical reality that

▶ FIGURE 6

Flexible decision-making at NICE.



NICE’s threshold for a good use of NHS resources starts at £20,000 per quality adjusted life year (QALY). Flexible decision-making based on the certainty of the ICER, adequate capture of the HRQL, innovative nature of the technology and non-health objectives of the NHS allows for increases in the recommendation to £30,000 per QALY. Committees are also able to increase the QALY to £50,000 to recommend treatments that extend life of the patients at end of life [13].

NICE might recommend treatments for a disease, such as hepatitis C, that are cost-effective but for which NHS England does not have the funds to cover within 3 months of the published NICE guidance. To address this issue, NICE and NHS England have introduced a budget impact test to balance cost and affordability by identifying technologies that might exceed £20M per year in any of the first 3 years. Such cases trigger an alarm for NICE to notify NHS England, giving it the opportunity to negotiate commercial arrangements with companies and apply for an extension to the implementation period of 3 months if needed.

What's new at NICE? As of April 2019, NICE started a cost-recovery tool for the technology appraisals process and is exploring new innovative payment methods that can help to offset the risks of drugs having substantial health benefits yet great uncertainty. NICE has also committed to timely guidance enabling patients to have access to treatments as soon as possible (Figure 7) [13], and has aligned its process so recommendations are available as close to marketing authorization


granted by the regulators, such as the European Medicines Agency (EMA) centralized procedure (NICE Guide to the Process of Technology Appraisal) [12]. The major change is at the technical engagement step where there is now a consultation to tackle the uncertainties before the first NICE committee meeting. Following an initial evaluation, the two main ways to manage uncertainty are to collect more data to mitigate the clinical uncertainties and to do commercial negotiations that lower the risk of making a wrong decision.

CAR T Evaluations at NICE. In the case of CAR T therapy evaluations, the committees could not recommend the technologies for routine commissioning to the NHS, with the following rationale.

1. All of the ICERs were above the threshold:
 - ▶ Tisagenlecleucel-T for ALL (up to 25 years): >£30,000 per QALY
 - ▶ Tisagenlecleucel-T for DLBCL: >£50,000 per QALY

► **FIGURE 7**


New NICE timeline for technology appraisals.



NICE has aligned its technology appraisal process (bottom panel) with the regulators (e.g. EMA) (top panel) to expedite patient access to treatments and increase the capacity of NICE. Key time saving steps - having the consultation before the first committee meeting and having only one instead of two committee meetings - allow NICE to publish final guidance as soon as marketing authorization is out. CHMP; Committee for Medicinal Products for Human Use [13].

► **FIGURE 8**

Committee rationale for recommending CAR T therapies to the Cancer Drugs Fund (CDF).



NICE inputs into the CDF since 2016 are understood as a tool for recommending technologies that wouldn't otherwise be recommended in the NHS because of their clinical uncertainty/high risk. The CDF serves as a gateway to evaluate if such technologies could be recommended for routine practice in the future. Following the steps shown, all three CAR-T therapies (Tisagenlecleucel for ALL, Tisagenlecleucel for DLBCL, and Axicabtagene ciloleucel for DLBCL) were recommended within the CDF [13].

- ▶ Axicabtagene ciloleucel for DLBCL: >£50,000 per QALY
- 2. The committee rejected the non-reference case of applying a 1.5 percent discount rate because they did not consider that there was robust evidence to demonstrate a curative effect to sustain near full health over a long period of time.
- 3. The committee accepted the EOL criteria as they were met for the DLBCL examples in adults, but it did not accept them for the children ALL appraisal because they considered that the life expectancy with standard of care would be more than 24 months.

As noted in 'Session 2: Health Economics', technologies that would not otherwise be recommended in the NHS because of the high degrees of uncertainty and risk can be considered for time-limited funding by the CDF.

The committee's rationale for recommending all three CAR T therapies within the CDF is shown in Figure 8 [13], with the requirement for ongoing data collection and re-evaluation after five years. For the benefit of companies, NICE now has an Office for Market Access to facilitate conversations between stakeholders, and also offers scientific advice, including a parallel service with CADTH. Companies are encouraged to think about their uncertainties early and plan their regulatory and

HTA submissions in parallel, consider the key issues early for HTA and engage in order to obtain scientific advice on topics such as:

1. Clinical trial design and feasibility to conduct comparisons with established practice;
2. Relevant outcomes, their relationship with health-related quality of life and mortality, and frequency of data collection;
3. Proposed modelling approaches (based on clinical plausibility and data available to date) to deal with uncertainty at the time of submission;
4. Long-term evidence generation plans (often forgotten at early stages) to increase relevance of post-marketing authorization studies including clinical effectiveness and adverse effects data; and
5. Data collection in the relevant setting.

HTA perspectives from Canadian Agency for Drugs & Technologies in Health (CADTH)

CADTH programs and services include drug reimbursement recommendations, health technology management, scientific advice and knowledge mobilization, and liaison officers. CADTH receives funding from Canada's federal, provincial and territorial governments, with the exception of Quebec, where there is a parallel organization called INESSS. CADTH also receives industry funds through submissions. Heather Logan reviewed the differences between a drug and clinical intervention HTA, with a particular focus on lessons learned from the first CAR T evaluation. On the drug side, CADTH accepts submissions to review specific drugs on a drug-by-drug basis. For medical devices and clinical interventions, CADTH typically identifies the processes to review and jurisdictions to prioritize followed by the HTA.

In Canada, the first step for a new drug to access the market is to obtain a Health Canada approval (Figure 9) [14]. The manufacturer then starts the HTA review process by making a submission to CADTH and/or INESSS. At

CADTH, drug submissions then track to one of two drug programs: the CDR (Common Drug Review) or pCODR (pan-Canadian Oncology Drug Review). On the drug side, CADTH looks at clinical and cost-effectiveness, patient values and implementation feasibility. Following that, the pan-Canadian Pharmaceutical Alliance (pCPA) negotiates on behalf of provinces that opt in to a negotiation. This work is designed to help provincial health ministries make decisions about drug and device funding, ensuring that the systems are sustainable.


With the intent of making the process as efficient as possible, CADTH is now conducting reviews in parallel with the Health Canada regulatory review. If the manufacturer is able to submit both the regulatory dossier and the HTA dossier at approximately the same time, the time to a CADTH recommendation after Health Canada approval can be shortened to mere days versus an average of six months previously.

Both the regulatory and HTA review processes in Canada are different for drugs and devices. Adding to the complexity, Canada is highly decentralized with every jurisdiction having the ability to make its own funding decisions. Within the HTA review for drugs, and particularly for pCODR, most cancer drugs, with the exception of biosimilars and line extensions, proceed through the HTA process. In contrast, medical devices and interventions can be implemented and funded in healthcare systems across Canada without going through the HTA review process. For devices, CADTH is asked to conduct a review on high-priority devices or technologies, often by provincial healthcare systems or other key players across the country.

The decision to evaluate a product as a pharmaceutical versus a clinical intervention/device depends on the mechanism for adoption within the province. For example, if the mechanism for adoption is being funded and placed on a formulary, then the pharmaceutical review process (pCODR or CDR) would apply. If the mechanism for adoption and funding is a complex implementation process, as for CAR T, the submission would

► **FIGURE 9**

Overview of Drug Review in Canada.



Drug review in Canada starts with submission to Health Canada which looks at regulation, safety, marketing and manufacture of drugs. Drug value is then assessed in Ontario by CADTH, through the CDR or pCODR programs, or in Quebec through INESSS. Following this step, the pCPA negotiates price on behalf of the provinces that opt in to the negotiation. Finally, the Ministries of Health make decisions about drug and device funding, ensuring that the systems are sustainable. In Canada, following a submission to Health Canada, and with manufacturer consent, HTA and regulatory reviews can run simultaneously [14].

be a clinical intervention. The HTA Framework for Adoption, showing the ways in which the CADTH Health Technology Expert Review Panel (HTERP) deliberates on value for different HTA pathways is shown in Table 4 [14].

CAR T Evaluations at CADTH. For the first CAR T product reviewed, HTERP recommended the provision of tisagenlecleucel with the condition of a reduction in price, and an emphasis on implementation and ethics. These products are now available in a small number of centres and require careful decisions about patient access and equity. Specific recommendations from HTERP include:

1. The creation of interprovincial agreements to ensure equitable access to eligible patients in all jurisdictions, including consideration of financial and logistical support for required travel and short-term relocation;
2. The development of clear and transparent eligibility criteria that are acceptable to the

needs of patients and clinicians, based on the approved indications; and

3. The collection of standardized outcome data in a pan-Canadian registry of patients, which uses a defined set of outcomes and definitions to generate real-world evidence for consideration in future reassessments of longer-term effectiveness, safety and cost-effectiveness (this speaks to some of the similarities of the NICE review).

From CADTH’s first HTA review of CAR T therapy, it is clear that these are not only disruptive technologies, but also complex interventions involving multiple parts of the healthcare system. They are different from drugs, but they are not just devices or simple clinical interventions and they require a different order of magnitude of conversation around discussion and planning.

In closing, Logan noted that Canada has done well at managing this very disruptive therapy, and has moved from HTA to health technology management, reflecting the need as these new innovative, complex therapies with high value and high price tags come forward. But there is room for improvement. With a willingness to collaborate, learn and adapt, Canada can become better and faster at developing the networks that support the needed discussions, and do a better job of addressing the implementation issues by balancing the vigorousness of HTA with what decision-makers need.

► **TABLE 4**
CADTH HTA framework for adoptions [14].

| | Drugs | Clinical intervention |
|--------------------------|-------|-----------------------|
| Relevance and unmet need | ✓ | ✓ |
| Benefits | ✓ | ✓ |
| Harms | ✓ | ✓ |
| Patient perspective | ✓ | ✓ |
| Economic impact | ✓ | ✓ |
| Implementation | | ✓ |
| Legal | | ✓ |
| Ethical | | ✓ |
| Environmental impact | | ✓ |

Insight from discussants: session 4

Competing for finite resources

For evidence generation that underpins complex products, one of the hallmarks is increasing uncertainty, which is important for payors who must make choices about where to spend finite resources. Additionally, people don't always take into account the opportunity cost of what is not being funded. For example, we could have demand for a therapy to fill a critical unmet need with high uncertainty and at the same time have demand for a complex intervention with less uncertainty and a greater likelihood of success, but they are both competing for finite resources.

“HTA processes are the single greatest influencer of the funding decisions that we have. They provide a significant amount of information to inform our decisions and in some jurisdictions in Canada they become a gatekeeper of a ‘yes’ or a ‘no’, making a decision as to whether a jurisdiction will even consider to move on funding.”

–Suzanne McGurn

Q and A from open discussion: session 4

(Q1) As more and more therapies come to market and as CADTH starts assessing non-T cell immunotherapies, will the classification of these drugs change?

(A1) At present, CADTH is still looking at CAR T therapies as clinical interventions because of the complexity of the cost. However, if supported by the jurisdictions, the need for a change in classification may arise and CADTH would need to consider that down the road.

(Q2) For disruptive technologies, are the de-implementation challenges greater because of the up-front investment in infrastructure?

(A2) NICE has had two technologies go through and exit the CDF and both have

proved to be cost-effective and have been recommended for routine commissioning. During the CADTH review process, there were many attempts at the system level to piggyback and work with infrastructure that already existed. The platforms weren't built *de novo* so a system might change but an entire system would not need to be removed.

(Q3) How will taxpayers be given equal access to complex interventions?

(A3) In a country as large as Canada, the question of equity always comes up and there are therapies that will only ever be available in southern Ontario or Toronto. As a result of these logistical challenges, making some of these products available in Canada in a cost-effective way requires a different solution each time. That said, CADTH works very closely with the Canadian Association of Provincial Cancer Agencies (CAPCA) to look at patient access provisions across jurisdictions to ask if there is a way for a centralized review to prioritize which patients receive therapy and when they receive it, regardless of their geographical location. Different kinds of indications will require different processes. The ethics review at the HTA level raised these considerations as a fundamental part of implementing complex and hard-to-access therapies given the small number of potential administering locations.

“If you are a patient, these are transformative therapies. So how do we approach it so that patients get early access and are not denied early treatment, but at the same time, there is some assurance that the payors are getting what they think they are paying for?”

– Rebecca Yu

Session 5: Payment System Mechanisms

Speakers

- ▶ Ana Duarte, Research Fellow, Centre for Health Economics, University of York (UK)

Discussants

- ▶ Rebecca Yu, Vice-President, Market Access & External Affairs Takeda Canada (Canada)
- ▶ Grace Hampson, Senior Principal Economist, The Office of Health Economics (OHE; UK)

HTA perspectives from the University of York, UK

In the past, the conventional reimbursement paradigm was ‘to accept or not to accept’. Currently, technologies with higher up-front costs and uncertain health outcomes may require novel policy options so that decision-makers can appropriately take into account these features. In this session, Ana Duarte provided an overview of existing payment mechanisms to serve as discussion points for the ensuing dialogue.

In 2012, Walker and colleagues proposed a taxonomy of alternative payment arrangements named managed entry agreements (MEA). Walker’s Framework for Coverage Decisions [15] distinguishes between two types of MEAs (Box 5). Walker concluded that it was important to go beyond considering the expected benefits of technology to also take into account the value of uncertainty around the estimate, how to incentivize further evidence generation, and the costs associated with the reversal of uncertain decisions and irrecoverable costs.

In 2016, Grimm updated the Walker taxonomy in ‘Framework for Analysing Risk in Health Technology Assessments and Its Application to Managed Entry Agreements’ [16]. Published by the NICE Decision Support Unit (DSU) the report developed a quantitative framework for MEAs a) with a reduction

in price and b) with evidence generation. The rationales underpinning these MEAs are different. MEAs with a reduction in price reduce the payor’s risk of funding a treatment that is not cost-effective, by ensuring that the treatment is more affordable (Box 6). MEAs with further evidence generation reduce uncertainty and with it the payor’s risk (Box 7).

Duarte stressed that while the framework allows the assessment of which MEAs may be more appropriate without placing a higher evidence burden on the manufacturers, it relies on the appropriateness of the decision model to produce plausible probabilistic cost-effectiveness estimates and that uncertainty is duly captured by the probabilistic analysis. Additional financing schemes (Box 8) were proposed by Towse in 2014 specifically for the world of regenerative medicine [17].

Insight from discussants: session 5

Novel payment mechanisms

If we are going to invoke novel payment models, what is it about specific technologies that will prompt the change in standard operating procedures? We have a fundamentally sound process for evaluating 95% of health technologies. However, when we see something that meets an unmet need or produces an enormous effect size in a very small data set, we feel ethically bound to not withhold that from patients for the usual period of time for the HTA process. But novel payment mechanisms entail considerable administration and burden to management.

Challenges of the amortization approach

Neither payors nor manufacturers nor governments want to hold the risk and we don’t

▶ BOX 5

Managed entry agreements (MEAs) in Walker’s framework for coverage decisions [15].

1. MEAs that consist of a reduction in the price of technology, outcomes-based or non-outcomes-based;
2. MEAs associated with further evidence generation, only in research or recommended with research.

▶ **BOX 6**

Managed entry agreement (MEAs) with reduction in price [16].

Outcome based: patient level

- ▶ Money-back guarantee: manufacturer refunds money or stock to payor
- ▶ Conditional treatment continuation: payment only when target is achieved
- ▶ Price linked to outcome: reimbursement linked and/or weighted with different health outcomes

Non-outcome based: patient level

- ▶ Discount treatment initiation – lower price initially and then price reverts to list price
- ▶ Utilization cap – regardless of length of treatment, a cap ensures reduced budget impact of drug
- ▶ Fixed cost per patient – regardless of the number of treatments

Non-outcome based: population level

- ▶ Single discount – most commonly seen at NICE
- ▶ Expenditure cap – cap is regardless of the quantity that is provided
- ▶ Price volume agreement – discounted price when certain volume is reached for economies of scale

want to give it to patients. Financial markets are used to purchasing financial risk and being repaid through risk premiums, so this approach might be worth exploring. Other models include the mining industry, which issues bonds. But involving financial institutions with the risk of healthcare requires artificially attaching upside to the risk. If the inherent upside to drug production lies with the manufacturer, it would be better to push the risk towards the manufacturer as much as possible to avoid having to create an artificial upside. If the manufacturers are holding the risk, then they would need to be compensated for the risk. Another challenge is how to deal with multi-payor situations, as would happen

if people were to change jobs and insurance providers part way through their treatments. Additionally, there are the legislative and accounting challenges that occur with party changes after elections.

Operationalizing pay-for-performance schemes

Governments and HTA agencies want to pay for what performs, but the challenges include limited resources, infrastructure and staffing, and the need for up-front investment. In addition, the two-payor system in Canada – the private and public sector – adds a layer of complexity. Another issue is trust and whether industry is the right group to monitor outcomes. One option would be to give resources to an organization like THETA to develop a group that could collect outcomes. Another option might be to have manufacturers provide funds up-front for infrastructure investment (e.g., electronic data collection) as a cost-effective way to incentivize pay-for-performance.

Another huge challenge around operationalizing pay-for-performance schemes is around defining outcomes. Registries have few people treated and there is no way to know if the drug is continuing to work unless

▶ **BOX 7**

Managed entry agreements (MEAs) with further evidence generation [16].

Recommended with research/only in research

- ▶ Reimbursement only – payor reimburses manufacturer for all patients but arrangements must be made as to who pays for research (payor, other entity, manufacturer?);
- ▶ Refund and reimbursement – payor initially pays for research but manufacturer provides refund if treatment or value was less than expected;
- ▶ Conditional flexible pricing agreement – price is revised at determined points as evidence is collected and further evidence is generated.

▶ **BOX 8****Financing schemes for regenerative medicines [18].**

- ▶ **Amortization:** spreading out higher up-front costs over a period that reflects the time profile of the benefits
- ▶ **Pay-for-performance:** requires tracking the payment and the performance measure of success
- ▶ **Leasing:** dividing the cost over time to reflect the expected benefits, and if the measure of success is not being reached, then price is revisited and reduced over time; can combine amortization and pay-for-performance
- ▶ **Innovative financing from the financial markets:** payer sets up bonds that another entity buys, and payer provides return on investment (e.g., vaccines)

you have a comparator group that has not received treatment. The practical reality is that in the real world, discerning modest improvements in health requires a trial or some method of indirect comparison.

**Highlights from open discussion:
session 5 (see also Box 9)**

1. How can we define data registries in a way that is relatively economical, and without a huge footprint in data entry? Electronic data collection in Canada is lacking. Currently, we can run parallel analyses across provinces, but we are not able to pool provincial data. We do, however, have provincial data that allows us to capture outcomes in a relatively cheap way, and we can look at survival, re-hospitalization and resource use in a way that doesn't cost a lot of money.

2. The challenge is to identify a core data set at the time that treatment is initiated. Ideally, this would include disease, stage, histology, line of therapy, pathology information, comorbidity information and untreated comparators, if available. Registries are often very expensive because they are data-hungry and require ongoing data collection. A lot of these analyses are done with the idea that the registry alone will be the full source of analysis, but a registry linked to administrative data is a way of making this national and economical.
3. HTA and payment schemes are separate but inter-related issues. In terms of the payment mechanism, setting up a data collection mechanism could be relevant before HTA. Perhaps the payors should be brought in at the scientific advice stage and decision-makers brought in as part of the journey of evidence generation. The challenge is that this would be time- and cost-prohibitive to get the perfect body of evidence and the right voices around the table.
4. How can we ensure that CAR T-like therapies are sustainable in the long term, especially if they are going to be used for solid tumors? This is a very complex question and it will be hard to put forth solutions until we know what's coming through the pipeline and how the original solutions that we have proposed and piloted actually play out. In the UK, these

▶ **BOX 9****Questions for further consideration: session 5.**

1. Does payment for regenerative medicine/ATMPs require intervention at the national level?
2. How can we take our well-established HTA processes to inform our public sector R&D investments and to help those in academia where a lot of the initial research is done?
3. For immunotherapies (such as CAR T) and other gene therapies, is there a way to bring people together at a discrete point in time, rather than at every step of the process for every therapy, to have a discussion around access to data and desired outcomes?
4. Who should be at the negotiating table where the payment scheme is being discussed?
5. Should the public have to bear some of the risk for novel payments so that equity for the population is ensured?

existing therapies have been deemed to be cost-effective so we would expect there to be some cost offsets down the line.

- Does the federated system in Canada present an additional challenge to novel payment methods? The interprovincial regulatory constraints in Canada mean that there are blockages in moving patient data and integrating data among provinces so that every piece of an analysis must be done in every province. In addition, payments are from the provinces, which do not have equal budget sizes, so not all provinces can implement all the different arrangements leading to equity of access interprovincially. It is not as simple as saying that there is a national body that can make decisions about the risk willing to be borne by the actual payor. The political will to address these challenges would have to occur at the inter-ministerial level.

Session 6: Adoption & Implementation

Speakers

- James Rose, Head of Clinical Innovation Adoption, Oxford Academic Health Science Network (OAHSN; UK)

Discussants

- Dr John Kuruvilla, Hematologist, Princess Margaret Cancer Centre, University Health Network (UHN; Canada)
- Linnea Doyle, Senior Director, Market Access & Government Relations, Gilead Sciences Canada
- Shahira Bhimani, Director, Health Solutions MaRS Partnerships (Canada)

Exploring adoption & implementation of ATMPs: a UK perspective

“Is the UK an attractive market for ATMPs?” This is the question posed by James Rose as he presented some real-world examples of how the UK is tackling the multi-faceted challenges in the field. He noted that meetings such as CHART are critical for bringing together the full gamut of stakeholders to drive the field forward.


The UK has invested heavily in the adoption of innovation across healthcare. With this mandate, the NHS funded 15 Academic Health Science Networks (AHSNs) in England. As one of the networks, the Oxford Academic Health Science Network (OAHSN) brings together 700 life science companies, six large acute hospital trusts, five universities and 3 million citizens. Their focus is to

▶ TABLE 5
ATMPs licensed in the UK [18].

| Name – manufacturer | Indication | Auth. | NICE TA |
|-------------------------|--|-------|----------|
| Strimvelis® – GSK | ADA-SCID | 2015 | Approved |
| Imlygic® – Amgen | Melanoma | 2015 | Approved |
| Holocar® – Chiesi | Severe limbal stem cell deficiency | 2015 | Approved |
| Zalmoxis® – Molmed | Stem cell transplantation (high-risk blood cancer) | 2016 | Approved |
| Spherox® – co.don | Cartilage defects in knee joint | 2017 | Approved |
| Alofisel® – Tigenix | Perianal fistulas in Crohn’s disease | 2018 | Rejected |
| Yescarta® – Kite/Gilead | B-cell lymphoma | 2018 | Approved |
| Kymriah® – Novartis | ALL, DLBCL | 2018 | Approved |
| Zynteglo® – Bluebird | Transfusion-dependent thalassaemia (TDT) | 2019 | Pending |
| Luxturna® – Bluebird | Inherited retinal disease | 2019 | Pending |

► **FIGURE 10**

Expectations of steep rise in submissions and authorizations.



Since 2009 to 2019, there have been 350 new scientific advice cases and 14 ATMPs approved. Of the 22 Managed Access Agreement (MAA) submissions, 10 are expected in 2019/2020 [19].

spread innovation ‘at pace and scale’, creating sustainable networks that improve health and generate economic growth.


The UK government has also invested specifically in the ATMP space, with £250M funneled to translation and adoption of ATMPs through Cell and Gene Therapy (CGT) Catapult, the CGT Manufacturing Centre, and Advanced Therapy Treatment Centres (ATTCs). Practically speaking, NHS England should be an attractive market for ATMPs: it is a single-payor market, with advantages in

centralized commissioning, coordination, standardization, operators, risk management and data collection. But more experience with ATMPs is required to develop the needed processes and systems for adoption and implementation.

To date, 10 ATMPs have been licensed in the UK (Table 5) [18], seven with positive NICE technology assessments, one not recommended and two pending. With a spike of 350 new device submissions and 22 Managed Access Agreement (MAA) submissions (Figure 10) [19], 10 expected in 2019/20

► **FIGURE 11**

Top-level road map to market access for licensed ATMPs in England.



The pathway to market access revolves around horizon scanning and feeds into NICE topic selection and assessment. The next steps involve a commercial negotiation, normally between NHS Specialized Commissioning and the manufacturer, with involvement from the Rare Diseases Advisory Group and Clinical Reference Groups [13].

alone, the EMA recognizes the need to be ready. The pathway to market access is relatively well-established in the UK (Figure 11) [13]. This process can be quite variable in terms of time, and sometimes NICE is criticized for how long it takes. But it can also happen quickly as it did in the example of CAR T, where there was a commercial arrangement 10 days after the first product was approved by the EMA. This demonstrates that speed is possible if there is political will.

Innovation adoption at its heart is a complex job. The pathway to adoption and implementation is much less established than market access, and there is considerable variation with hospital processes, governance structures and approval boards. Feedback from the 11 CAR T centers in the UK has flagged six institutional barriers to adoption (Box 10), with capacity and retraining dozens of staff for each new ATMP being the biggest issues.

The ATTCs are ‘innovation hubs’ set up across the UK to develop and deliver systems for cutting-edge cell and gene therapies. There are currently three ATTC hubs linking different geographical regions: Northern Alliance (Edinburgh and Newcastle), iMATCH (Manchester), and MW-ATCC (Midlands and Wales). In addition to these three centers, there are other centers that provide support and infrastructure for ATMPs such as the CGT Catapult, its Manufacturing Centre and the London Advanced Therapies Network. These networked hubs will increase the

ability of NHS to deliver disruptive medicines by innovating around systems and processes (e.g., sample traceability and tracking) that can be rolled out to other centers. Some of the challenges the ATTCs are currently exploring include establishing clear pathways to gather industry feedback, defining a common framework to help companies navigate with harmonized procedures and practices, contract standardization, clinical scale-up requirements, patient engagement, patient monitoring, data collection and sharing.

The need to maintain a healthy public perception and manage expectations around availability and eligibility of ATMPs will also require understanding different perspectives of patients, clinicians, hospital managers and policy makers. Facilitating patient pull for these therapies will require more work around joint decision-making and patient education. Facilitating clinical champions will mean having more clarity around roles, responsibilities and governance. Buy-in from hospital managers will require them to understand the level of risk versus benefit for these therapies and how they align within the strategic priorities of their hospital trusts. Policy makers are willing to invest money in ATMPs, but there needs to be better alignment of policy and practice with patient need, up-scaling and the role of pharmacists, quality assurance, training, and creating a sustainable ATMP workforce to carry the therapies forward.

▶ BOX 10

Institutional barriers to CAR T therapy [18].

1. **Capacity:** challenges around apheresis, stem cell freezing, staffing, ward intensive treatment unit (ITU) capacity
2. **Training:** standardized training and/or delivering more generic training
3. **Expression of interest accreditation:** thousands of person hours invested in accreditation and huge resource commitment to standards of practice, policies, pathways and guidelines
4. **Contracting:** variable rates and hospitals negotiating contracts separately and interpreting risk differently
5. **Governance:** multiple governance processes and more defined role of pharmacy in providing oversight of quality assurance required
6. **Patient management:** appropriate referral and patient review pathways and weekly meetings to review CAR T patients needed; ensuring that non-CAR T sites also have access to therapies

In summary, Rose urged that we need to take this opportunity to learn from each other's innovation systems and how these complex problems are being tackled. We could manage the challenges of individual ATMPs, such as CAR T, but our systems are looking to adopt numerous ATMPs, underscoring the challenge of co-ordination and collaboration to ensure sustainable models for adoption.

Insight from discussants: session 6

Perspectives from clinicians

In Canada, accreditation is through a governing body called the Foundation for the Accreditation of Cellular Therapy (FACT). For clinicians looking to implement cellular therapy, the first question is the scope of cells involved (e.g., autologous or allogeneic stem cells, hematopoietic cells, cord blood, induced pluripotent stem cells, cardiac or musculoskeletal cells). As we start to navigate the delivery of such cells, building teams of content and modality experts will be key, but not without its challenges given the way that money and politics play into hospital decisions. Product cost is huge, but so too are the costs and resources for the machinery, freezers, apheresis, personnel, and beds needed to deliver the product.

For the short term, implementation of CAR T therapy can be grafted on to what is already in place for transplant work. But the data requirements, monitoring and follow-up clearly surpass the 'bricks and mortar' cash cost of the product. Lag time is also an issue because infrastructure takes time to build and is virtually non-existent apart from a few groups doing these therapies in research settings.

“Building teams of knowledgeable experts will be key for adoption and implementation of CAR T therapies.”

– John Kuruvilla

From a patient perspective, equity of access is an issue in Canada, where the majority of

expertise is in southern Ontario. Interprovincial funding relationships will need to be set up so that people outside Ontario can access the major treatment centers. Small centers will also face challenges in expertise around disease management versus modality expertise as it could be difficult to find people who can wear both hats. It is critical that people who have the expertise are involved earlier than at first-in-human studies. For early biotechnology start-ups, big centers are the place to go to look for people with the right expertise.

Perspectives from Canadian industry

CAR T therapy represents a new and unique space for pharmaceutical manufacturers. Because CAR T manufacturing uses an individual patient's T cells, comprehensive support systems are required to ensure that chain of custody and chain of identity for the patient's T cells are securely maintained both pre- and post-manufacturing of the cells. Unique systems, procedures, and processes are required from manufacturers to support product transport, delivery and administration and to ensure that quality requirements are met throughout with the least burden on institutional resources.

In Canada, manufacturers engage at three different levels to support adoption and implementation of CAR T therapies: the site level, the provincial health system level, and the national and interprovincial level. Opportunities and challenges at each level are shown in **Box 11**. Implementation at the site level builds on an existing network of FACT-accredited and transplant centers in hematological malignancies, with an established foundation for the multi-step pathway (quality, training, agreements) involving multiple stakeholders.

At the provincial and territorial level, Canada has 13 different health systems, each with a unique network of decision-makers (e.g., cancer agencies, provincial and regional health authorities, drug programs, Ministries of Health). Because CAR T therapy involves drug budgets and institutional

▶ **BOX 11**

Engagement with Canadian manufacturers insight from the site level [20].

Site level opportunities

- ▶ Pre-existing FACT accredited stem cell transplant network
- ▶ Site level clinical/administrative champions
- ▶ High commitment to ensure readiness
- ▶ Extensive US experience (Kite/Gilead)

Site level challenges

- ▶ Number of people engaged in site readiness and training
- ▶ All sites unique (no 'one size fits all')
- ▶ Investment in readiness challenging in advance of confirmed provincial funding
- ▶ Time needed for contract reviews and finalization
- ▶ Site capacity
- ▶ Different standards of practice and work instructions for different manufacturers

Provincial level opportunities

- ▶ High awareness within ministries of health
- ▶ High engagement/interest for readiness
- ▶ Desire to set long-term system framework

Provincial level challenges

- ▶ Evolving pathways for decisions/multiple parties
- ▶ Budget alignment/ownership for CAR T therapies
- ▶ Inconsistencies in expectations/outlook may occur between sites and ministry of health
- ▶ Hospital capacity and capability – now and forward

National level opportunities

- ▶ Health Canada approach to address CAR T specific issues and to modernize framework for review of advanced technologies
- ▶ Novel HTA review process with high engagement
- ▶ Unique federal/provincial CAR T committee
- ▶ Pre-existing interprovincial frameworks
- ▶ Desire to set long-term system framework
- ▶ Willingness to regroup and debrief learnings through pan-Canadian process (CADTH, INESSS)

National level challenges

- ▶ Equity in access across provinces with and without sites
- ▶ Unique/evolving pan-Canadian negotiation pathway
- ▶ Longer-term policy development for cell and gene therapy

resources, a broader set of decision-makers are involved in the process. In light of this, Canada is seeing an evolution of provincial CAR T committees to support aligned decision-making.

At the national level, an important lesson has been the value of collaborative engagement, for example through the development

of the initial CAR T Health Technology Assessment (HTA) review pathway with CADTH and INESSS. Industry engagement with Health Canada was also key. As CAR T pipelines evolve, industry will need to engage as early as possible to better understand the gaps and take that information back to R&D decision-makers to help build in the

solutions as early as possible. Looking ahead to the multiplication of cell therapies in the hematological malignancy space and beyond, ongoing dialogue will be key to success.

**Highlights from open discussion:
session 6 (see also Box 12)**

Lack of leadership in Canada

In Canada, one of the challenges is that there is a lack of ownership and leadership in this space. The Canadian Cancer Trials Group (CCTG) is interested in taking research forward: its mandate is to have real value for patients in Canada, but its expertise is around drugs. It has very little infrastructure around cells and is cancer-directed. The Canadian Bone Marrow Transplant group has just been rebranded as Cell Therapy Transplant Canada, and that group now sees the opportunity to take the lead on ATMPs and CAR Ts nationally. It has the people who run the labs, technicians who know how to handle cells, freezing, release criteria, etc., so it could provide leadership in this space.

Risk evaluation for contracts

The contracts coming to hospitals are of different qualities but the aspiration in the UK is that there might be a gold standard applied by NHS England to make sure contracts are up to scratch. It may mean bringing all the stakeholders around the table so that all partners are willing to sign the contracts. In Canada, there are some National Centres of Excellence (NCEs) and Centres of Excellence for Commercialization and Research (CECR), such as CellCAN, and CCRM, that could help with contracts. However, relying on them could be problematic as Canada has been defunding these types of network that bring actors together around knowledge mobilization and co-ordination activities.

Resources for adoption

In the UK, making business cases for additional staff is not trivial and there are many competing business cases being put forward.

That will be a big challenge and the ATTCs are exploring what can be done. In Canada, therapies are becoming more and more complex and the busier things get, the more fatigue staff have and the more risk there could be to patients.

Developing expertise

In Canada, there aren't as many unique structures as in the UK or USA, and the same people are being called on to write responses to CADTH. In the UK, physicians typically engage through conferences and professional development as part of ongoing training, but there might not be training specific to ATMPs.

Pharmacist network connection

Some pharmacists in Canada recognize that they lack experience with ATMP products. Some argue that it would be better to minimally involve pharmacy since there are enough people already in the system who know how to deal with cells and release criteria etc. For example, at Princess Margaret Cancer Centre, UHN, pharmacy won't be involved because there is already quality infrastructure, auditing and management in place.

Harmonizing on-boarding processes

With multiple products and companies in this space, it appears that there are different on-boarding processes for every site to go through. This is not sustainable for every ATMP, so it will be important to find points of similarity (e.g., sampling, apheresis, logistics) to harmonize the process between products and reduce the burden of training and onboarding.

Selecting the workforce

Institutions in the UK are looking at apprenticeship programs to drive down the cost of ATMPs. For example, rather than having PhD students and career scientists making these products, it would be better to have apprentices brought up to that level. In the UK, the ATTC apprenticeship programs address

▶ **BOX 12****How to ease the pathway to implementation and adoption of ATMPs.**

1. Find a solution for capacity. It is one of the single biggest challenges that will affect the sustainable adoption of future ATMPs.
2. Implement strategic proactive planning.
3. Start with the end in mind to understand how the policy-makers are engaged in the discussion and how the system could be structured.

the need for operators, managers and senior leaders, from bachelor's to masters-like technology qualifications. Done with success in the bioprocessing industry, this approach creates an incentive for partners to take on mentorship roles to help complement the workforce. Similarly, CCRM is recruiting for a broad spectrum of abilities in this space.

Speeding implementation & adoption

Having clinicians get involved with clinical trials might speed the implementation and adoption processes; the team would be more knowledgeable and pharmacists involved in the trial could help educate other pharmacists. It's also important to have policy makers, such as the provincial CAR T Committee in Canada, and decision-makers on hand because the clinical buyers of technology and innovation are different from the economic buyers.

Equity of access for children

Few places in Canada have the background expertise and facilities to do ATMPs and a much smaller number have experience in pediatric leukemias, so access for children will be an issue.

TRANSLATIONAL INSIGHTS

Globally, the ATMP space is bursting with opportunity. Canada, the USA and UK are well-positioned to be part of this ecosystem through their leadership in regenerative medicine clinical trials, centers of excellence hosting first-in-human pivotal studies, and early-phase clinical trial manufacturing capabilities. Around the world, hundreds of

ATMP trials are being planned and within the next few years, numerous therapies could be approved and brought to market. The demand for such regenerative medicine products/ATMPs and the number of patients treated with them is therefore poised to increase significantly.

The adoption of new therapeutic products is predicated on the value assessment of clinical safety and efficacy as well as cost-effectiveness within a healthcare setting. While the challenges in the adoption of ATMPs are not unique to the regenerative medicine field, there are still many uncertainties, spanning from research and development to regulatory review and approval, manufacturing, reimbursement, ethics, and implementation. Adding to the complexity of the adoption process, ATMPs, such as CAR T therapy, are highly disruptive, enormously costly and onerous to bring to market, posing important challenges from an HTA perspective. Clear policies are urgently needed to inform how ATMPs will be sustainably paid for and to adequately consider the social, ethical and legal issues around their adoption.

The consensus from the CHART workshop point to seven touchpoints that need to be further explored to advance the adoption and implementation of complicated ATMPs, such as CAR T therapy.

1. Current methods of evaluation are applicable to ATMPs but the biggest challenge for these novel therapies is providing evidence that reduces the uncertainty of their long-term effects. Currently, there is a paucity of well-controlled clinical evidence driving the adoption of ATMPs, with examples of products having case studies of only 100

participants who are non-randomized and non-controlled. This is not sufficient to evaluate outcomes over time.

2. The generation of evidence of clinical effectiveness needs to be improved by ensuring clinical trial designs employ robust controls and increase their sample sizes while collecting data in the relevant setting. It is critical to develop a research and policy agenda around improving the clinical evidence base as well as collecting real-world evidence – as distinct from real-world data such as patient submissions or economic evaluations – through vehicles such as registries and trials. Addressing five critical needs could improve the evidence base: (1) conduct controlled trials; (2) define evidence versus data; (3) develop methods to evaluate real-world evidence and outcomes over time; and (4) consider costs, patients and relevance to policy.
 3. Incentives for real-world evidence capture should be established to ensure that data are gathered and can be used to further evaluate the therapies for long-term clinical effectiveness and adverse effects.
 4. The implementation of ATMPs will require concerted efforts from multiple stakeholders to ensure that the adoption pathways are efficient and effective, and aligned with social values. The question is how best to ensure politicians will pay attention and invest in the infrastructure required to facilitate the adoption and implementation of ATMPs with the appropriate evidence base and HTA. A targeted approach could involve: (1) using documents such as this one to inform relevant scientific, policy, traditional HTA and economic groups; (2) creating unique business cases including outcomes and impact to mitigate risk; and (3) creating targeted messaging for financial asks.
 5. There needs to be greater interaction with policy makers, as political will is essential for research to progress into meaningful efforts. For example, Canada has a long and complex list of policy makers, so it is important to be selective about who to engage and how to engage them to avoid diluting efforts. Practical strategies within Canada might include: (1) watching for shifts in provincial health because Ontario Health (including Cancer Care Ontario, Health Quality Ontario, eHealth Ontario, Trillium Gift of Life Network, Health Shared Services Ontario, HealthForceOntario Marketing and Recruitment Agency, and 14 Local Health Integration Networks) is evolving; (2) securing top-level buy-in at the Executive Director level for integrated implementation and adoption work in the ATMP field; (iii) continuing to have regular conversations with other provinces and jurisdictions as changes unfold within the provinces; (4) making a value case to policy makers and framing health outcomes and budget as well as broad societal perspectives and the return on investment.
 6. There is a need to improve patient management and data management to aid in evidence generation and facilitate outcome-based payment mechanisms. To that end, we should identify allies in our ecosystem who might have the same problems or challenges. In the ATMP field, obvious partnerships to leverage would be from other high-value, high-risk fields such as oncology, rare diseases and pediatrics.
 7. Payment mechanisms remain a challenge; in addition, the sustainability of current payment methods for expensive therapies will need to be evaluated, prior to the approval of more ATMPs. Creative payment mechanisms including amortization, pay-for-performance, leasing, bonds and risk fund hedging exist in other industries (e.g., accounting, natural resource extraction, aerospace) and could be further explored for ATMPs.
- In summary, addressing the challenges in adoption and implementation of regenerative medicines/ATMPs requires a deeper

understanding of the landscape. Future working groups could prioritize evidence generation issues, stakeholder and targeted policy maker engagement, and payment system mechanisms. The creation of a stakeholder

map would also be a valuable tool for identifying stakeholders who could help tackle the remaining challenges, create targeted information for policy makers, and drive the field forward.

REFERENCES

1. Tafuri G, Paganini M, Mosely J *et al.* How aligned are the perspectives of EU regulators and HTAB bodies? A comparative analysis of regulatory-HTA parallel scientific advice. *Br. J. Clin. Pharmacol.* 2016; 82: 965–73.
2. Neelapu SS, Locke FL, Bartlett NL *et al.* Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N. Engl. J. Med.* 2017; 377: 2531–44.
3. Locke FL, Ghobadi A, Jacobson CA *et al.* Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. *Lancet* 2019; 20(1); 31–42.
4. Hettle R *et al.* Exploring the assessment and appraisal of regenerative medicines and cell therapy products. CRD and CHE Technology Assessment Group, University of York, Heslington, York YO10 5DD. 2016; 1-296: <https://www.nice.org.uk/Media/Default/About/what-we-do/Science%20policy%20and%20research/final-york-report-march-16.pdf>
5. NHS England. Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund): <https://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop.pdf>
6. Ana Duarte, Centre for Health Economics (OHE), University of York, UK; Siofradh McMahon, CCRM, Canada.
7. Wong W. Impact of Increasing Wait Times on the Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy in large B-cell lymphoma: A Discrete Event Simulation Model. Canadian Agency for Drugs and Technologies in Health Symposium, 2019.
8. Agile Regulations for advanced therapeutic products and clinical trials. Discussion paper. Health Canada, July 2019: https://www.sac-oac.ca/sites/default/files/resources/healthcanada_atp_discussion-paper.pdf
9. Dalla Lana School of Public Health.
10. Stilgoe J, Owen R, Macnaghten P. Developing a framework for responsible innovation. *Res. Pol.* 2013; 42: 1568–80.
11. Silva HP, Lehoux P, Miller FA, Denis J. Introducing responsible innovation in health: a polity-oriented framework. *Health Res. Pol. Syst.* 2018; 16: 90.
12. NICE Guide to the processes of technology appraisal: <https://www.nice.org.uk/process/pmg19/chapter/selecting-technologies>
13. National Institute for Health and Care Excellence (NICE).
14. Heather Logan, Canadian Agency for Drugs and Technologies in Health.
15. Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. CHE Research Paper 77. Centre for Health Economics (CHR), University of York, U.K. April 2012: https://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP77_a_framework_for_coverage_decisions_only_in_research_evidence_development.pdf
16. Grimm S, Strong M, Brennan A, Wailoo A. Framework for Analysing Risk in Health Technology Assessments and Its Application to Managed Entry Agreements. Report by the Decision Support Unit, 2016: <http://nicedsu.org.uk/wp-content/uploads/2018/05/DSU-Managed-Access-report-FINAL.pdf>
17. Towse A. Regenerative Medicine: a European HTA Perspective. ISPOR 17th Annual European Congress, Amsterdam, the Netherlands, 8–12 November 2014.
18. James Rose, Oxford Academic Health Science Network, June 25, 2019.
19. Schüssler-Lenz M. Marketing Authorisations of Advanced Therapies in EU—a regulatory update by the EMA Committee for Advanced Therapies. ASGCT 2019 Pre-Approval Commercialization Workshop, April 28, 2019: https://www.asgct.org/ASGCT/media/about/Approved-Marketing-authorisations-of-AT-MPs-in-EU-_M.pdf
20. Linnea Doyle, Gilead Sciences, Inc.

AFFILIATIONS

Maya Chaddah
Science Communications

Allison Brown
Director, Strategy & Translation,
Medicine by Design, University of
Toronto

Siofradh McMahon

Senior Manager, Clinical Translation & Regulatory Affairs, CCRM

James Kusena

Centre for Biological Engineering and Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, UK

Karen Bremner

Research Associate, Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network (UHN)

Ann Perry

Associate Director, Administration,

Medicine by Design, University of Toronto

Murray Krahn

Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network (UHN)

AUTHORSHIP & CONFLICT OF INTEREST

Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgements: None.

Disclosure and potential conflicts of interest: Ann Perry and Allison Brown have received grants from the Canada First Research Excellence Fund, Government of Canada.

Funding declaration: The authors received no financial support for the research, authorship and/or publication of this article.

ARTICLE & COPYRIGHT INFORMATION

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Attribution: Copyright © 2020 Chaddah M, Brown A, McMahon S, Kusena J, Bremner K, Perry A & Krahn M. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

Article source: Invited.

Revised manuscript received: Jul 23 2020; **Publication date:** Aug 13 2020.

MARKET ACCESS: EVOLVING
COMMERCIALIZATION TRENDS &
STRATEGIES

SPOTLIGHT

COMMENTARY

Innovative payments for innovative therapies: adopting value-based models in the regenerative medicines & advanced therapy sector

Janet Lambert

With this new wave of transformative therapies rushing towards us, payors, policymakers, and other stakeholders must implement the infrastructure necessary to ensure broad patient access and appropriate value-based reimbursement. As the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, the Alliance for Regenerative Medicine (ARM) is laser focused on the legislative, regulatory, and reimbursement initiatives that will incentivize this innovation and help patients access these therapies as quickly as possible post-approval. This article details key priority areas for advancing market access to cell and gene therapies, as well as recent successes and remaining challenges in the USA and Europe.

Cell & Gene Therapy Insights 2019; 6(7), 941–945

DOI: [10.18609/cgti.2020.104](https://doi.org/10.18609/cgti.2020.104)

In May of this year, despite the challenges presented by the COVID-19 pandemic, the Alliance for Regenerative Medicine (ARM) hosted its largest ever US Legislative Fly-In – one of the first large-scale

virtual advocacy days attempted in the USA. More than 120 ARM members from 24 US states scheduled conference calls and Zoom meetings with Members of Congress and their staff. The participants

urged lawmakers to remove legislative barriers to value-based payment models for regenerative medicines and advanced therapies.

Across the USA and Europe, payors and policymakers are already

preparing for a revolution in healthcare. Recently approved regenerative medicines and advanced therapies demonstrate profound, durable, and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. And hundreds of additional product candidates are contributing to a robust pipeline of potentially life-changing therapies.

With this new wave of transformative therapies rushing towards us, payors, policymakers, and other stakeholders must implement the infrastructure necessary to ensure broad patient access and appropriate value-based reimbursement. As the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, ARM is laser focused on the legislative, regulatory, and reimbursement initiatives that will incentivize this innovation and help patients access these therapies as quickly as possible post-approval.

PROMOTING A POSITIVE VALUE STORY

With durable or curative therapies near at hand for a range of severe diseases and disorders, it has become clear that payors need a different model for assessing the value of these innovative treatments. Existing models are intended to evaluate traditional pharmaceuticals, which are often administered over a long period – sometimes throughout a patient's lifetime – to alleviate the symptoms of a disease. These models fail to adequately capture the full value of regenerative medicines and advanced therapies, which can provide significant increases in quality of life and productivity for patients, their family caregivers – many of whom have historically sacrificed their careers to provide better care for their loved ones – as well as overburdened health care systems and society.

This past January, ARM published a study on the potential for regenerative medicines and advanced therapies to provide

medium-to-long-term cost savings to society. Performed by the Marwood Institute, the study used a first-of-its-kind 'Transformational Therapy Value Model' (TVM) to demonstrate the benefits of durable therapies for three rare blood diseases: multiple myeloma, sickle cell disease, and hemophilia A.

These diseases are cumulatively projected to cost the US \$163 billion per year by 2029; however, there are currently late-stage innovative product candidates in development to treat each of them, with likely approvals in the short-to-medium term. Looking at a 10-year time frame – the same as used by the Congressional Budget Office when evaluating policy decisions – the study found that a durable therapy for each of these indications could result in aggregate cost-savings of \$33 billion by 2029. These savings could begin to be realized in as few as 5 years.

MITIGATING BARRIERS TO INNOVATIVE PAYMENT MODELS

While regenerative medicines and advanced therapies can provide substantial cost-savings over a patient's lifetime, the high upfront cost of these new treatments can present a significant obstacle for existing reimbursement systems. These systems are typically designed to pay for treatment over an extended period – potentially even throughout a patient's lifetime. While reimbursement systems still have a way to go to catch up with the immense value provided by regenerative medicines and advanced therapies, they have begun to make changes to accommodate these new treatments.

Advances in value-based reimbursement can help both public and private payors absorb the higher upfront costs of innovative therapies and realize the medium-to-long term cost-savings they can provide. One example of a new value-based payment model is tied to clinical outcomes. In this case, a payor does not have to pay for the full cost of a therapy if it fails to produce the intended health outcomes, which allows payors to

share the perceived risk of a new therapy with the developer.

Spark Therapeutics offers outcomes-based arrangements for Luxturna[®], their gene therapy to treat certain forms of inherited blindness. In January of this year, bluebird bio announced that they had reached an agreement with multiple statutory health insurances (sick funds) in Germany for outcomes-based reimbursement of their gene therapy Zyntegl[®] to treat transfusion-dependent β -thalassemia, a rare blood disorder that can cause severe and potentially fatal anemia. In the USA, the Centers for Medicare and Medicaid Services (CMS) recently proposed a draft rule that would allow state Medicaid programs to enter into outcomes-based arrangements without running afoul of Best Price and Average Manufacturer Price (AMP) requirements.

Another form of value-based financing that can help to alleviate the high cost of new therapies is the annuity – or payment over time. This model, which can be used as a stand-alone or in combination with outcomes-based arrangements, allows payors to make installment payments for a therapy over a predetermined period, amortizing the cost of the therapy to the value it provides. This type of payment option is offered by bluebird bio for Zyntegl[®], as well as by AveXis, a Novartis company, for their gene therapy Zolgensma[®] for the treatment of spinal muscular atrophy, a rare neuromuscular disease which, in the most serious cases, leads to death or permanent ventilation by the age of 2.

Other forms of value-based payment models are beginning to receive traction as well. Cigna's Embarc Benefit Protection program, which allows payors to enroll for about \$1 per employee per month, is intended to create a dedicated fund for innovative therapies, alleviating high out-of-pocket costs for patients and preventing shock claims for employers and plan sponsors. The 'Netflix Model', a subscription-style payment plan adopted last year by the Louisiana state Medicaid program to pay for expensive Hepatitis C drugs, has been suggested as a potential option to pay for regenerative medicines and advanced therapies

as well. This model allows the state to pay a fixed price each year to the developer to treat all patients, eliminating uncertainty for both the payor and the developer in forward-looking budgets as well as lower per-patient cost. Other strategies – including risk-pooling and reinsurance – have been used for years to cushion payers against high-cost procedures like bone marrow and solid organ transplants.

Innovative therapies require innovative payment models. Existing reimbursement system were not designed for these new therapies or these new payment models and in many cases, they have structural barriers that prevent or inhibit the adoption of new financing options. Fortunately, given the growing number of regenerative medicine and advanced therapy products on the market, we have begun to see a shift in both public and private payors. ARM continues to advocate for broad-based adoption of value-based payment models and is working with stakeholders around the world to identify and mitigate barriers.

ADVANCING PATIENT ACCESS TO ATMPs IN EUROPE

Europe has been a leader in scientific innovation and regulatory advancement in the sector, overseeing some of the earliest approvals of advanced therapy medicinal products or ATMPs. Nevertheless, the region has also seen commercial failures: Glybera[®] was the first gene therapy to receive approval from the European Medicines Agency (EMA) in 2012. It was marketed to treat lipoprotein lipase deficiency (LPLD), an ultrarare inherited disorder that can cause severe pancreatitis, affecting only one in 1,000,000 people. The therapy, which was only ever administered to 31 patients, was withdrawn from the market two years post-approval due to lack of coverage by health insurers.

While Europe has made extensive strides since its first gene therapy approval, commercial challenges remain. Individual countries have their own respective healthcare systems, requiring developers to negotiate with

multiple, even dozens, of payors to ensure equal access across the region. Specialized ‘centers of excellence’ for the administration of innovative therapies can lower costs and help to improve patient outcomes – but navigating cross-border access when there are only a handful of administration sites throughout Europe can prove challenging for patients and payors alike. Furthermore, rigidity and lack of harmonization in Health Technology Assessments (HTAs) requirements, which are often ill-suited for the evaluation of durable or curative therapies, can pose a significant barrier to effective value demonstration.

In 2019, ARM released ‘Getting Ready: Recommendations for Timely Access to Transformative Therapies in Europe’. This report, designed to create consensus on recommendations for improved patient access, provides a comprehensive review of the regulatory and market access framework across key European countries and identifies potential hurdles to the uptake of ATMPs in these areas.

In the report, ARM highlights four recommendations for improved patient access to ATMPs in Europe. These include (1) better adapting HTA frameworks to ATMPs; (2) wider application of conditional reimbursement schemes to offset uncertainty concerning the durability of innovative therapies at the time of approval; (3) the development of harmonized pan-European initiatives in areas such as Real World Evidence infrastructure, new early dialogue opportunities for developers and payors, and timely access to cross-border healthcare; and (4) a more comprehensive application of innovative financing arrangements like those detailed earlier in this article.

With the EMA expecting an uptick in the number of cell and gene therapy approvals in coming years – and multiple Marketing Authorization Application (MAA) decisions expected in the coming months, including those for BioMarin’s gene therapy for Hemophilia A and Orchard Therapeutics’ gene therapy for metachromatic leukodystrophy, ensuring timely patient access post-approval will be critical.

CMS & CELL-BASED IMMUNOTHERAPIES IN THE USA

The 2017 approval of two novel chimeric antigen receptor T cell (CAR-T) therapies – Novartis’s Kymriah® and Kite/Gilead’s Yescarta® – meant the Centers for Medicare and Medicaid Services (CMS) was faced with reimbursing these novel therapies in the Medicare program. The effectiveness of CAR-T is unprecedented among patients with blood cancers where multiple previous lines of treatment have failed. Many of these patients are experiencing complete remission or positive responses after a single administration of CAR-T.

While the New Technology Add-On Payment (NTAP) program provided an additional short-term payment for CAR-T providers, the lack of a dedicated diagnosis-related group (DRG) meant that, once the NTAP expired, hospitals that administered CAR-T therapies could lose an average of \$50,000+ per Medicare patient, disincentivizing its use. In 2019, CMS extended the NTAP payment for CAR-Ts in response to commentary from ARM as well as other patient and industry groups – the first time the agency has ever done so. Stakeholders are continuing to urge CMS to implement a longer-term solution.

In May of this year, CMS released their FY21 Inpatient Prospective Payment System (IPPS) proposed rule, which included a provision establishing a new DRG for CAR-T therapies. Since the rule was published, a broad range of stakeholders – including ARM, the American Cancer Society Cancer Action Network, and the Association for Clinical Oncology, among others – have voiced their support for this hard-fought success, ensuring Medicare patients will continue to be able to receive this life-saving therapy.

With additional CAR-T therapies poised to come to market in the coming years for a wide variety of serious cancers – from multiple myeloma to solid tumors – there is no doubt that the creation of this DRG is a timely victory. Furthermore, CMS’s decision signals its commitment to ensuring patient access to a wide variety of innovative therapies

– from cell-based immunotherapies like tumor-infiltrating lymphocytes and natural killer-cell therapies, which help the immune system to better target and kill cancer cells, to gene therapies for rare disease.

MARKET ACCESS AMIDST COVID-19

Managing and reacting to the ongoing public health crisis caused by COVID-19 has become the priority for many policymakers, regulators, and public sector payors. Additionally, the pandemic has created new financial pressures that could impact payors' ability and willingness to reimburse high-cost therapies appropriately.

Nonetheless, huge unmet medical needs remain for hundreds of thousands of patients with rare diseases, cancer, cardiovascular diseases, and other severe diseases. For these patients, timely access to life-saving treatments is critical, and any disruption in care, due to COVID-19 or to cost, can have devastating consequences.

Regenerative medicines and advanced therapies can offer profound, durable, and potentially curative treatments that can not

only mitigate unmet medical needs, but can also change how, where, and how frequently healthcare is administered to patients. Durable and curative treatments for serious diseases can reduce the amount of care many patients need amidst the unprecedented strain of COVID-19 on global healthcare systems. In addition, these therapies have the potential to offer tremendous value to the healthcare system through the realization of increased economic, productivity, and quality-of-life gains for patients, their caregivers, and society.

Payors must continue to shape and adopt systematic approaches to innovative payment models to ensure patient access to regenerative medicines and advanced therapies while minimizing the economic burden on patients and payors alike. As the voice of this groundbreaking sector, ARM is committed to continued collaboration with policymakers, payors, and other stakeholders to bring these life-changing therapies to patients in need.

AFFILIATION

Janet Lambert

CEO, Alliance for Regenerative Medicine

AUTHORSHIP & CONFLICT OF INTEREST

Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgements: None.

Disclosure and potential conflicts of interest: The author declares that they have no conflicts of interest.

Funding declaration: The author received no financial support for the research, authorship and/or publication of this article.

ARTICLE & COPYRIGHT INFORMATION

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Attribution: Copyright © 2020 Lambert J. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

Article source: Invited.

Revised manuscript received: Jul 30 2020; **Publication date:** Aug 5 2020.

INTERVIEW

From rare monogenic diseases to Parkinson's: market access considerations for gene therapy across large and small indications



PARAG V MESWANI, PharmD, serves as Axovant Gene Therapies senior vice president of commercial strategy and operations. Dr Meswani has over 17 years of experience in the biopharma industry, having served in various commercial and medical affairs leadership roles at Novartis, Pharmacia, Biogen, and most recently, Spark Therapeutics. At Spark, he served as head of US marketing and diagnostics, leading the development and execution of the brand strategy for LUXTURNA™. Prior to Spark, Dr Meswani held several corporate and franchise leadership roles at Biogen, including serving in the office of the CEO, commercial operations, the multiple sclerosis franchise and the US hemophilia franchise. Dr Meswani earned his MBA from Columbia University and his PharmD and BS from the Ernest Mario School of Pharmacy at Rutgers University.

Cell & Gene Therapy Insights 2020; 6(7), 1057–1065

DOI: 10.18609/cgti.2020.115

Q What are you working on right now?

PM: I lead commercial strategy and business operations at Axovant Gene Therapies, a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases.

On one end of the spectrum, we are focused on rare diseases for pediatric lysosomal storage disorders, specifically GM1 and GM2 gangliosidosis (also known as Tay-Sachs and Sandhoff disease), which we view as classical applications of AAV-gene therapies. In many ways, this is an area that is viewed as de-risked: these are monogenic diseases using adeno-associated virus (AAV)-based approaches that have been used in the past - for instance, for the approval of LUXTURNA™ and ZOLGENSMA®. These indications also benefit from a robust natural history dataset, where we are leveraging learnings both scientifically and from a regulatory/commercialization perspective towards the development of those programs.

On the other end of the spectrum, we have a gene therapy program for Parkinson's disease (PD). We are one of the few companies that is extending the reach of gene therapies beyond these rare monogenic conditions to more complex diseases like PD, following the science that has been accumulated over the course of the past several years. We're in an ongoing Phase 2 study right now and we intend to have some data available later in Q4 2020 that's going to inform our next steps and the likely start of a randomized, controlled clinical trial in 2021.

Q What were the key learnings you took from your experience with LUXTURNA™ at Spark Therapeutics that you are seeking to leverage now at Axovant to succeed in what is an increasingly challenging healthcare marketplace?

PM: If you think about orphan drugs and about cell and gene therapies, what you find at the intersection is that they require a specialist approach and mindset that cuts across local intervention.

In terms of finding patients, we know that with rare diseases it can take a decade before a proper genetic diagnosis is made. That's a massive issue, especially in the setting of gene therapies for rare diseases where it is so vital to raise awareness, accelerate diagnosis timelines, and ultimately deliver a therapeutic intervention. You are reliant on finding these patients and finding many of them as early as possible within their disease continuum. That is a challenge that needs to be managed and dealt with early in the drug development process, well before you think about commercialization.

Secondly, there are now many gene therapies in development. As I look to the future, I predict that the role of patients and caregivers

“In terms of finding patients, we know that with rare diseases it can take a decade before a proper genetic diagnosis is made.”

in patient-centric drug development, and the role of policy makers in drug development, will only increase. It behooves us to think about those considerations now. Patients deserve to have a voice in what endpoint you are measuring, what treatments to consider, and how this may impact their lives. At the same time, policy makers have a say in considering how you develop these drugs, how you measure response, and how you measure

the durability of that response over time. And ultimately, how you think about paying for it, which is something we think about often in the context of PD. We're talking about millions of patients across the globe. Here in the USA alone, there are slightly over a million patients according to the Michael J. Fox Foundation for Parkinson's Research. It's key to have a mindset towards shaping your efforts around the needs of the patients, the needs of policy makers, in addition to traditional stakeholders like physicians and payers.

The elephant in the room is what does the future look like with respect to the cost and payment model? As I mentioned, we're talking about the fast growth of the orphan disease market in general, and we've seen this trend for over a decade now. This growth is now compounded by growth in the cell and gene therapy market that is targeting these orphan diseases. We're going to see – I think we're already seeing to some extent – a meaningful increase in the overall prescription drug market and the landscape for advanced therapies. This is only going to be compounded as more and more gene therapies make it through development to commercialization.

This is a good thing from a scientific perspective, and it is a great thing for patients, but it is also a burden on the global healthcare system. Various countries are dealing with it differently. The USA is starting to put some frameworks around this both at a commercial payer level and much further behind, from a government insurance perspective. In many ways, I think the government insurance policy perspective in the USA is very similar to where things are in Europe and perhaps other places: they are playing catch-up and trying to figure out how they're going to contain costs in future.

This poses quite a challenge for gene therapies where there is a one-time delivery that may come at a substantial cost. When considering the high annualized cost of these drugs versus traditional prescription drugs, the need to advance alternative financing models is paramount. Right now, companies are performing pilots for therapies that are approved and on the market. However, it's going to be incumbent on companies that are moving through their drug development and registration process to be smart and proactive, and to think about unique pathways towards patient access. This could include a spectrum of financing options, from paying for it in the traditional way we do now as an upfront cost, to trying to spread the cost out over the course of several years. Another option is to get even more creative and put outcome-based models into place, so that providers or payers can get a rebate or refund if the drug does not work for certain a period of time, or if certain predefined metrics are not met.

This is all incredibly complex stuff and I don't think we're anywhere near figuring it out. Even so, I am optimistic because there are a lot of incredibly smart people and companies working on

“The elephant in the room is what does the future look like with respect to the cost and payment model?”

“...it’s going to be incumbent on companies that are moving through their drug development and registration process to be smart and proactive, and to think about unique pathways towards patient access. This could include a spectrum of financing options, from paying for it in the traditional way we do now as an upfront cost, to trying to spread the cost out over the course of several years.”

the problem, and there is great collaboration occurring right now across stakeholders that I don’t think has happened before. We’re seeing dialogue and cross-talk between payers and biopharma, between patient groups and payers, and between all three parties, to figure out what benefits can be derived for patients and how to ensure these innovations ultimately make it to them.

Going back in a roundabout way to the lessons I’ve learned, a big one is that we have to iterate. We have to iterate on these dimensions: how you find patients, how you manage stakeholder pressure, and how you leverage all those learnings in order to drive innovative ways to finance these gene therapies.

Q What specific challenges did you experience while working on LUXTURNA™?

PM: There were two key issues that arose as a byproduct of market development that we uncovered fairly early on in the process for LUXTURNA™.

Awareness of rare diseases is low, and awareness of inherited diseases of the eye is incredibly low. As a result, many rare disease patients with blindness caused by a genetic mutation were undiagnosed, as they weren’t getting a genetic test and being genotyped to identify the gene causing their disease. One reason why a genetic diagnosis can take many years is that there is a perceived element of complexity around getting a genetic test done, and not enough knowledge of what to do when those results come in.

Because patients weren’t being genetically tested, you could not find patients early on that would benefit from LUXTURNA™. LUXTURNA™ was a breakthrough; the clinical trial data was exceptional. The challenge was how to find the patients with very specific mutations in one very specific gene.

One of the solutions to mitigate this and try to increase the rate of patients you could identify was to figure out a way to accelerate the adoption of genetic testing in patients with any form of inherited retinal blindness. The specific gene associated with LUXTURNA™ is *RPE65*,

but there are over 250 different genes that can contribute to an inherited form of blindness – the only way to know which gene mutation you have is to get a genetic test. So the company sponsored genetic testing programs in order to accelerate the adoption of genetic testing in any patient with an inherited retinal disease, and to ultimately facilitate ease of access to that test. The aim was to make it very simple and accessible so that a physician and patient can do it in a straightforward way, to empower physicians and patients to get that genetic diagnosis.

The benefit for the patient is they get a genetic diagnosis, and for the company, you can help identify patients who will benefit from LUXTURNA™ while supporting the community in a way that isn't purely self-serving. If we were just trying to find patients that would benefit from LUXTURNA™, it wouldn't have worked as well because the disease is so rare. With this approach, you're actually launching an initiative that can target the needs of a much broader subset of patients and empowering them with a genetic diagnosis that would not otherwise have occurred.

A lesson learned from that process is that it was a good program and it worked, but it can't be done in isolation. You have to look at multiple different levers to support patient identification. There is not a one-size-fits-all approach for gene therapies and rare diseases.

Genetic testing is one component of that, and patient advocacy and patient education is another lever, meaning that you have to make sure the patients know where to find information. You have to make it accessible online or through social media, as this is how a lot of these groups communicate. You have to be part of that conversation with them.

The final lever is finding the right physician and provider targets. Getting in front of the right physicians, with the right analytics so that you can find advocates and champions in support of your patient identification efforts is key – and all of these things work hand-in-hand: you find the right physician who can do genetic testing, then you offer a genetic testing program. At the same time, you activate patients to want to seek more information about these types of resources and tools. From a patient identification perspective, these strategies were relevant and impactful for LUXTURNA™, and they're relevant and impactful for many other rare disease therapies in development today.

Q Turning to PD, how does targeting these larger indications with a gene therapy compare and contrast with targeting a rare monogenic disease – for example, when it comes to health technology assessment (HTA) considerations?

PM: PD is an interesting one. Most of the rare diseases that are being targeted by gene therapies do not have any therapies available. This is both a pro and a con in my view. Because there are no therapies, you are in a white space and you can build your own economic model, assuming there is a safe and effective gene therapy being developed. You can take that white

“You have to look at multiple different levers to support patient identification. There is not a one-size-fits-all approach for gene therapies and rare diseases.”

“When you introduce a therapy where there was none before, you add cost to the system. You have to look at creative ways to justify what the price might be and what a demonstration of economic evidence of effect might be.”

space and really make the case for gene therapy. That can be challenging – for LUXTURNA™, this was a disease that didn't have any approved therapies. So the question was: how do you put a price on blindness? How do you quantify the value of restoring vision, when there aren't any comparables out there, and no therapies? When you introduce a therapy where there was none before, you add cost to the system. You have to look at creative ways to justify what the price might be and what a demonstration of economic evidence of effect might be. The case we looked at was when somebody is injured at their job, what is their vision worth? If they go

to work and sue their employer, what do juries award in that setting? We did some work there and found some analogues, and we found what juries tend to award victims of loss of vision at work – that gave us an analogue to look at price. It was a very non-traditional way of doing things.

With something as prevalent as PD, there's a different challenge. There are already very well-articulated direct and indirect costs of the disease. So you have to build the right assessment into your clinical trial process very early on to demonstrate response in the setting of standard of care, and prove that you actually remove cost from the system with a one-time gene therapy. You have to show that can have durable response out to 3–5 years or more. You also need to compare and contrast with standard care and the cost of those offerings based on what they deliver, in order to demonstrate the incremental benefit that gene therapy can provide above and beyond what's on the marketplace.

As you think of evidence generation, you have to understand and evaluate the commercial potential early on, and make sure you're mapping out some of the pricing evidence requirements in the context of standard of care. To contrast that again with the rare disease side, it's a little bit different. Where there is a gap, you can fill that gap with a drug that has proven to be safe and effective, and you need to decide how to price it in an appropriate way. That's one part of evidence generation.

You also need to consider value communication. This goes back to stakeholder mapping and understanding the needs of patients, payers, physicians, and advocacy groups. You can use that insight to pre-empt potential evidence gaps and get ahead of it, and to leverage the feedback from stakeholders to inform value communication.

All of these considerations ultimately inform your route to market and your decisions on the appropriate commercialization model, the appropriate regulatory pathways on that route, and how that informs price, access, launch sequencing, and so on.

Q What will be the key challenges in getting gene therapies into larger patient populations, potentially on a global basis, and what are the next steps towards addressing them?

PM: When considering PD, in the US, there are about a million patients who have some form of the disease. The question will be: who are the patients who will benefit most?

The total addressable market is quite large, but that doesn't mean gene therapy is appropriate for all of these patients. It will require being smart about patient segmentation, and beginning to paint a very clear picture of what the correct area for gene therapy is: who will benefit and equally importantly, who may not benefit. Having that level of clarity in the drug development process will open doors and help provide a lot of understanding on who might benefit best from this type of approach, and on what continuum in their disease. Keeping it open and lacking that specificity will just create concerns and complexity. Our job will be to create clarity out of the clutter in these larger diseases, and fit ourselves into the treatment algorithm in a way that is understandable, data-driven, and rational. At the same time, we want to avoid overly minimizing the impact the therapy could have across the spectrum of different PD populations.

At Axovant, we're addressing this through the creative design of our clinical trials as well as through regulatory engagement. The feedback we have received from regulators has been very clear on patient populations, and that they want to see safety and efficacy first.

We will begin to open the aperture over time, so that we can think about expanded patient populations that can be evaluated within the context of our clinical development program, according to the lifecycle management of that initiative. We are looking at the holistic group of addressable patients that could benefit, but we're not just trying to jam all that into one. We are taking a sequential, phased, and methodical approach towards drug development that starts with one core of patients and will then expand out.

This is not something that's going to end in Phase 2 or Phase 3, which is similar to the situation with other biologics for larger indications, and other large-market indication drugs in general. We can take a page from their playbook and look at lifecycle management in a holistic way for large indications with gene therapy, which is something that you just can't do with rare or orphan disease therapies because the market is so small.

Q What's your current view the most likely pathways forward for gene therapy reimbursement models that suit all stakeholders?

PM: With gene therapies, you obviously need to ensure you're collecting payer input early on to optimize gene and cell therapy pricing and payment modalities. A trend we are likely to see is that you shouldn't allow yourself to be beholden to a single path. There are multiple different options, multiple modalities, that have been identified. There are likely to be others that will emerge as more gene therapies advance and get approved. If you want to take the traditional route and start with a one-time payment, plus performance-based milestones, that's fine. If you want to have outcome-based reimbursement model in some other way, which is how LUXTURNA™ tried to approach it using prespecified milestones and pre-specified metrics, that's also fine. Ultimately, it's about having optionality by giving your payers different means to assess price and value for money, and being able to manage what are likely to be not-insignificant price points.

For PD, because of the large population, the trade-off is a price and volume one. With rare diseases, you are going after much smaller indications, so you will likely have to price these therapies for the vast majority of those patients. For larger indications, in order to have broad market access, you are going to have to come up with an equally responsible way to price it. If you do that, you have the opportunity to be utilized in a much larger segment of the PD population. This is the price/volume trade-off specific to larger market indications. This goes back to the point I made about weaving these considerations into your clinical trial process, thereby allowing you to be a bit more creative with payment modalities and pricing potential across different countries.

Q Can you sum up Axovant's chief goals and priorities over the next 12–24 months?

PM: For the company, our priorities are focused around our three clinical programs. For PD, our goal is to continue to advance the program in development and initiate a placebo controlled clinical trial where we aim to begin enrolling patients in 2021 within the USA and Europe. That will be an important milestone for the company and an important milestone for the PD space, and it will be one of the furthest along gene therapies for a large target indication that is out there. We are laser focused on executing our clinical plan for PD and believe we have a treatment that could tackle the greatest challenge for people living with PD – improving motor function and quality of life

On our rare diseases side, we have a GM1 gangliosidosis program, and a program on Tay-Sachs and Sandhoff disease (GM2). We have a very clear clinical development plan laid out that starts initially with an assessment of safety and secondarily efficacy, which is then supplemented by a program that is focused primarily on efficacy. Our goal is to advance that through drug development in an expedited manner, and to make the case to regulators for these diseases as quickly as we can based on the evidence and the data we are generating, and the massive need that exists for these children. These are devastating diseases. Many of these children will die by about 3 years of age and there are no approved disease modifying therapies on the market that can stabilize or perhaps even improve function. We feel a personal responsibility to move these through the clinic and hopefully, to registration in an expedited manner over the course of the next 12–24 months, with the goal of commercializing within the next few years.

AFFILIATION

Parag V Meswani, PharmD

Senior Vice President of Commercial Strategy and Operations, Axovant Gene Therapies

AUTHORSHIP & CONFLICT OF INTEREST

Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgements: None.

Disclosure and potential conflicts of interest: Dr Meswani is an employee and receives compensation from Axovant as party of his employment.

Funding declaration: The author received no financial support for the research, authorship and/or publication of this article.

ARTICLE & COPYRIGHT INFORMATION

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Attribution: Copyright © 2020 Meswani PV. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

Article source: Invited.

Interview conducted: May 13 2020; **Publication date:** Aug 28 2020.

MARKET ACCESS: EVOLVING
COMMERCIALIZATION TRENDS &
STRATEGIES

SPOTLIGHT

COMMENTARY

Bringing advanced therapies to the clinic: the Swedish National ATMP Consortium (CAMP/SWElife ATMP)

Stefan Scheduling, Heather Main & Pontus Blomberg

Advanced therapy medicinal products (ATMPs) have the potential to transform medicine, with the promise to treat, manage and cure some of the most severe diseases. However, the development of ATMPs is complex and successful transition from preclinical research to the approved clinical product faces a number of hurdles regarding technical as well regulatory and societal challenges. The closely interacting national initiatives CAMP (Center for Advanced Medical Products) and SWElife-ATMP aim to establish Sweden as one of the international leaders in the ATMP field. Taking into account Sweden's systems and organizational challenges, these programs nationally coordinate efforts focusing on industry and SME growth, clinical practice, research and education, advanced production, and a flourishing innovation and business environment that in the long term has potential to become a major driving force for the development of a new sector in the Swedish life science industry.

Cell & Gene Therapy Insights 2020; 6(7), 947–953

DOI: 10.18609/cgti.2020.105

TRANSLATION INSIGHT

Background

Although it has been more than a decade since the publication and entry into force

of the European Regulation 1394/2007/EC on advanced therapy medicinal products (ATMPs) (Box 1) [1], these novel forms of therapeutics have first started to enter

broader clinical practice in the last few years.

A recent European Union (EU) survey showed that numbers of clinical trials using ATMPs were only slowly

▶ **BOX 1****Advanced therapy medicinal products (ATMPs).**

Any of the following medicinal products for human use:

- ▶ A gene therapy medicinal product as defined in Part IV of Annex I to Directive 2001/83/EC.
- ▶ A somatic cell therapy medicinal product as defined in Part IV of Annex I to Directive 2001/83/EC.
- ▶ A tissue engineered product defined by containing or consisting of engineered cells or tissues, having properties for, or is used in or administered to human beings with the intent to regenerating, repairing or replacing a human tissue.

Cells or tissues shall be considered 'engineered' if they have been subject to substantial manipulation* or are not intended to be used for the same essential function or functions in the recipient as in the donor ('non-homologous' use).

*Substantial manipulation is negatively defined by a list of manipulations that are particularly considered as non-substantial.

increasing during 2010–2015 while the focus was still in early development [2]. Furthermore, the work was mainly carried out by small and medium-sized enterprises (SMEs), academia, and hospitals [2]. One likely reason that contributed to this modest development of ATMPs was the lack of necessary multidisciplinary skills that were needed to overcome the complex regulatory barriers [3]. Accordingly, a survey of European academic and non-industrial facilities showed that facilities experienced in manufacturing cell therapy transplant products were the most successful in developing ATMPs whereas new centers lacking this background faced considerable difficulties to enter the field [4]. Furthermore, gene therapy development was delayed by lethal side effects and insertional mutagenesis events leading to intense efforts to develop safer vectors and therapy designs. So, at the end of the extended transitional period of Regulation 1394/2007 in 2012 only two products, ChondroCelect® (autologous *ex vivo* expanded cartilage cells) and Glybera® (gene therapy product containing the active substance alipogene tiparvovec), were centrally licensed in the EU (central market authorization, MA), but limited commercial success has led to the discontinuation of both products.

However, after these early years of slow development, the ATMP field has gained considerable momentum, in parallel with an increasing engagement of larger pharmaceutical

companies. In 2018, the numbers of ATMPs with MA in the European Union (including those that were suspended and withdrawn, respectively) accounted to twelve [5,6], and also numbers of scientific recommendations on ATMP classification by the European Medicines Agency's Committee for Advanced Therapies (CAT) clearly show an increasing trend [7]. The recent rapid clinical development of chimeric antigen receptor (CAR)-T cell products, some of which have already entered routine clinical practice, is an excellent example of the dynamics in the field. However, one has to keep in mind that it has taken more than 30 years from the initial report of the concept of a chimeric antigen receptor to the approval of the first anti-CD19 CAR-T cell therapy [8].

The European Regulation 1394/2007/EC aims to apply, harmonize and extend the principles of existing legislation on medicines and to assure the position of the EU in scientific innovation. It furthermore clearly lays out marketing authorization as the default development path for ATMPs, which resulted in the difficulties that especially academia and hospitals faced to adapt to the novel and complex regulatory environment. Moreover, the situation was additionally complicated due to heterogeneous implementation of the regulation and preexisting profound differences in the organization of research and healthcare across and within EU member states (MS).


Sweden traditionally scores high on the European Innovation Scoreboard despite being one of the smaller European countries [9]. Here, it was realized that the development of the countries' full potential in this new and exciting field would critically depend on serious efforts to effectively coordinate and consolidate all stakeholders, i.e. industry, academia, healthcare, regulatory bodies/authorities and patients. It was furthermore realized that any public investment to facilitate Sweden to become one of the future leading countries in the field had to be coordinated on a national level. Applying this strategy would adequately address Sweden's systems and organizational challenges that had been identified as hurdles for development of ATMP research, production and commercialization. Based on these considerations, two closely interacting national initiatives (CAMP, Center for Advanced Medical Products, and SWElife-ATMP) were founded, both receiving substantial funding from the Swedish Innovation Agency, VINNOVA, which is a government agency under the Swedish Ministry of Enterprise and Innovation. These initiatives form a national center for ATMP development as presented below.

National initiatives to address system & organizational challenges for the development of ATMPs in Sweden

Beside regulatory considerations regarding clinical ATMP development which are common for all European MS, there are some aspects that are more country-specific, such as organization of the Swedish public healthcare system in relation to academic research institutes, universities and the commercial sector. For example, Sweden consists of 21 regions and it is the responsibility of the regions to organize health and medical care. Regional healthcare is conducted at all seven university hospitals in Sweden. However, some of the highly specialized medical care is centralized to one or two hospitals in order to achieve higher quality and more efficient use of resources. Any clinical development of ATMPs will therefore rely on the coordination of the different healthcare regions, which fortunately has already been established during 10 years' work in the national cell therapy group within the Swedish Association of Local Authorities and Regions' (SALAR) National

► FIGURE 1

Swedish companies involved in ATMP development and production.



GTMP: Gene therapy medicinal products; sCTMP: Somatic cell therapy medicinal products; TEP: Tissue engineered products.

Source: ATMP Sweden [14].

▶ **BOX 2**

CAMP partners.

Healthcare Regions and University Hospitals:

- ▶ Region Uppsala, Uppsala University Hospital*
- ▶ Region Stockholm, Karolinska University Hospital*
- ▶ Region Skåne, Skåne University Hospital*
- ▶ Region Örebro, Örebro University Hospital*
- ▶ Region Västerbotten, Umeå University Hospital*
- ▶ Region Östergötland, Linköping University Hospital*

Large Pharmaceutical/Life sciences companies:

- ▶ AstraZeneca AB*
- ▶ Pfizer AB*
- ▶ GE Healthcare Bio-Sciences AB (now: Cytiva Sweden AB)*
- ▶ Takara Bio Europe AB*
- ▶ Novartis Sweden AB

SMEs:

- ▶ Boobicell AB*
- ▶ Cellseed Sweden AB*
- ▶ Idogen AB*
- ▶ TATAA Biocenter AB*
- ▶ Xintela AB*
- ▶ Your Special Delivery Service Stockholm AB*
- ▶ Acousort AB
- ▶ Noricon AB
- ▶ Cellink AB
- ▶ Cobra Biopharma AB
- ▶ Nextcell Pharma
- ▶ Verigraft AB
- ▶ VivaBioCell S.p.A

Universities and Research Institutes:

- ▶ Umeå University (program coordinator)*
- ▶ University of Gothenburg*
- ▶ Karolinska Institutet, Stockholm*
- ▶ KTH Royal Institute of Technology*
- ▶ RISE Research Institutes of Sweden*

Others:

- ▶ Medicon Village AB*

*Indicates founding member.

for CAR-T cell production. Also, the public healthcare system serves as the resource for patient recruitment into academic and industry-sponsored clinical studies and will finally have to find solutions to finance effective but likely highly expensive future ATMP treatments and identify mechanisms to provide it to all Swedish citizens in need, once a treatment has entered routine clinical practice. In addition, university hospitals have to be prepared to process ATMPs and even to produce those ATMPs that already have or will enter standard clinical practice, but which are not developed commercially due to lack of (expected) profitability. One example for such a product are cultured autologous keratinocytes that have been used in many years for the treatment of severely burned patients in the two Swedish national burn centers. Cultured autologous keratinocytes were previously handled as other products intended for transplantation but have now to be produced as ATMPs by hospitals, i.e. non-commercial entities, with current regulations not being adapted to this special situation in which a standard-of-care product is not intended for, or even legally prohibited from commercial development. Lastly, ATMP research and development is traditionally concentrated in academia and SMEs (Figure 1), which ideally need to be interconnected with both the healthcare system and large pharmaceutical companies to enable effective ATMP development towards MA. Obviously, large pharmaceutical companies are also depending on the close cooperation with healthcare and academia, so that one of the obvious goals of the national ATMP initiatives is to provide the framework for a successful cooperation of these partners, ideally in close cooperation with the regulatory agencies.

CAMP & SWElife-ATMP structure, governance & participants

The application for the formation of CAMP as a national ATMP center was submitted to Vinnova by a total of 22 partners including all

Tissue Project [10]. Additionally, industrial production of a number of cell-based ATMPs will require the use of public tissue establishments for the procurement of patient and donor cells, e.g. autologous apheresis products

▶ **BOX 3**

CAMP: overall goals.

- ▶ Build a strong public private partnership with government, universities, healthcare, patient organizations and industry to accelerate new breakthrough ATMP therapies to patients.
- ▶ Create strong research and development activities in Sweden to attract global interest and investments in the ATMP area.
- ▶ Provide a national infrastructure to pave the way for commercialization of ATMPs for the benefit of patients and the society.

The overall long-term objective is to develop general ATMP development principles and methods for an effective transfer from preclinical to clinical, GMP-compatible production.

Swedish Medical Regions, large pharmaceutical companies and SMEs as well as Swedish universities and the Swedish Research Institute, RISE (Box 2). The total budget of CAMP is 148 million SEK between 2018 and 2023. Vinnova will contribute 48 million SEK, which is a part of the 320 million SEK commitment of the Swedish government towards making Sweden a World leader in biologics. SWElife-ATMP was initiated by a mostly overlapping group of applicants aiming to complement the activities in CAMP. Since its inauguration in 2018, the number of partners and participants as well as activities and projects in both programs have increased considerably.

The organizational structure of CAMP was designed to realize the overall goals of the program (Box 3). All partners are represented in the General Assembly as the ultimate decision-making body, which elects the executive board as the supervisory body. The operational management is performed by the program office and the work is organized in work packages (WPs) and cross-cutting priorities (CCPs) (see below). New partners can join the consortium upon application and the program is open for proposals for new

projects that fit the aims and objectives of the center. A new project can be initiated after submission and approval of a proposal, thus providing CAMP the opportunity to expand the program quantitatively and qualitatively. Strong focus is put on that partners from the different groups participate in the projects. Results generated in the projects and technologies resulting from the project work are made available to the consortium. A strong international scientific advisory board (Box 4) was appointed to support the program, evaluate progress and give important input on the future development of the center.

SWElife-ATMP is a project within the strategic innovation program SWElife [11] and is tightly connected and coordinated with CAMP. Both programs use common decision-making bodies and share organizational and supporting infrastructures. The work in CAMP and SWElife-ATMP thus complement each other, with CAMP currently focusing on ATMP infrastructure and process development, whereas SWElife-ATMP projects focus on regulatory, ethical and financial aspects (see below). SWElife-ATMP is funded until the end of 2020. Activities will be continued in the recently-funded program

▶ **BOX 4**

International advisory board members.

- ▶ Karin Hoogendoorn – Lonza, The Netherlands & Switzerland
- ▶ Mark Lowdell – Royal Free Hospital, London, United Kingdom
- ▶ Michael May – Center for Commercialization of Regenerative Medicine, Toronto, Canada
- ▶ Roke Oruezabal – Andalusian Initiative for Advanced Therapies, Spain
- ▶ Seppo Ylä-Herttua – University of Eastern Finland, Finland

‘Vision Driven Innovation Milieu’ (for more details on this project, please see [12]).

Work packages & projects

The work in CAMP and SWElife-ATMP is organized in work packages, WPs. CAMP WPs address the topics process development, infrastructure for GMP manufacturing, quality control (QC), shelf-life and logistics. Currently, a total of seventeen projects are being performed ranging from work with pluripotent stem cells, stromal cells, immune cells and extracellular vesicles to the establishment of pre-GMP facilities and the design of QC and logistics strategies.

In addition to the WPs ‘project management’ and ‘communication’, SWElife-ATMP is responsible for the organization of the national conference ‘ATMP Sweden’, which has received increasing attention in the last years. The planned 2020 conference has been delayed due to the continuing Coronavirus

situation but will hopefully be held in the Spring of 2021. Finally, five so-called System-Development Programs (SDPs) in SWElife-ATMP address questions regarding regulatory aspects for ATMPs, the ethical and legal framework of stem cell-based ATMPs in Sweden, business models and health economics for ATMPs, opportunities and challenges for Sweden to become internationally leading in the field of gene therapy as well as the foundation of Sweden’s CAR-T Cell Competence Network (SWECARNET). Thereby, the work in SWElife-ATMP covers the topics that were initially outlined in the CAMP CCPs.

Progress and results of the center activities, such as a recently published draft report on health economy and business models for ATMPs, are regularly published on the common project homepage ‘Sweden ATMP’ [13]. The reader is therefore invited to visit this homepage, which also provides more in-depth and additional information about the center as well as general information about ATMPs.

REFERENCES

1. Regulation (EC) No. 1394/2007 of the European Parliament and of the Council on Advanced Therapy Medicinal Products and amending Directive 2001/83/EC and Regulation (EC) No. 726/2004. *OJ L* 2007; 324: 121–37.
2. Boran T, Menezes-Ferreira M, Reischl I *et al.* Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving? *Hum. Gene Ther. Clin. Dev.* 2017; 28(3): 126–35.
3. Cuende N, Izeta A. Clinical translation of stem cell therapies: a bridgeable gap. *Cell Stem Cell.* 2010; 6(6): 508–12.
4. Pearce KF, Hildebrandt M, Greinix H *et al.* Regulation of advanced therapy medicinal products in Europe and the role of academia. *Cytotherapy* 2014; 16(3): 289–97.
5. Cuende N, Rasko JEJ, Koh MBC, Dominici M, Ikonomidou L. Cell, tissue and gene products with marketing authorization in 2018 worldwide. *Cytotherapy* 2018; 20(11): 1401–13.
6. Detela G, Lodge A. EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation. *Mol. Ther. Methods Clin. Dev.* 2019; 13: 205–32.
7. Summaries of scientific recommendations on classification of advanced therapy medicinal products | European Medicines Agency: <https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/advanced-therapies/advanced-therapy-classification/summaries-scientific-recommendations-classification-advanced-therapy-medicinal-products>
8. Braendstrup P, Levine BL, Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. *Cytotherapy* 2020; 22(2): 57–69.
9. European innovation scoreboard: https://ec.europa.eu/growth/industry/policy/innovation/scoreboards_en
10. National Tissue Project: www.vavnad.se
11. SWElife: <https://swelife.se/en>
12. Vision Driven Innovation Milieu: <https://atmpsweden.se/atmp-innovation-environment/vdh-projects>
13. Sweden ATMP: <https://atmpsweden.se>

14. ATMP Sweden map: <https://atmpsweden.se/resources/atmp-map/>

AFFILIATIONS

Stefan Scheduling

Author for correspondence:
Division of Molecular Hematology
and Lund Stem Cell Center, Lund
University, Lund, Sweden

and
Department of Hematology, Skåne
University Hospital, Lund, Sweden
stefan.scheduling@med.lu.se

Heather Main

Department of Clinical Science, Inter-
vention and Technology, Karolinska
Institute, Stockholm, Sweden
and
Karolinska Cell Therapy Center,

Karolinska University Hospital, Stock-
holm, Sweden

Pontus Blomberg

Karolinska Cell Therapy Center, Karo-
linska University Hospital, Stockholm,
Sweden
and
Department of Laboratory Medicine,
Karolinska Institute, Stockholm,
Sweden

AUTHORSHIP & CONFLICT OF INTEREST

Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgements: Supported by Vinnova project CAMP (Contract no. 2017-02130) and Swelife-ATMP, a common investment of Vinnova, Formas and the Swedish Energy Agency (Contract no. 2017-02453).

Disclosure and potential conflicts of interest: Dr Scheduling is founder and shareholder of AcouSort AB, Lund, Sweden.

Funding declaration: The authors received no financial support for the research, authorship and/or publication of this article.

ARTICLE & COPYRIGHT INFORMATION

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Attribution: Copyright © 2020 Scheduling S, Main H & Blomberg P. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

Article source: Invited.

Revised manuscript received: Jul 30 2020; **Publication date:** Aug 20 2020.

INTERVIEW

How should health technology assessment of ATMPs evolve in Europe?



MONDHER TOUMI is MD by training, has an MSc in Biostatistics, and in Biological Sciences (option pharmacology) and a PhD in Economic Sciences. He is Professor of Public Health at Aix-Marseille University. After working for 12 years as Research Manager in the department of pharmacology at the University of Marseille, he joined the Public Health Department in 1993. In 1995, he embraced a carrier in the pharmaceutical industry for 13 years. Dr Toumi was appointed Global Vice President at Lundbeck A/S. In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support health industries and authorities in strategic decision-making. In February 2009 he was appointed Professor at Lyon I University in the Department of Decision

Sciences and Health Policies. He launched the first European University Diploma of Market Access (EMAUD), an international course already followed by about more than 500 students. He is editor in Chief of the *Journal of Market Access and Health Policy* (JMAHP). In September 2014, he joined the research unit EA3279 of the public health department, at Aix-Marseille University (France), where he is a full Professor. Dr Toumi is also a visiting Professor at Beijing University (Third Hospital). He is a recognized expert in health economics and an authority on market access and risk management. He has more than 200 scientific publications and oral communications, and has contributed to several books. He authored the reference book on Market Access.

Cell & Gene Therapy Insights 2020; 6(7), 1095–1101

DOI: 10.18609/cgti.2020.119

Q What are your reflections on the current state of play regarding health technology assessment (HTA) methods of analysis and tools, especially in the advanced therapies area?

MT: It has become obvious that HTA current evidence analysis frameworks are poorly adapted to assess the specificities of regenerative medicines. Overall, the HTA bodies are very anxious to adjust their assessment framework for advanced therapy medicinal products (ATMPs) because the manufacturers of every other class of drugs are going to consider themselves differently and will request a specific process. Indeed, personalized medicines, drug–device combinations, and orphan drugs may all claim they are specific and deserve a specific framework. Therefore, manufacturers are going to push hard for changes as to how their specific product is assessed, whether it be a gene therapy, a cell therapy, etc. Adjustments to the process are justified for this specific therapeutic class, but you can say the same thing for other classes, such as orphan drugs – and in that particular case, it took a lot of time before the HTA bodies were ready to make any adjustments and some adjusted their practice but not their framework.

The European HTA agencies routinely say that there is too much uncertainty around ATMPs, but in practice, they do seem to be adopting them – especially Germany, the UK and France. However, the decisions of other countries are still pending, and if you look across the larger European countries and Canada, you see that most products have only been assessed in two or three of them. Of course, this does not apply to Kymriah® and Yescarta®, which have been assessed in all of these countries – Kymriah® has three indications and was recommended positively with no restrictions across the board, while Yescarta® has been recommended in all countries but one. But other ATMPs have received only very limited assessment to date.

Q How do you see these HTA models and tools evolving further over time, particularly as the ATMP field continues to grow and mature?

MT: The big issue for HTA is that one ATMP is not comparable to all ATMPs; it is a very heterogenous class. Some products have the potential to provide a dramatic benefit and some products have modest or little benefit. Additionally, the actual benefit may not be

where you might expect it to be, and that is the real issue.

If you consider a genetic disease where the patient is facing a significantly shortened lifespan or severe disability and there is no treatment, and your gene therapy is going to provide a dramatic improvement or prevent further deterioration, that is considered very important. However, if you take the same disease but we already have a therapy available that is working

“The European HTA agencies routinely say that there is too much uncertainty around ATMPs, but in practice, they do seem to be adopting them.”

“...if products get rejected, investors may become less inclined to fund these programs. If we want the flow of new ATMPs to continue, payers have to show that they are open to them and to paying a fair price that is profitable for companies and fair to their budget. If none of these products are reimbursed ... companies will stop developing them.”

pretty well, the situation will be different. For example, for some forms of mucopolysaccharidosis (MPS), there are effective enzyme replacement therapies (ERT) available. If you consider gene therapy in those specific indications, the comparative benefit would be in the convenience of use – you don't need to administer the gene therapy periodically, as you would the ERT (where delivery, often to children, is via IV or subcutaneous injection). The potential benefits of gene therapy are very different between these two scenarios, so the value arguments are not the same.

It is difficult for HTA bodies to simply create a new route to assess such diverse therapies. However, one very common aspect of ATMPs that does require a new, specific process is that we don't know what the long-term benefits are, because we don't have enough follow-up with patients. There could be future adverse events or issues with the durability of efficacy of these treatments. HTA bodies are not yet ready for this, though, as they are concerned about moving too quickly and making decisions that would be difficult to work back from.

The decision analysis framework needs to change and a certain degree of uncertainty needs to be accepted in order to allow companies to move forward. In most cases, long-term follow-up through the registry is already a regulatory requirement.

If we do not improve on the current situation, it could have a big impact on cell and gene therapy development – for instance, if products get rejected, investors may become less inclined to fund these programs. If we want the flow of new ATMPs to continue, payers have to show that they are open to them and to paying a fair price that is profitable for companies and fair to their budget. If none of these products are reimbursed, again, companies will stop developing them. There is a need to encourage companies and to encourage the development of scientific knowledge.

Q How do you predict the market access scenario will evolve in the rare disease space?

MT: The rare disease field has evolved a lot and for the most part, this evolution has been positive. In Germany, for example, there is a regulation that allocates – by law,

“...the field of orphan drugs is being reasonably rewarded. The problem for payers and for HTA is the sheer number of these products that are now coming through, each with the expectation of a high price-point.”

and without assessment – additional benefit to any orphan designated product, whether it is a gene therapy or otherwise. And in the UK, therapies for ultra-rare conditions can go to a highly specialized therapy committee and benefit from the possibility of gaining a conditional reimbursement while they collect data to reduce any uncertainty. They also benefit from receiving the highest incremental cost–effectiveness ratio (ICER) threshold for recommendation. This is quite a unique opportunity.

If you look at nusinersen (Spinraza®), it has been shown to have a very high cost per qual-

ity-adjusted life year (QALY), according to the UK’s National Institute for Health and Care Excellence (NICE). But despite this, it was endorsed for spinal muscular atrophy (SMA) type 1. And because patient groups were unhappy with that decision, NICE then decided to extend the recommendation to SMA type 2 patients, despite the data not being particularly impressive in that indication with regards to the ICER. This shows that the field of orphan drugs is being reasonably rewarded. The problem for payers and for HTA is the sheer number of these products that are now coming through, each with the expectation of a high price-point. Even if the individual numbers of patients are small per product, the budget impact of individual products may be affordable despite a high price-point. But when you multiply by the increasing number of products, it has a big impact on budget. Several orphan drugs have reached blockbuster status over the last ten years, and the spending on orphan drugs is growing much faster than for other pharmaceuticals, but this is causing regulators and payers to turn increasing scrutiny on these products.

Regulations have not increased, as such, but regulators used to be quite accommodating in terms of the data available, and would try to find a solution to accept and reimburse these products even if the data was not at the level of their usual requirements. Today, they are becoming increasingly stringent, requesting more robust data. A single arm study may no longer be accepted, unless there are very specific conditions demonstrating that it was necessary and not possible to do otherwise. The level of indulgence that orphan drugs have previously received is now reducing.

Q Moving to the uptake and integration of ATMPs into the various European healthcare systems, how should these therapies be made available, and who should be responsible for their administration to patients?

MT: At the moment, most of the products available are targeting severe conditions that are treated by highly specialized centers. These specialists are the ones

diagnosing and treating patients, and in my view, they are the ones who should be administering these products.

But this model won't work in all cases: let's assume you have a gene therapy for diabetes. Most patients with diabetes are treated by their GP, not a specialist. The questions of whether a GP is going to prescribe this product, and what that process might look like, are both complicated. If you have a large patient population, you simply can't limit treatment to specialized centers. Another example is heart failure. If you have a cell therapy available, who will decide on the prescription? In my view, we can't rely on niche specialists in these cases; we need to open it up more widely – but the product may still need to be administered under specific medical supervision that can't be arranged at a doctor's office. Only experience will help decision-making in the future as there is still too much uncertainty and too many unknown features associated with this heterogeneous class of drugs.

Q We've discussed long-term follow-up as a standard for ATMP products reaching the market. But how will healthcare systems in Europe accommodate the extensive follow-up testing and monitoring that will be required? And who should be responsible for that?

MT: To date, it has always been the company that is responsible – they may receive a conditional approval for reimbursement and if that condition is long-term follow-up, it is the company that is going to pay for it and be rewarded if the evidence is conclusive. This is fair, because the onus is on the company to deliver the evidence that their product is reasonably priced and effective. When there is high uncertainty about the long-term results, it is their responsibility.

Some payers may agree to reimburse and then scrutinize the data collected through registries, as occurs in Sweden and The Netherlands, whilst others will accept a high listed price and request a high rebate until new evidence is available, as is the case in the UK and France. When new evidence is available, reducing uncertainty, then the rebate may be reduced – this is the case in the UK, but in France, this option remains theoretical and does not happen in practice.

Compared to other European countries, the UK and France have the highest net price of drugs, with discounts comfortably reaching 60%. But while UK pricing remain somewhat predictable, pricing in France has become unpredictable, lengthening the price negotiation period whilst patients are treated through a compassionate use program called post-ATU (Autorisations temporaires d'utilisation).

However, although there is agreement on who should pay for these therapeutics, there is a lot of discussion about who should perform the long-term follow-up. Should the pharma industry be doing it, the same way they do their development, or should an independent third-party be chosen? There are still question marks there and as yet, there is no clear consensus of opinion.

What we currently see is companies performing long-term registries for their products for 10 to 15 years. The manufacturers of Yescarta® are possibly the only ones doing a long-term clinical trial and not a routine clinical practice data collection.

Q How will countries with relatively decentralized healthcare systems, such as the UK, cope with an increasing number of ATMPs reaching the market?

MT: The UK is a highly decentralized system where GPs have much greater decision-making responsibility than their counterparts in Germany or France, where patients are regularly referred to office-based and hospital-based specialists. It would be a real challenge to find enough resources to treat patients in this way in the UK and unless new investments are made, I don't see how it will be possible.

Covid-19 has also shown us that in the case of a pandemic, without the infrastructure to isolate infected patients, there is a high risk of nosocomial infection for anyone going to hospital. This has led to a lot of patients abandoning their care. As a result, countries have decided to rethink and reinvest in their healthcare infrastructure. When doing so, it is important that they consider how ATMP therapies and the patients receiving them should be handled.

For a very long time, infectious disease has been considered a problem solely for developing countries. In developed countries, we have come to believe that we have such good health infrastructure that if a pandemic reaches our own country, we can easily control it and our risk is low. This caused countries to stop investing as much in infrastructure, because we considered ourselves to be well prepared. Obviously, we have now realized that this is not the case. Despite the dire current situation, this rethinking of infrastructure is actually a very positive thing.

Q What are your words of advice for developers to help them ensure their R&D plans for new ATMPs align to HTA requirements in Europe?

MT: An important step is to accurately identify your target population. Avoid aiming for the whole population – if some have less severe disease and others are much more severely affected, targeting mild severity patients will impact the value of your product. Understand which population you want to target, and why.

For the most part, developers should stop performing single arm trials because in the future, payers and HTA will accept or rely on these less and less. (Of course, this excludes very specific conditions where you have evidence that the product is going to work, and it would be unethical to give a placebo to patients – for example, if patients are going to die within 1 year and your product can help them to survive for three or four years, there is no need to have a comparator to show that three years is better than one). But the efficacy of the product needs to be outstanding. You also need to understand the confounders so that you can adjust for them when performing historical comparisons. Finally, you need to understand the heterogeneity of the population in order to compare apple with apple, and not apple with pear.

Right now, most companies are not moving in the right direction. In the future we may see products being stopped at HTA level because they don't fulfil the requirements for HTA assessment. For now, HTA are looking past this: they are complaining about it, but still

recommending products. In the future they may not be so willing to do this. So I would also advise developers to anticipate changes in HTA assessment. It is the responsibility of the pharmaceutical industry to act and to work for adjustments in the way that HTA is being performed. There should be a lot of adjustment in how we value gene therapy and on the discount rates for gene therapy in the long-term that is used for health economics assessments. Finally, developers will have to work on market access conditions through specific market-entry agreements.

Possibly the most important issue will be to work on making these therapies eligible for amortization and depreciation, which is not the case today. If you buy a table for your office, you are going to amortize the table over 5 years. But if you buy a gene therapy that is a single administration with a 10, 15, or 20-year benefit, you have to put it on the budget within the year you acquire it. You cannot amortize this therapy and therefore, it has a very high impact on payer budget. When you delay a payment over 5 years, this time-delayed payment is just contributing to the payer cashflow, not contributing to the budget. The budget has to be entirely in the first year. There is a need for adjustment to the public accounting law in most countries to make this change feasible.

AFFILIATION

Mondher Toumi

Public Health Department, Research Unit EA 3279, Aix-Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille, France
mondher.toumi@univ-amu.fr

AUTHORSHIP & CONFLICT OF INTEREST

Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgements: None.

Disclosure and potential conflicts of interest: Dr Toumi is a consultant for a vendor providing services for Industry and governmental bodies.

Funding declaration: The author received no financial support for the research, authorship and/or publication of this article.

ARTICLE & COPYRIGHT INFORMATION

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Attribution: Copyright © 2020 Toumi M. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

Article source: Invited.

Interview conducted: Aug 10 2020; **Publication date:** Sep 2 2020.